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ABSTRACT 
During development the heart is the first organ to form and function in the embryo 
proper. Along with being fundamental for contraction, Ca2+ is also a key signalling 
molecule known to regulate cardiac genes, however, it is unclear how Ca2+-handling 
feeds-back onto the initiation of beating and whether this directly impacts on early 
embryonic heart development per se. The aim of this study was to investigate how 
initial contractions of the early mouse heart are established and what the downstream 
consequences of function are on cardiac differentiation and heart development. Using 
ex vivo Ca2+ imaging we found evidence of randomly distributed Ca2+ transients in the 
forming cardiac crescent, prior to contraction, suggesting early Ca2+ handling is 
essential for cardiomyocyte differentiation and subsequent heart development. To 
study the downstream effects of early Ca2+ we used a murine embryonic stem cell 
(mESC) model of cardiomyocyte differentiation which recapitulated heart 
development in vivo. Assessment of Ca2+ handling proteins indicated that the Na+-Ca2+ 
exchanger (NCX) was one of the earliest sarcolemmal transporters to be expressed, 
prior to the L-type Ca2+ channel (LTCC). Pharmacological inhibition of NCX revealed an 
essential early role in establishing and maintaining the first Ca2+ transients through to 
initiation of contraction; a role superseded by the LTCC as differentiation progressed. 
Upon NCX blockade cardiomyocyte differentiation was inhibited, coincident with the 
down-regulation of signature cardiac genes and calmodulin kinase signalling, which 
culminated in the failure of beating cardiomyocytes to form. This study points to a 
novel mechanism by which form and function are intricately linked such that, from the 
outset, Ca2+ acts to initiate contraction as well as regulate cardiac differentiation and 
the formation of the heart, adding an important layer onto our current understanding 
of mammalian cardiovascular development. 
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1. INTRODUCTION 
1.1 Development of the heart 
1.1.1 Introduction 
The heart is required to continuously circulate blood throughout the body, delivering 
oxygen and nutrients whilst removing metabolic waste (Figure 1.1a). It is composed of 
three different layers of tissue including; the endocardium (the internal endothelial 
lining that is contiguous with the systemic vasculature), the myocardium (the muscular 
tissue which makes up the majority of the heart) and the epicardium (the epithelial 
layer surrounding the myocardium) as well as interstitial cells - consisting of cardiac 
fibroblasts, endothelial cells and vascular smooth muscle cells (Figure 1.1b). The 
human myocardium is comprised of billions of specialised muscle cells termed 
cardiomyocytes which have a defined phenotype and form branched interlocking 
networks that allow the heart to beat in a coordinated and uniform manner. The 
ability of cardiomyocytes to contract is due to the electrochemical properties of these 
cells and their ability to regulate the influx and efflux of different ions via sarcolemmal 
channels and exchangers. As well as being fundamental for contraction, ionic fluxes are 
also involved in the regulation of gene transcription and have been linked to the 
pathological progression of diseases such as cardiac hypertrophy and arrhythmias. 
Whilst cardiomyocytes represent a highly differentiated and specialised population of 
cells, the transition from pluripotent stem cell to immature cardiomyocyte happens 
relatively quickly, with the embryonic heart beginning to beat by around a third of the 
way through gestation. Although formation of immature cardiomyocytes and the 
initiation of contraction begins during the early stages of embryogenesis, complete 
maturation of cardiomyocytes does not occur until adulthood with the loss of 
proliferative capacity and cell plasticity. Over this period there are dynamic changes in 
gene expression, cell signalling and electrophysiology which ultimately results in the 
formation of terminally differentiated cardiomyocytes. 
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Figure 1.1: Anatomy of the adult heart 
Schematic representation of the heart highlighting major anatomical features including the 
conduction system pathway (a). SA, Sinoatrial node; AV, Atrioventricular node; RA, Right Atria; 
LA, Left Atria; RV, Right Ventricle; LV, Left Ventricle; IVS, Inter-ventricular septum. Blood enters 
the heart from the body via the vena cava before being sent to the lungs to be re-oxygenated, 
it then returns to the heart and is then pumped back around the body via the aorta. 
Innervation of the heart begins at the SA node, before passing through the atria to the AV 
node and moving down the intraventricular septum via the left and right branches of the AV 
bundle block (Bundle of His), activating the Purkinje fibres and triggering co-ordinated 
contraction of the ventricles. The wall of the heart is composed of the myocardium, 
endocardium, epicardium as well as interstitial cells, such as fibroblasts, vascular smooth 
muscle cells and connective tissue (b) (Adapted from (Harvey 2002)(Martini 2006)).  
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1.1.2 Murine embryogenesis 
Embryogenesis is the process by which an embryo forms and develops from a single 
cell, with the subsequent specification and differentiation of pluripotent progenitor 
cells to contribute to specialised cell lineages throughout gestation. Embryogenesis is 
initiated by the fertilisation of an oocyte by sperm, resulting in the formation of a 
zygote, which undergoes three rounds of cell division to form 8 blastomeres which 
have no overt morphological differences (Figure 1.2a) (Arnold & Robertson 2009). By 
embryonic day(E) 3.0 (Morula stage) in the mouse, asymmetrical divisions have begun 
to occur forming two distinct cellular subpopulations, which segregate to form the 
inner cell mass and the outer trophectoderm before the embryo cavitates to form the 
early blastocyst (Sutherland et al. 1990). The inner cell mass is characterised by the 
expression of the transcription factor Oct-4 which maintains pluripotency in this 
subpopulation of cells (Niwa et al. 2005). During maturation of the blastocyst, the 
inner cell mass segregates into the outer most layer of cells, forming the primitive 
endoderm and giving rise to the yolk sac, the remaining inner cells form the 
pluripotent epiblast at E4.5 (Chazaud et al. 2006). The epiblast is the founding stage 
which gives rise to all germ cell lineages and subsequent somatic tissues of the embryo 
proper.  After the formation of the epiblast the embryo undergoes a number of 
morphological changes to establish both the proximal-distal and anterior-posterior 
axes via early molecular asymmetries (Beddington & Robertson 1999). Shortly after 
implantation of the blastocyst into the uterine wall, a cavity forms in the centre of the 
epiblast and the conceptus elongates along the proximal-distal axis to form the ‘egg 
cylinder’ stage embryo. Although molecular evidence for anterior-posterior axis 
formation becomes evident at around E6.0, the mouse embryo remains 
morphologically radially symmetrical until the onset of gastrulation at E6.5. At this 
stage, epiblast cells begin to converge towards the posterior proximal pole of the 
embryo to form the primitive streak which, over the next 36 hours,  initiates 
gastrulation as the streak elongates and extends towards the distal tip of the embryo 
(Figure 1.2b) (Lawson et al. 1991). Gastrulation is the morphogenetic process in which 
cells from the epiblast undergo epithelial-to-mesenchymal transition and ingress at the 
primitive streak to give rise to the three primary germ layers; endoderm 
(gastrointestinal and respiratory tracts, pancreas and liver), mesoderm (muscle, blood 
and vasculature) and ectoderm (nervous tissue and skin), producing the progenitor 
cells required to form all adult tissue and organs (Figure 1.2c) (Lawson 1999). 
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Figure 1.2: Schematic representation of early embryogenesis and lineage segregation in the 
blastocyst and gastrulation 
The primary tissue types of the mouse embryo – trophectoderm (TE), inner cell mass (ICM), 
epiblast and primitive endoderm- are established before implantation at around embryonic 
day 4.5 (E4.5). At E2.5, the mouse zygote is formed of eight identical blastomeres, by E3.0 the 
first binary cell fate decision has occurred to form the trophectoderm or inner cell mass (ICM). 
The next round of cell divisions generates larger outer TE cells and smaller inner ICM cells, 
before the primitive endoderm and the epiblast lineages segregate from the ICM at the 
blastocyst stage (E3.5-E4.5) (a). By E6.25, epithelial cells of the epiblast sheet converge 
towards the primitive streak, initiating gastrulation and the formation of the embryo proper 
(b). VE, visceral endoderm: AVE, anterior visceral endoderm. During gastrulation, formation of 
the nascent mesoderm and endoderm is a result of an epithelial-mesenchymal transition 
(EMT) and tissue migration through the primitive streak (c). Ectoderm cells will not go through 
the primitive streak. RNA in situ hybridization highlights the localized expression of mesoderm 
transcriptional regulators at gastrulation (d). Brachyury (Bra) is broadly expressed throughout 
the entire streak, the node and the notochord. The related T-box gene eomesodermin (Eomes) 
is restricted to the anterior streak region, whilst the cardiogenic mesoderm marker Mesp1 is 
expressed in the intermediate primitive streak. (Adapted from (Arnold & Robertson 2009) and 
(Wolpert et al. 2006)) 
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1.1.3 Heart development 
During embryogenesis the heart is the first functional organ to form in the embryo 
proper, critical in supplying the embryo with sufficient oxygen and nutrients. The 
commitment and specification of the cardiac cell lineage occurs early in development 
and due to the fundamental role of the heart early perturbations in this process 
frequently result in embryonic lethality (Copp 1995). Indeed, congenital heart disease 
accounts for 10% of all spontaneous abortions and heart defects are present in 1% of 
all live births (Hoffman & Kaplan 2002). 
Specification of cardiac progenitors occurs in the pre-gastrulation mouse embryo at 
around E6.5 (Auda-Boucher et al. 2000), however, the first morphologically 
recognisable heart structure does not form until E7.5, when mesodermal derived 
cardiac progenitor cells delaminated through the primitive streak and migrate in an 
anterior-lateral direction to below the head folds and form a crescent-shaped 
epithelium across the midline, the cardiac crescent (Figure 1.3) (for reviews see 
((Harvey 2002)(Buckingham et al. 2005)(Bruneau 2008)(Evans et al. 2010)). The cardiac 
crescent, in which myocardial markers are first detected, is composed of the first heart 
field (FHF) which contributes primarily to the left ventricle. The crescent migrates 
towards the midline to form the linear heart tube which is composed of an inner 
endothelial tube covered by contractile mesoderm derived cardiomyocytes. Elongation 
and expansion of the linear heart tube occurs via proliferation as well as the addition 
of cells from the so-called second heart field (SHF) – derived cardiomyocytes to both 
poles. In conjunction with this expansion, the linear heart tube undergoes rightward 
looping, with its posterior region moving anteriorly and the future ventricles become 
distinct and ballooning outwards. During looping the SHF cells from the anterior-dorsal 
region of the embryo contribute to the atrial regions and systemic venous tributaries 
which are forced dorsally and cranially so that they are now above the developing 
ventricles. Following cardiac looping, a large number of complex morphogenetic 
processes transform the tube into the characteristic four chambered heart. Precursors 
of the atrioventricular (AV) values (tricuspid and mitral values) form in the AV canal 
and are composed of cells from the endocardial layer of the heart which migrate and 
proliferate to form opposing tissue masses called endocardial cushions. Endocardial 
cushions also form in the outflow tract and are the precursors of the aorticopulmonary 
septum which divides the outflow tract into the aorta and pulmonary artery as well as 
giving rise to the aortic and pulmonary values. Neural crest cells originating from the 
hindbrain migrate into the heart via the outflow cushions and participate in outflow 
septation as well as initiating neuronal innervation by around E10.5. At this stage the 
ventricular myocardium undergoes trabeculation, whereby cardiomyocytes along the 
inner surface of the ventricles extrude into the extracellular matrix (ECM) lying 
between the myocardium and endocardium layers (the cardiac jelly) to form sheet-like 
projections resulting in a spongiform layer of myocytes along this inner surface. During 
the later stages of heart development around E14.5, septation of the heart is 
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completed forming distinct left and right ventricles and atria. The ECM of the cardiac 
jelly begins to break down, causing the trabeculae of the ventricles to collapse and 
thicken into a compact layer of myocardium (myocardial compaction) and 
development of the conduction system and cardiac pace-making is completed. 
 
 
Figure 1.3: Morphogenesis of the developing mouse heart 
Myocardial progenitor cells originate in the primitive streak (PS), from where they migrate to 
the anterior part of the embryo at around E7.0. These progenitor cells go on to form the 
cardiac crescent at E7.5 which is located below the nascent head folds (HF) and above the 
midline (ML). The early linear heart tube forms through the fusion of the cardiac crescent 
(E8.0) before subsequently undergoing looping at E8.5. By E10.5, the chambers of the fetal 
heart have begun to form with complete septation not occurring until E14.5, when the 
myocardium has become compacted and the heart has a similar morphology to the adult. RV, 
right ventricle; LV, left ventricle; RA, right atria; LA, left atria; OFT, Outflow tract; IVS, 
interventricular septum; AA, aortic arch; Ao, Aorta; PT, pulmonary trunk. (Adapted from 
(Buckingham et al. 2005)(Laugwitz et al. 2008)) 
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1.1.4 Molecular regulation of cardiomyocyte differentiation 
During formation of the heart the underlining changes in cardiac morphology and 
cellular identity are controlled at the level of gene expression. Stage and cell type-
specific patterns of gene expression are reached by cell type-specific transcription 
factors which bind to specific DNA sequences adjacent to the genes that they regulate. 
Ultimately, a cascade of transcription factor activation results in the cardiac 
specification and differentiation of pluripotent progenitor cells to mature 
cardiomyocytes (for reviews see (Paige et al. 2015)(Bruneau 2002)). 
Initially myocardial precursor cells express the mesoderm T-box transcription factor T 
(Brachyury), which specifies the newly formed mesoderm as it migrates through the 
primitive streak (Wilkinson et al. 1990). During this stage another T-box transcription 
factor Eomesodermin (Eomes) activates the basic helix-loop-helix transcription factor 
mesoderm posterior 1 (Mesp1) (Costello et al. 2011)(van den Ameele et al. 
2012)(Figure 1.2d). Mesp1, along with its family member Mesp2, are the earliest 
markers of cardiovascular specification in the developing embryo and represent the 
first molecular step towards cardiogenesis (Saga et al. 1999) (Bondue et al. 2011) 
(Figure 1.4). Mesp1 is first expressed in the FHF which makes up the cardiac crescent, a 
later wave of Mesp1-positive cells produces cardiac progenitors of the SHF. Although 
both the FHF and SHF cells express Mesp1, clonal analysis in mice has suggested that 
these progenitor cells are committed prior to the onset of Mesp1 expression (Devine 
et al. 2014). The mechanism by which Mesp1 drives cardiac specification is 
multifaceted in that it promotes the expression of cardiac specific transcription factors 
whilst also repressing genes that are involved in pluripotency (Bondue et al. 2008). As 
cardiac differentiation progresses, these early genes become down regulated as the 
expression of genes encoding cardiac transcription factors such as Nkx2.5, Gata-4 and 
Mef2c increases. Within the cardiac crescent and during migration to the linear heart 
tube, the FHF can be identified by the expression of transcription factors such as Tbx5, 
Nkx2.5 and HCN4 (Paige et al. 2015). As cardiac looping occurs the atrial and 
ventricular cells selectively proliferate and differentiate leading to cardiac chamber 
morphogenesis, this process is controlled by a large number of different transcription 
factors including T-box transcription factors Tbx2, Tbx3, Tbx5 and Tbx20 as well as 
Nkx2.5, Gata-4, Irx4 and Hand1 which interact with each other to trigger various 
processes in different parts of the heart. For example, Tbx5 and Tbx20 act in 
combination with Nkx2.5 and Gata4 to promote specification of the chamber 
myocardium, whilst in contrast Tbx2 and Tbx3 interact with Nkx2.5 and Gata4 to 
repress chamber specification in regions such as the outflow tract (Christoffels et al. 
2010)(Christoffels et al. 2004). Within the myocardium, the 4 chambers are 
represented by unique gene expression patterns which define their subsequent 
phenotype and function in the adult heart. The mouse atria and ventricles express 
myosin light chain isoforms Mlc2a and Mlc2v, respectively (Small & Krieg 2004), whilst 
the homeobox gene Irx4 is only expressed in the ventricles, activating ventricular 
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isoforms of myosin heavy chain and suppressing atrial isoforms (Bao, Science 1999). In 
the left atria there is a high level of Pitx2 expression which supresses Sino-atrial (SA) 
node development thus preventing ectopic pacemaker formation (Wang et al. 2010). 
 
 
Figure 1.4: Schematic overview of the specific stages and markers during cardiomyocyte 
differentiation 
Simplified model of cardiomyocyte differentiation from pluripotent embryonic stem cells to 
immature cardiomyocytes via sequential progenitor cell types. Stages are identified by the 
expression of genes known to encode key transcription factors and cardiomyocyte specific 
proteins. Genes in brackets represent specific second heart field transcription factors. 
(Adapted from (Mummery et al. 2012)) 
 
1.1.5 Development of cardiac function 
Studies of mammalian heart development have typically focused on the molecular 
basis for cardiac lineage determination and the spatial-temporal allocation of cardiac 
progenitors whilst insight into the development of cardiac function is limited. It is 
commonly stated that initiation of contraction begins with the formation of the linear 
heart tube (Paige et al. 2015), however, initiation of cardiac contraction has been 
reported prior to this stage in historical studies. Initiation of cardiac function was first 
studied in the early 20th century using chick (Sabin 1920)(Patten & Kramer 1933) and 
rat (Goss 1938).  Initial studies in rat reported that contractile activity began at E9.5 
(equivalent to E8.5 in mice), with contractions having a regular rhythm and a rate of 37 
to 42 beats per minute (bpm). Further characterisation described pacemaker-like 
activity in regions either side of the embryonic midline suggesting contraction was 
occurring prior to formation of the linear heart tube (Goss 1952). More recent studies 
in mouse have reported twitching of heart rudiments in embryos around the 3-4 
somite stage (E8.0) (Nishii & Shibata 2006). In these studies, the precise determination 
of when the first cardiac contractions are initiated is difficult due to the variability in 
staging as assessed using somite number, embryonic day and heart morphology.  
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By E10.5 the embryonic heart beats at approximately 127 bpm  increasing throughout 
embryonic development to 380bpm at postnatal day 0 before rising to over 600bpm in 
the adult, highlighting key changes in cardiac physiology during heart development 
(Keller et al. 1996).  
1.1.6 Differentiation of embryonic stem cells into cardiomyocytes  
Investigating the cellular biology of early processes during mammalian embryogenesis 
such as cardiac lineage specification is technically challenging due to the size and 
accessibility of mammalian embryos. Embryonic stem cells have emerged as a useful in 
vitro tool for studying embryogenesis and differentiation at the cellular level. Mouse 
embryonic stem cells (mESCs) were first isolated from the inner cell mass of pre-
implantation blastocysts in the early 1980’s (Evans & Kaufman 1981)(Martin 1981) and 
could maintain pluripotency in vitro when grown on a layer of feeder cells (mouse 
embryonic fibroblasts, MEFs) and by using leukaemia inhibitory factor (LIF).  Cultured 
mESCs that are injected into blastocysts have the ability to form chimeras (Bradley et 
al. 1984)(Beddington & Robertson 1989), as previously observed with cells from the 
inner cell mass (Gardner 1968), giving rise to derivatives of all three germ layers and 
consequently viable mice. mESCs, therefore, represent a pluripotent population of 
undifferentiated cells capable of proliferation, self-renewal and the generation of large 
numbers of differentiated cell progeny. These properties have seen mESCs emerge as a 
valuable research tool enabling the generation of gene-targeted mice as well as 
providing an in vitro model to study normal and pathological differentiation and 
development. 
Early studies using mESCs have shown that these cells can differentiate into functional 
cardiomyocytes in vitro and recapitulate the pre-gastrulation and post-gastrulation 
cardiogenic events which occur in vivo (Mercola et al. 2011)(Mummery et al. 
2012)(Burridge et al. 2012).  mESC cardiomyocyte differentiation is initiated by the 
formation of aggregates, termed embryoid bodies (EBs), which triggers the 
spontaneous differentiation of cells into all 3 primary germ layers. As the field of mESC 
cardiomyocyte differentiation has expanded a large number of studies have 
investigated the parameters which influence cardiomyocyte formation in order to 
promote differentiation. The differentiation protocols developed for ESC 
cardiomyocyte formation usually recapitulate the signalling cues that direct cellular 
specification within the embryo. This is achieved by the addition of the same growth 
factors such as bone morphogenetic proteins (BMPs) and fibroblast growth factors 
(FGFs), or by stimulating the same pathway or receptor using related growth factors 
such as ActivinA and Nodal (Reissmann et al. 2001)(Kattman et al. 2011). Furthermore 
there is an increasing number of small molecule modulators for various cardiomyocyte 
signalling pathways (Willems et al. 2011). These different factors allow the activation 
and inhibition of developmental pathways and can be used to increase speed and 
efficiency of ESC-cardiomyocyte differentiation (Chambers et al. 2012). 
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1.2 Cardiac physiology  
1.2.1 Cardiomyocyte electrical excitability 
Cardiomyocytes like neurons are excitable cells which, due to their electrochemical 
properties, can be stimulated to create an electrical impulse, leading to the onset of 
contraction. Contraction in the adult heart is initiated by the spontaneous electrical 
activity of the SA node, which generates an action potential that can propagate rapidly 
throughout the heart, thereby activating cardiomyocytes and generating a coordinated 
heartbeat (Brown 1982). The sinoatrial node is composed of a specific subtype of 
cardiomyocytes which are unique in having the ability to automatically generate 
repetitive action potentials due to the intrinsic expression of ion channels (Mangoni & 
Nargeot 2008). Action potentials are generated by the movement of ions across the 
sarcolemmal membrane via ion channels, these ionic fluxes result in membrane 
potential changes (Figure 1.5). The membrane potential is the difference in electrical 
charge between the inside and outside of a cell and is the result of differences in extra-
cellular and intra-cellular ion concentration as well as sarcolemmal membrane 
permeability. In non-stimulated cells this potential is termed the resting membrane 
potential and is negative due to the interior of the cell containing less positive ions 
relative to the exterior. The resting membrane potential arises due to the 
sodium/potassium ATPase, which uses ATP to pump 2x K+ into the cell whilst removing 
3x Na+, and “leaky” potassium channels which allows slow facilitated diffusion of K+ out 
of the cell (Glitsch 2001). In mature cardiomyocytes, the resting membrane potential is 
around -85mV, as calculated by the Goldman-Hodgkin-Katz equation, due to the 
concentration of intracellular and extracellular ions in the heart as well as the ion 
transporting enzymes present within the cell membrane (Goldman 1943)(Hodgkin & 
Katz 1949). A cardiac action potential is generated when the sinoatrial node derived 
electrical impulse reaches a cardiomyocyte, triggering Na+ channels to open (increased 
Na+ membrane conductance) and thus a rapid influx of Na+ down its concentration 
gradient and into the cell leading to membrane depolarisation as the interior of the 
cell becomes more positive (Grant 2009). The positive membrane potentials reached 
during depolarisation trigger the activation of both Ca2+ and K+ channels leading to a 
plateau in the membrane potential at around 10mV, due to the balanced influx of Ca2+ 
and efflux of K+. Towards the end of this plateau phase, Ca2+ channels become 
inactivated whilst K+ channels remain open leading to a repolarisation of the cell 
membrane as  K+ continues to diffuse out of the cell until the resting membrane 
potential is reached and ionic fluxes become balanced.  
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Figure 1.5: Action potential timecourse in a ventricular cardiomyocyte  
Schematic diagram to show the typical action potential of a ventricular cardiomyocyte 
highlighting the different phases of depolarisation and repolarisation as well as the main ionic 
currents (i) responsible for them.  
 
1.2.2 Cardiac Contraction 
In order to generate contraction cardiomyocytes have a highly defined phenotype 
which allows them to respond to electrical excitation and generate the force needed to 
pump blood around the body in a coordinated and rhythmic manner. The main 
contractile components of cardiomyocytes are long filaments which run throughout 
the cell and are termed myofibrils (Figure 1.6a). Myofibrils are composed of thick 
(myosin) and thin (actin) filaments which repeat along the length of the cell forming 
sarcomeres and give cardiomyocytes their characteristic striated appearance (Clark et 
al. 2002). Upon cardiomyocyte activation, the concentration of cytoplasmic Ca2+ 
increases and binds to troponin. Troponin is a protein complex composed of three 
subunits, TnC, TnI and TnT, which integrates cytoplasmic Ca2+ concentration with the 
regulation of force generation (Westfall & Metzger 2001). The binding of Ca2+ to 
troponin results in conformational change which prevents tropomyosin from inhibiting 
contraction by exposing the active sites of the actin filaments (Figure 1.6b)(McKay et 
al. 1997)(Herzberg & James 1988). Myosin is then able to bind to the exposed actin by 
forming cross bridges and by alternative attachment and detachment it pulls the actin 
filaments towards the sarcomere, generating contraction (Vale & Milligan 2000). This 
cycling process relies on energy produced by ATP hydrolysis and, therefore, 
cardiomyocytes have large quantities of mitochondria in order to supply the 
contractile apparatus with sufficient levels of ATP in accordance with a high energy 
demand. Muscle fibre relaxation occurs when the cytosolic Ca2+ concentration 
decreases and the troponin complex once again blocks contraction by blocking the 
active sites of actin.  
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Figure 1.6: Contractile apparatus of cardiac muscle tissue  
Myofibrils occupy most of the cardiomyocyte cell volume and are what generate contraction. 
Myofibrils are composed of sarcomeres and appear striated due to the arrangement of thick 
(myosin) and thin (actin) filaments, which form the repeating A bands (overlapping thick and 
thin filaments) and I bands (only thin filaments). Each sarcomere runs between Z discs which 
are primarily composed of alpha actinin. The H zone represents the region of thick myosin 
filaments which are not superimposed by thin actin filaments, in the middle of the H-zone is 
the M-line which is composed of cross connecting elements of the cytoskeleton (a). 
Contraction occurs via the binding of Ca2+ to troponin which removes the blocking action of 
tropomyosin, myosin can then bind to actin via cross bridges and trigger contraction (b). Insert 
shows the timecourse of action potential, Ca2+ influx and contraction measured in rabbit 
ventricular cardiomyocytes at 37oC. (Figure adapted from (Bers 2002) and (Martini 2006)) 
 
1.2.3 Excitation contraction coupling 
In the adult heart, coordinated electrical excitation is coupled to physical contraction 
in a process termed excitation contraction coupling (ECC), which creates the force 
needed to pump blood around the body (Bers 2002). ECC relies on the second 
messenger Ca2+, which binds to cardiac myofilaments resulting in contraction. Upon 
electrical excitation an action potential causes voltage sensitive Ca2+ channels to open 
creating an inward Ca2+ current (Figure 1.7). This inward Ca2+ current triggers the 
release of Ca2+ from the sarcoplasmic reticulum (SR) through ryanodine receptors 
(RyR) via a mechanism  known as Ca2+ induced Ca2+ release (CICR) which was first 
proposed in skinned muscle fibres (Fabiato & Fabiato 1979). In adult cardiomyocytes, 
the SR is the main intracellular Ca2+ store and contributes to between 20-90% of the 
Ca2+ required for contraction depending on species and myocyte type (Shiels & Galli 
2014). The release of Ca2+ from the SR via RyRs along with the influx of Ca2+ through L-
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type Ca2+ channels increases the cytosolic Ca2+ concentration (systolic Ca2+ transient) 
leading to the activation of  myofilaments and the generation of cardiac contraction 
(figure 1.6) (Bers 2002). For relaxation to occur the increase in cytoplasmic Ca2+ from 
the systolic transient needs to be removed. The majority of Ca2+ is removed by the 
sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA) which pumps Ca2+ back into the SR. 
A smaller proportion of Ca2+ is pumped out of the cell by the Na+/ Ca2+ exchanger 
(NCX1), however, this ratio is again dependent on species and cardiomyocyte subtype 
(Shiels & Galli 2014). 
 
Figure 1.7: Schematic representation of excitation-contraction coupling. 
Depolarisation of a cardiomyocyte triggers the opening of Cav1.2 channels and the influx of 
Ca2+, this leads to the release of Ca2+ from the SR, raising the concentration of cytoplasmic 
Ca2+ and resulting in myofilament activation and contraction. Relaxation occurs by removing 
Ca2+ from the cytoplasm via reuptake into the SR via SERCA or by sarcolemmal efflux by NCX1. 
RyR, ryanodine receptor; PLB, phospholamban; SERCA, Sarco(endo)plasmic reticulum Ca2+ 
ATPase; SR, sarcoplasmic reticulum; NCX1, Na+/ Ca2+ exchanger; Cav1.2, L-Type Ca2+ channel.  
 
1.2.4 Early embryonic cardiac physiology 
Although ECC has been well described in adult cardiomyocytes, the mechanism by 
which cardiac contraction occurs during early heart development is still poorly 
understood. Targeted disruption of genes encoding ECC proteins in mice has shown 
that the early contractile activity of immature cardiomyocytes does not require ECC 
(Table 1.1). In these transgenic models the immature heart remained contractile until 
around E10.5 suggesting a different unknown mechanism was occurring. During early 
cardiogenesis, studies have shown that immature cardiomyocytes have both an 
excitable membrane (Doevendans et al. 2000), functional sarcoplasmic reticulum 
(Moorman et al. 2000)(Seki et al. 2003) and express a variety of voltage-activated ion 
channels and exchangers (Seisenberger et al. 2000)(Linask et al. 2001)(Cribbs et al. 
2001), however, the expression and activity of these proteins is distinct from that in 
adult cardiomyocytes (Liang et al. 2010). In order to explain the mechanism and source 
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of contractile Ca2+ in the early heart, two contrasting mechanisms have been proposed 
on the basis of experiments with isolated cells and genetically manipulated animals 
and cells. One line of evidence suggests that myocyte contraction is triggered by 
sarcolemmal Ca2+ influx through voltage activated Ca2+ channels with little or no 
contribution from the SR (Nakanishi et al. 1988)(Takeshima et al. 1998). whilst the 
opposing view is that early spontaneous Ca2+ oscillations originate from the SR, 
triggering electrical activity as well as contraction (Viatchenko-Karpinski et al. 
1999)(Méry et al. 2005)(Sasse et al. 2007). Although in immature cardiomyocytes the 
exact mechanism for contractile activity and the development of a functional SR is still 
poorly understood, studies have clearly shown there is a significant difference 
compared to the adult, with an increased requirement for sarcolemmal Ca2+ influx and 
dynamic changes occurring in channel and exchanger expression and function during 
development of the heart (Sissman 1970)(Gomez et al. 1994)(Husse & Wussling 1996). 
This is clearly highlighted by the difference in relative contribution of Ca2+ release from 
the SR vs. sarcolemmal transport between neonates and adult cardiomyocytes (Bers & 
Bridge 1989)(Haddock et al. 1999). 
 
Protein 
(gene) 
Tissue of gene 
modification 
Cardiac phenotype Reference 
NCX1 
(Slc8a1) 
Germline 
deletion 
Lethality E9 to E10; thin 
myocardium with reduced 
cardiomyocytes; no heart beat 
observed. 
Lethality E9.0 to E9.5; 
Underdeveloped heart with 
dilated pericardium; contractile 
although significantly slower than 
WT littermates. Mutant and WT 
hearts indistinguishable at E8.5. 
Lethality E11.5 to E13.5; Lack of a 
spontaneous beating heart and 
organised myofibrils. 
(Wakimoto 
et al. 2000) 
(Cho et al., 
2000). 
(Cho et al. 
2000) (Cho et 
al., 2000) 
(Koushik et 
al., 2001) 
(Koushik et. 
(Koushik et 
al. 2001) 
Cav1.2 
(Cacna1c) 
Germline 
deletion 
Lethality prior to E14.5; Normal 
development until E12.5, 
contractile rate the same as WT 
littermates. 
(Seisenberger 
et al. 2000) 
Cav1.3 
(Cacna1d) 
Germline 
deletion 
Viable embryos. Pronounced 
bradycardia and arrhythmias at 
rest in the adult. Altered 
sinoatrial pacemaker activity. 
(Platzer et al. 
2000) 
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RyR2 
(RYR2) 
Germline 
deletion 
Lethality E10.5 to E11.5; 
Rhythmic contractions at E9.5, 
although irregularly arranged 
myocardium. No heart beat at 
E10.5, anatomically similar to 
E9.5.  
(Takeshima 
et al. 1998) 
SERCA2a 
(Atp2a2) 
Germline 
deletion 
Deletion in 
myocardium 
No mutant embryos detected.               
n 
Lethality at E11.5; Yolk sac 
circulation and heartbeat 
observed until E10.5. 
(Periasamy et 
al. 1999) 
(Andersson 
et al. 2009) 
Nav1.5 
(Scn5a) 
Germline 
deletion 
Lethality E10.5 to E11.5; Some 
uncoordinated beating at E10.5, 
however, none observed at 
E11.5. Reduced ventricular 
chamber size, trabeculation and 
cardiomyocytes. Common Atria, 
endocardial cushions and truncus 
arteriosus appear normal. 
(Papadatos 
et al. 2002) 
Cav3.1 
(Cacna1g) 
Germline 
deletion 
Bradycardia and slowing of 
atrioventricular conduction. 
(Mangoni et 
al. 2006) 
Cav3.2 
(Cacna1h) 
Germline 
deletion 
No effect on heart development 
or beating frequency. Abnormal 
coronary function. 
(Chen et al. 
2003) 
TPC1 
(Tpcn1) 
Germline 
deletion 
Mice were viable and bred 
normally. 
(Lin-Moshier 
et al. 2012) 
TPC2 
(Tpcn2) 
Germline 
deletion 
Mice were viable and bred 
normally. 
 
(Calcraft et 
al. 2009) 
Table 1.1: the role of cardiac channels and exchangers during embryonic heart 
development 
Summary of studies in which proteins required for cardiac physiology and Ca2+ 
handling have been deleted in mice.  
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1.2.5 The sodium calcium exchanger  
The NCX is an electrogenic plasma membrane antiporter responsible for Ca2+ 
homeostasis in a wide range of cell types. In mammals, three different NCX genes have 
been identified; Slc8a1 encoding NCX1 (Nicoll et al. 1990), Slc8a2 encoding NCX2 (Lee 
et al. 1994) and Slc8a3 encoding NCX3 (Nicoll et al. 1996). The different isoforms of 
NCX are expressed in a tissue-specific manner, with NCX2 and NCX3 found in the brain 
and skeletal muscle whereas NCX1 is the major cardiac isoform although it is 
ubiquitously expressed (Philipson & Nicoll 2000). In the heart, NCX1 is the 
predominant mechanism by which Ca2+ is removed from the cell following contraction, 
using the Na+ gradient across the cell membrane to remove one Ca2+ whilst bring in 
three Na+ which generates an inward current (forward mode activity) (Mechmann & 
Pott 1986). In adult hearts the inward current generated by NCX1 has been suggested 
to trigger ectopic action potentials and lead to delayed after depolarisation mediated 
arrhythmias (Despa & Bers 2013). Whilst NCX1 predominantly favours forward mode 
activity it can also work in reverse mode to trigger Ca2+ influx and Na+ efflux. The 
direction and amplitude of NCX1 depends on the membrane potential and on the 
internal and external Na+ and Ca2+, with depolarised membrane potentials favouring 
reverse mode activity, resulting in Ca2+ influx and Na2+ efflux. In the early embryonic 
heart NCX1 has been suggested to have a predominant role in contraction due to its 
ability to generate spontaneous action potentials as well as trigger Ca2+ influx (Linask 
et al. 2001). In the developing mouse embryo at E7.0, NCX1 expression is located 
primarily in the heart-forming mesoderm before being highly expressed in the cardiac 
crescent and linear heart tube (Koushik et al. 1999). Targeted disruption of the NCX1 
gene leads to embryonic lethality between E9.5 and E10.5 (Wakimoto et al. 
2000)(Koushik et al. 2001). Mutant mice were significantly smaller by E9.5, although 
the development of limb buds, cranial neural tube, and somites were unaffected. In 
terms of cardiac development, the NCX1 KO mice exhibited non-contractile heart 
tubes with thin ventricular walls that contained fewer cardiac myocytes. In summary, 
this suggests that NCX1 has a crucial role in cardiac development, not only in 
contractile function but also in the formation of the heart. 
1.2.6 Voltage dependent Ca2+ channels 
In adult cardiomyocytes, sarcolemmal Ca2+ influx is dependent on two types of voltage 
gated Ca2+ channels; L-type (low threshold-type) and T-type (transient-type) channels, 
which couple membrane depolarisation with Ca2+ influx and contraction. L-type Ca2+ 
channels have a relatively large conductance, are activated by depolarised potentials 
(~-30mV), and contribute most of the Ca2+ required for CICR during ECC. On the other 
hand, T-type Ca2+ channels are activated at lower membrane potentials (~-60mV) and 
become rapidly inactivated (Bers & Perez-Reyes 1999). Whilst L-Type channels are 
expressed in all contractile cardiac cell types, T-type channels are found principally in 
pace-maker, atrial and Purkinje cells due to their role in action potential generation 
(Hagiwara et al. 1988). Voltage-dependent Ca2+ channels are formed as complex of 
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subunits including the main, pore-forming, α-subunit along with other regulatory α2δ, 
β and γ subunits which determine their physiological characteristics. 
L-type Ca2+ channels are identified by their pore-forming α-subunit and encoded by 4 
different genes; Cav1.1 (α1S), Cav1.2 (α1C), Cav1.3 (α1D) and Cav1.4 (α1F). Whilst 
Cav1.2 is the predominant ECC L-type Ca2+ channel within cardiomyocytes Cav1.3 is 
also expressed within the heart and contributes to diastolic depolarisation of the SA 
node, highlighted by SA node dysfunction in mice with genetic ablation of Cav3.1 
(Mangoni et al. 2003). In isolated embryonic cardiomyocytes, L-type Ca2+ channel 
activity has been reported to have a fundamental role in the generation of 
spontaneous action potentials at E8.5 with transcripts for both Cav1.2 and Cav1.3 
detectable (Liang et al. 2010)(Acosta et al. 2004). Targeted gene disruption of Cav1.2 in 
transgenic mice caused embryonic lethality prior to E14.5, although hearts at E12.5 
were grossly normal with a normal-rate of beating (Seisenberger et al. 2000). In these 
Cav1.2 knockout mice it was observed that the expression of Cav1.3 was up regulated 
at both the RNA and protein level (Xu et al. 2003). These results suggest that up until 
E12.5, Cav1.2 is dispensable for normal heart development and that contractions prior 
to E13 are not due to Cav1.2 but occur via compensation or a different unidentified 
mechanism. In contrast, mice with targeted Cav1.3 gene disruption were viable with 
no differences in growth or reproduction (Platzer et al. 2000).  
T-type Ca2+ channels are encoded by 3 different genes; Cav3.1 (α1G), Cav3.2 (α1H), 
Cav3.3 (α1I), although Cav3.1 (α1G) and Cav3.2 (α1H) are the main channels within 
heart (Perez-Reyes et al. 1998). The expression of Cav3.1 and Cav3.2 in the heart is 
developmentally regulated, being high in embryonic and neonatal hearts and 
decreasing in the adult (Niwa et al. 2004). Functional studies in embryonic 
cardiomyocytes have shown that T-type Ca2+ channel activity is required for the 
generation of spontaneous action potentials at E8.5 (Liang et al. 2010). Ablation of 
Cav3.1 in transgenic mice resulted in both bradycardia and a slowing in atrioventricular 
conduction, however, the ablation of Cav3.2 expression did not affect beating 
frequency or heart development per se (Mangoni et al. 2006). During in vitro 
differentiation of ESCs to cardiomyocytes it has been reported that the subtype of T-
type channel switches from Cav3.2 to Cav3.1 (Mizuta et al. 2010), consistent with 
findings in the embryonic heart (Niwa et al. 2004) and suggesting that the role of T-
type Ca2+ channels may vary between developmental stages and cardiomyocyte 
subsets. 
1.2.7 The sarcoplasmic reticulum and ryanodine receptors 
The SR is the main Ca2+ storage organelle in the adult heart and is responsible for the 
release of Ca2+ upon electrical excitation through RyR2 as well as the removal of 
cytoplasmic Ca2+ via SERCA. The exact timing of functional SR development from the 
rough endoplasmic reticulum is poorly understood, however, cytosolic Ca2+ oscillations 
originating from the SR have been observed in isolated E8.5 cardiomyocytes (Sasse et 
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al. 2007), providing support that SR Ca2+ release is involved in early contractile activity. 
Early SR derived Ca2+ oscillations are believed to trigger forward-mode NCX1 activity, 
thereby generating inward currents capable of initiating spontaneous action potentials 
and contraction. Contrary to these observations, it was reported that RyR2 knockout 
mice died at around E10.0 due to morphological abnormalities in the heart tube, 
despite normal contractions occurring in knockouts at E9.5 (Takeshima et al. 1998). 
Mutants also exhibited delayed development in both size and appearance when 
compared to control embryos. Moreover, treatment of control myocytes between E9.5 
and E11.5 with ryanodine, a compound which locks RyR2 in its open state, did not 
exert a major effect on spontaneous Ca2+ transients. This observation strongly suggests 
that RyR2 is not required for early embryonic contractions but instead is required for 
cellular Ca2+ homeostasis. The other main ECC related SR protein, responsible for filling 
the SR with Ca2+, is SERCA2a. Cardiac-specific deletion of SERCA2a at around E8.0, 
using alpha-MHC promoter driven Cre-lox leads to embryonic lethality at E11.5, 
potentially highlighting a later role for SR Ca2+ stores during heart development. 
1.2.8 NAADP signalling and two-pore channels 
Two pore channels 1 and 2 (TPC1/2) were identified as novel Ca2+ release channels 
located on lysosomes and activated by nicotinic acid adenine dinucleotide phosphate 
(NAADP) (Calcraft et al. 2009)(Brailoiu et al. 2009). NAADP is a potent Ca2+ mobilising 
second messenger (Lee 2003)(Lee 1997), known to have signalling roles in the 
pancreas and T-cells as well as regulating contraction in smooth muscle (for review see 
(Patel et al. 2011)). Its role was first documented in the fertilisation of sea urchin eggs; 
where extracellular stimuli were shown to raise NAADP levels leading to an increase in 
cytosolic Ca2+ (Hon Cheung Lee & Aarhus 1995). Levels of NAADP can be very transient, 
spiking and returning to basal levels within seconds, indicating the dynamic nature of 
NAADP signalling and making it difficult to assay. TPC1/2 display significant sequence 
similarity to voltage-gated Ca2+ and Na+ channels (Ishibashi et al. 2000). Both proteins 
have been shown to localize to the endo-lysosomal system (Brailoiu et al. 2009), which 
are known to contain high levels of Ca2+ due in part to their acidic pH. NAADP signalling 
has recently been shown to play a pivotal role in the heart, influencing ECC as well as 
playing a role in the formation of arrhythmias (Collins et al. 2011)(Nebel et al. 2013). 
This raises the question of whether lysosomal Ca2+ may have a role in early cardiac 
contraction and signalling, although this is yet to be examined. 
1.3 Heart failure and Ca2+ signalling 
1.3.1 Cardiomyocyte adaption to heart failure 
Heart failure is the leading cause of mortality worldwide and is characterized by 
impaired cardiac function and altered Ca2+ homeostasis, this is a result of adverse 
cardiac remodelling due to pathological stress such as hypertension, myocardial 
infarction and valvular disease or arising due to genetic defects and structural protein 
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anomalies. During ventricular remodelling, a combination of myocardial hypertrophy, 
cell death and interstitial fibrosis occurs (Koitabashi & Kass 2011). Cardiomyocyte 
hypertrophy is characterized by an increase in cell size without cell division, altered 
ECC and the induction of fetal cardiac genes such as Mef2c, Nkx2.5, Gata 4 and NFATc1 
(Dirkx et al. 2013). 
During the progression of heart failure a number of physiological adaptions occur in 
order to try and preserve cardiac function. Initial cardiomyocyte remodelling is 
beneficial (as observed during physiological hypertrophy), allowing cardiac output to 
increase, however, as remodelling progresses “decompensation” occurs, with the 
ventricular wall reducing in thickness and the heart becoming unable to meet the 
cardiovascular demands of the body, resulting in sudden death (Levy et al. 1990).  
During beneficial adaptive hypertrophy Ca2+ transients increase in order to raise 
contraction and cardiac output (Roderick et al. 2007). The increased Ca2+ transient 
amplitude is a result of increased SERCA and RyR2 activity as well as a decrease in Ca2+ 
removal via NCX1. Whilst these initial changes maintain cardiac output they have been 
suggested to contribute to the progression of heart failure via altered Ca2+ signalling 
mediating the hypertrophic response (Molkentin 2006). As the heart progresses to 
failure, a significant decrease occurs in Ca2+ transient amplitude resulting in decreased 
contractile activity (Hasenfuss 1998). Underlying this change is a decrease in SERCA 
activity due to reduced protein expression and increases in the SERCA inhibitor, 
phospholamban. The decreased ability to pump Ca2+ back into the SR leads to an 
increase in the diastolic concentration of cytoplasmic Ca2+ resulting in prolonged 
cardiomyocyte relaxation as well as an increase in the occurrence of arrhythmias 
(Gomez 1997). NCX1 expression is also increased during heart failure and is suggested 
to compensate for the decreased SR Ca2+ uptake and increase diastolic Ca2+ 
concentration (Sipido et al. 2000)(Hobai & O’Rourke 2000). During heart failure 
increased sarcolemmal Ca2+ flux, spontaneous RyR2 opening and the inward current 
generated by increased NCX1 mediated Ca2+ efflux cause both early and delayed after 
depolarisations and result in arrhythmias and sudden cardiac death (Pogwizd et al. 
2001).  
1.3.2 Pathological Ca2+ signalling during heart failure 
Whilst numerous intermediate signalling molecules, including mitogen-activated protein 
kinase (MAPK) and protein kinase B (PKB/AKT), have been implicated in the pathological 
remodelling associated with heart failure, a widely supported hypothesis is that 
changes in Ca2+ cycling mediate this hypertrophic response via Ca2+ dependent 
signalling pathways, thereby linking cardiac physiology and gene transcription 
(Molkentin 2006). Two of the most commonly discussed Ca2+ dependent second 
messengers include the Calcium/Calmodulin-dependent kinase II (CaMKII) and 
calcineurin. 
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CaMKII is a serine/threonine kinase that binds Ca2+ via its EF hands leading to the 
activation and phosphorylation of downstream targets, including transcription factors 
such as Mef2c. CaMKII consists of 4 different isoforms which have distinct expression 
patterns (Tombes et al. 2003). CaMKIIδ is the most abundant CaMKII isoform in the 
heart (Edman & Schulman 1994). Overexpression of this isoform in mice results in the 
early onset of hypertrophy whilst ablation leads to protection from hypertrophy and 
fibrosis (Hoch et al. 1999)(Zhang et al. 2002)(Backs et al. 2009). Activation of CaMKII 
during cardiac stress results in a broad range of biological effects, including the 
phosphorylation of ion channels (Cav1.2, RyR2, Nav1.5) and Ca2+ handling proteins 
leading to changes in cardiac physiology and Ca2+ homeostasis but it also 
phosphorylates proteins responsible for the regulation of gene transcription (Anderson 
et al. 2011). In terms of gene transcription CaMKII is known to be involved in the 
regulation of many transcription factors including the myocyte enhancer factor 2 
(Mef2), cAMP-response element binding protein (CREB) (Sun et al. 1994), the serum 
response factor (SRF) (Flück et al. 2000) and the activation protein-1 (AP-1) (Antoine et 
al. 1996). Whilst CaMKII is known to directly regulate these factors it is also known to 
play an indirect role in transcription by phosphorylating proteins of the epigenetic 
machinery such as histone deacetylases (HDACs). In a mouse model of heart failure, 
CaMKII activation resulted in the phosphorylation of the repressor HDAC4 triggering its 
exit from the nucleus, leading to chromatin remodelling and Mef2c mediated 
transcription (Figure 1.8). 
Calcineurin is a Ca2+ dependent protein phosphatase composed of a CaM-binding 
catalytic subunit (CnA) and a smaller regulatory subunit (CnB), whilst there are three 
genes known to encode the main catalytic subunit (CnAα, β, γ), the mammalian heart 
only expresses CnAα and CnAβ (Muramatsu et al. 1992) (Klee et al. 1998). Calcineurin 
has been identified as a key regulator of cardiac hypertrophy via the de-
phosphorylation, and nuclear translocation of the nuclear factor of activated T-cells 
(NFAT) transcription factor family, resulting in gene transcription. NFAT transcription 
factors have been shown in genetic mouse models to mediate cardiac hypertrophy 
(Shimoyama et al. 1999)(Wilkins et al. 2002). Transgenic mice which overexpressed 
calcineurin demonstrated a striking hypertrophic response that rapidly progressed to 
dilated heart failure within 2-3months (Molkentin et al. 1998). In terms of calcineurin 
enzyme activity, a number of studies have reported that in various models of heart 
failure that calcineurin enzyme activity increases and have suggested that this is a 
result of abnormal Ca2+ handling at the physiological level (De Windt et al. 2000)(Saito 
et al. 2003)(Zou et al. 2001). In the human, increases in calcineurin activity and 
expression were associated with failing or hypertrophic hearts (Lim & Molkentin 1999). 
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Figure 1.8: Schematic representation of CaMKinaseII and calcineurin signalling. 
CaMKIIδ can acutely regulate ion channels (that carry INa and ICa) and Ca2+ handling proteins 
(RyR2 and phospholamban (PLN)), contributing to triggered arrhythmias such as early and 
delayed after depolarization (EADs and DADs). CaMKII can phosphorylate (P) histone 
deacetylases (HDAC), and calcineurin (CaN) can dephosphorylate nuclear factor of activated T 
cells (NFAT), altering nuclear MEF2- and GATA-dependent transcription, which contribute to 
cardiomyocyte hypertrophy and heart failure (HF). SR, sarcoplasmic reticulum; CaM, 
calmodulin. (Adapted from (Mattiazzi et al. 2015)) 
 
1.4 Thesis rationale, hypothesis and aims 
Given the forming mammalian heart contracts from an early stage, this raises the 
important question of when and how Ca2+ transients in cardiac progenitors are 
initiated during development and to what extent this defines the progression of 
differentiation and subsequent cardiac morphogenesis. Thus far it has been well 
documented that contractions in mice are evident during formation of the linear heart 
tube stage (Navaratnam et al. 1986) (Linask et al. 2001)(Nishii & Shibata 2006), 
whereas historical studies in the rat have described earlier beating, with pacemaker-
like activity observed in lateral regions either side of the embryonic mid-line (Goss 
1952). However, it is difficult to conclusively determine when contraction is initiated 
during heart development due to variation in embryonic staging, as determined by 
somite number or embryonic day, which do not accurately correlate with early cardiac 
crescent through to linear heart tube stages of development (Kaufman & Navaratnam 
1981). As well as difficulties with staging, current studies have not investigated how 
initiation of contractile activity within the cardiac crescent relates to the onset of Ca2+ 
transients at the single cell level. In terms of mechanistic insight, a number of studies 
have performed detailed electrophysiological analysis of immature cardiomyocytes, 
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however, these studies have relied on dissociated ex vivo cardiomyocyte preparations 
from linear heart tubes and, therefore, do not address or represent cardiac crescent 
physiology in vivo.  
The ability of Ca2+ to act as second messenger has been well described in the adult 
heart especially during disease where Ca2+ signalling is known to regulate the 
pathological reactivation of embryonic genes. These studies have begun to correlate 
changes in cardiac function with changes in cardiac gene expression, however, 
deciphering the specific role of individual Ca2+ influx and efflux proteins is difficult due 
to the large global Ca2+ transients which occur with every contraction. By using a 
developmental model in which rapid Ca2+ transients have not yet developed, I 
proposed to dissect out the role of specific Ca2+ handling proteins in cardiac gene 
regulation and provide insight into the correlation between form (cardiomyocyte 
differentiation and morphogenesis) and function (Ca2+-handling and contraction) in the 
heart. This has wider implications for understanding the mechanistic basis for 
congenital heart defects, the pathological progression of both cardiac hypertrophy and 
arrhythmias as well as the establishment of integrated contraction during cell-based 
approaches to myocardial regeneration during post-ischaemic heart disease. 
The aim of this thesis project was to test the hypothesis that early cardiac function is 
required for cardiomyocyte differentiation and heart development via the integration 
of functional Ca2+ influx and Ca2+ signalling pathways. This required analysis of both in 
vivo cardiac crescent formation to determine the onset and mechanism by which early 
Ca2+ influx occurs and in vitro ESC-derived cardiomyocyte differentiation, to examine 
how Ca2+ influx may regulate cardiac gene expression. To this end, I sought to address 
the following:  
(i) The temporal onset of both contractile activity and Ca2+ transients within 
the forming cardiac crescent. 
(ii) To identify and evaluate the channels and exchangers that are required for 
Ca2+ influx during linear heart tube formation. 
(iii) Whether the mechanisms required for Ca2+ influx in contraction also play a 
role in the regulation of cardiomyocyte differentiation. 
(iv) Whether early Ca2+ influx integrates with known Ca2+ signalling pathways to 
regulate gene expression, during early heart development as analogous to 
adult cardiac hypertrophy. 
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2. MATERIALS AND METHODS 
2.1 Mouse strains and husbandry 
Mice were housed and maintained in controlled environment and all procedures were 
carried out according to UK Home Office project licence PPL 30/3155 and 30/2887 
compliant with the UK animals (Scientific Procedures) Act 1986 and approved by the 
local Biological Services Ethical Review Process.  To obtain wild-type embryos C57BL/6 
males were crossed with CD1 females. All mice were maintained in a 12-hour light-
dark cycle.  Noon of the day finding a vaginal plug was designated E0.5.  In order to 
dissect the embryos, the pregnant females were culled by cervical dislocation and 
death was confirmed by exsanguination in accordance with the schedule one of the 
Animal Scientific Procedures Act.   
2.2 Embryo collection 
Embryos were collected and dissected in M2 media (Sigma) at noon of the desired 
embryonic day, as determined by vaginal plug. Embryos were collected for cardiac 
crescent stages 0 – LHT between 23:00 and 03:00 depending on the stage of crescent 
required, although staging was determined after analysis. Embryos were then 
processed for the required protocol: mounted in glass bottom petri dishes for DIC 
imaging; loaded with a Ca2+ sensitive dye for Ca2+ transient imaging; formaldehyde 
fixation for immunofluorescence or histological examination; snap-freezing of hearts 
or whole embryos in liquid nitrogen for RNA extraction. If required, embryos were 
imaged before further processing using a Zeiss SteREO discovery.V8 microscope with a 
Zeiss HRc AxioCam attachment and Zen software (all Carl Zeiss). 
2.3 Embryo Staging 
Given that the stage of cardiac crescent folding and development does not correlate 
precisely with day of embryonic development, or somite stage, progressive crescent 
stages were defined based on morphological criteria (Kaufman & Navaratnam 1981).  
For this purpose the length (left-right axis) and the maximum height (rostral-caudal 
axis) of the cardiac crescent was measured for each embryo. Embryos were considered 
to be at the linear heart tube stage once both sides of the cardiac crescent were 
completely folded and fused. The ratio between width and maximum height 
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measurements (µm) was used to categorise the embryos from stage 0 through to stage 
3 (Table 3.1).  
2.4 Live embryo imaging - Differential Interference Contrast and Ca2+ 
imaging 
Cardiac contraction in the developing cardiac crescent was imaged on freshly dissected 
embryos in a mix of 50% CMRL (Life Technologies) supplemented with 10 mM 
L/glutamine (Sigma-Aldrich) and 50% Knockout Serum Replacement (Life Technologies) 
using Differential Interference Contrast Imaging on a Spinning Disk Confocal 
microscope at 37oC and at an atmosphere of 5% CO2+ Air. Images were acquired at 10 
frames per second (fps) for no longer than 20 seconds. Ca2+ imaging was performed 
using the fluorescent Ca2+ dyes Cal-520 and Rhod-2 AM. Loading of stage 0 to linear 
heart tube embryos was performed with Cal-520 AM (8 µM) and Rhod-2 AM (4 µM) 
cultured in 50% CMRL + 50% Knockout Serum Replacement for 15 min at 37oC and an 
atmosphere of 5% CO2 + Air. The embryos were then transferred to fresh media and 
mounted in glass bottomed MatTek dish (MatTek Corporation) with vacuum grease 
and imaged on a Zeiss 710 LSM confocal microscope at 10 fps with a 20x, 0.6 NA Air 
Objective. For acute inhibition studies, Ca2+ transients were first imaged at baseline 
before drug-containing media was added. Imaging was performed at 5, 15 and 30 min 
post drug treatment. Treatments included control (DMSO only), nifedipine (10 µM; 
Sigma) and 3-Amino-6-chloro-5-[(4-chloro-benzyl)amino]-N-[[(2,4-dimethylbenzyl)-
amino]iminomethyl]-pyrazinecarboxamide (CB-DMB) (20 µM; Sigma), all treatments 
contained the same concentration of DMSO.  
2.5 Embryo Culture 
Embryos were cultured in the presence of drugs (CB-DMB or nifedipine) for 12 h, from 
E7.25 prior to cardiac crescent formation using a rolling culture system (Cockroft & 
Copp 1990). Embryos were cultured in a mix of 50% CMRL and 50% Knockout Serum 
Replacement at 37oC and with an atmosphere of 5% CO2+ Air. After culture, embryos 
where imaged using a Moticam camera (Motic) before being snap frozen for RNA 
isolation or fixed in formaldehyde for staining. 
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2.6 Embryonic stem cell culture  
Nkx2.5-GFP and Eomes-GFP ESCs were maintained in an undifferentiated state by 
culturing with KO-DMEM supplemented with  2 mM glutamax , 15% embryomax FBS 
(Millipore), 0.1 mM non-essential amino acids, 1% penicillin - streptomycin (10,000 
U/ml penicillin; 10,000 µg/mL streptomycin stock), 0.1 mM β-mercaptoethanol (Sigma) 
and 1000 U/ml Leukaemia inhibitory factor (Millipore). Cells were maintained in a 
humidified atmosphere of 5% CO2 at 37
oC and media was replaced every day. ESCs 
were passaged at 70-90% confluence every 2 days using 0.25% trypsin. All cell culture 
reagents were from Invitrogen unless otherwise stated. 
2.7 Embryonic stem cell cardiomyocyte differentiation  
Cardiomyocyte differentiation from ESCs was carried out as previously described using 
Nkx2.5-GFP (S. M. Wu et al. 2006) and Eomes-GFP (Arnold et al. 2009) cell lines. 
Differentiation was induced using the hanging drop culture method (Chen et al. 2011). 
Undifferentiated ESCs were dissociated using 0.25% trypsin and counted using a 
haemocytometer after being re-suspended in differentiation media containing; 25 mM 
glucose/DMEM, 20% embryomax FBS, 0.1 mM nonessential amino acids, 1% penicillin 
– streptomycin (10,000 U/ml penicillin; 10,000 µg/mL streptomycin stock), 0.1 mM β-
mercaptoethanol. Approximately 500 ESCs were plated in 20 μl drops of differentiation 
on the lids of petri dishes (contained warm PBS) using a 50 μl multi-channel pipette 
and cultured in a humidified atmosphere of 5% CO2 at 37oC as hanging drops 
throughout the first 4 days of differentiation, allowing embryoid bodies (EBs) to form. 
At day 4, the EBs were plated onto 0.1 % gelatin coated plates for a further 10 days of 
culture before collection at day 14 of differentiation.  1 µM CB-DMB and 10 µM 
nifedipine were added to the differentiation media at day 0. For control experiments, 
DMSO was added at the same concentration found in the drug containing media. Once 
the EBs had been plated at day 4, drug-containing media was changed every 2 days up 
until day 14. For immunostaining, ESCs were cultured on 0.1% gelatin coated glass 
coverslips before being fixed with 3.7% PFA for 30 minutes on ice. For RNA isolation 
tissue samples were dissociated for 2 min using 0.25 % trypsin-EDTA at 37 oC prior to 
snap freezing. All imaging was performed with a Zeiss Axio Vert.A1 epi-fluorescent 
microscope with a Zeiss HRc AxioCam attachment and Zen software (Carl Zeiss) 
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allowing bright field assessment of EB beating and cell outgrowth as well as fluorescent 
assessment of Nkx2.5-GFP expression. 
2.8 Hanging drop model development 
The hanging drop method of differentiation is both well established and widely used in 
the formation of ESC derived cardiomyocytes (Boheler et al. 2002). Whilst establishing 
the model a number of steps were taken to establish a robust protocol. Two of the 
major variables known to influence ESC cardiomyocyte differentiation are the starting 
number of cells and serum. To determine the optimum number of initial cells per 20 μl, 
hanging drops were created with varying numbers of cells (500, 800 and 1000) per 
drop. Using the Nkx2.5-GFP cell line as a direct read out of cardiomyocyte 
differentiation, 500 cells per drop led to the largest amount of cardiomyocyte 
differentiation. Another key variable was serum; I tested the effect of two different 
serum types, embryomax serum and normal serum on cardiomyocyte differentiation 
with embryomax serum being the best in terms of Nkx2.5-GFP expression and EB 
morphology. It is important to note that batch variation may have led to variation in 
speed and efficacy of differentiation, thereby affecting the gene expression profiles 
between experiments. Therefore, to account for possible variation, multiple 
experimental repeats were conducted using different serum batches although the 
same batch was used throughout each individual experiment.  
In our initial experiments using the Nkx2.5-GFP ESC line, I assessed time points at days 
0, 2, 4, 7, 10 and 14, however it became apparent that for future studies it would be 
informative to increase the number of time points over which specification and 
differentiation of cardiomyocytes occurred. Therefore samples were collected daily 
from days 2-7 when using the Eomes-GFP ESC line, allowing more precise 
determination of the timing of changes in cardiac genes. 
2.9 Inhibitor experiments with ESC-derived cardiomyocyte 
To conduct bright field inhibitor experiments, ESCs were cultured in hanging drops for 
4 days before 1 EB was plated per well of a 0.1% gelatin coated 48 well plate (Falcon) 
with 250 µl differentiation media. Imaging was then conducted at days 7 and 14 of 
differentiation using a Zeiss Axio Vert.A1 epi-fluorescent microscope with a Zeiss HRc 
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AxioCam attachment and Zen software to record brightfield movies of cardiomyocyte 
beating. Initial recordings were taken at baseline before the same wells were re-
imaged 30 min later after the addition of drug (10 µM nifedipine; 10 µM CB-DMB; 30 
µM KB-R7943), or vehicle (DMSO).  
2.10 Chemical reagents 
3-Amino-6-chloro-5-[(4-chlorobenzyl)amino]-N-
[(2,4dimethylbenzylamino)(amino)methylene-2-pyrazinecarboxamide (CB-DMB, 
Sigma) was stored at -80oc as a stock concentration of 10 mM in DMSO and used at a 
final working concentration as stated.  KB-R7943 (Tocris) and SN-6 (Tocris) were stored 
as a stock concentration of 100 mM in DMSO at -20oc and diluted to final working 
concentrations of 10 µM and 30 µM, respectively. Nifedipine (Sigma) was stored at a 
stock concentration of 100 mM in DMSO at -20oc and used at a final working 
concentration of 500 nM and 10 µM. Ned-K and Ned-19 were also kept at a stock 
concentration of 100 mM in DMSO at -20oc but used at a working concentration of 30 
µM. All Ned compounds used in this study were kindly supplied by Dr Raj Gosain, 
School of Chemistry, University of Southampton. 
2.11 Imaging of Ca2+ in ESC-derived cardiomyocytes 
To image Ca2+ transients in ESC-derived cardiomyocytes, ESCs were cultured in hanging 
drops for 4 days before ~10 EBs were plated onto 0.1% gelatin coated 35 mm glass 
bottomed MatTek dishes with 1 ml of differentiation media.  At day 7 the cells were 
loaded with 8 µM Cal-520-AM for 20 min in media without serum at room 
temperature before being transferred to 37 oC and an atmosphere of 5% CO2 + air for a 
further 10 min. After this, the dye-containing media was removed and differentiation 
media containing serum was added before imaging. Inhibitor experiments were 
conducted on embryos as previously described, with a baseline recording taken prior 
to addition of drug-containing media, subsequent recording were taken after 5, 15 and 
30 min incubation. All Ca2+ imaging was performed with the Zeiss 710 LSM at 10 fps 
with a 20x, 0.6 NA air objective.  
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2.12 Cardiomyocyte isolation 
Single ventricular myocytes were isolated from C57BL/6 mice aged between 3 – 4 
months. Mice were killed by cervical dislocation before their hearts were quickly 
removed and the coronary arteries retrogradely perfused via the aorta with a 
physiological salt solution (PSS) containing (mM): NaCl 134, KCl 4, MgSO4 1.2, NaH2PO4 
1.2, Glucose 11.1 and HEPES 10 (pH 7.34 with NaOH at room temperature) using a 
Langendorff perfused heart apparatus. The hearts were initially perfused at 37 oC for 5 
min with PSS before collagenase type 2 and protease type 14 were added to achieve a 
final collagenase concentration of 0.3 mg ml-1 and a protease concentration of 0.04 mg 
ml-1. After 6.3 min of digestion, the ventricles were perfused for 10 min with a taurine 
solution containing (mM): NaCl 115, NaH2PO4 1.2, KCl 4, MgSO4 1.2, CaCl2 0.1, taurine 
50, glucose 11.1, HEPES 10 (pH 7.34 with NaOH at room temperature). The tissue was 
then minced and single myocytes were obtained by filtering it through 200 µm nylon 
mesh. Cells were then incubated in taurine solution for 20 min allowing the cells to 
pellet. The supernatant was then removed and the cells were re-suspended in taurine 
solution at room temperature before being plated onto laminin-coated coverslips and 
allowed to attach for 2 h. Dead and non-adhered cells were then removed by rinsing. 
2.13 OCT Cryo-embedding and cryosectioning of embryos 
E12.5 Embryos were dissected as described and then fixed in 4% formaldehyde/PBS for 
2 h on ice, before being washed in PBS and equilibrated in 30% sucrose (VWR) in PBS 
overnight at 4 oC. Samples were then transferred to a 50:50 solution of 30% sucrose 
and OCT (Thermo Scientific Raymond Lamb) and left to rotate at room temperature for 
30 min. Embryos were then embedded on their backs in plastic moulds using OCT and 
frozen in a dry ice and ethanol bath. 7 μm sections were cut using a Bright Model OTF 
cryostat with 5040 Microtome (Bright Instruments), collected on SuperFrost Plus slides 
(VWR) and stored at - 80 oC until use. 
2.14 Immunofluorescence of whole mount embryos  
To perform whole-mount immunofluorescence, dissected embryos were fixed in 4% 
formaldehyde/PBS for 1 hour at room temperature. The embryos were then washed 3 
times in PBT-0.1% (PBS containing 0.1% Tween-20) for 15 min, permeabilised in PBT-
0.25% for 40 min and washed again 3 times in PBT-0.1%. The embryos were 
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transferred to blocking solution overnight at 4oC.  Primary antibodies (Table 2.1) were 
then added to the solution and incubated o/n at 4oC. The embryos were washed 3 
times in PBT-0.1% and incubated overnight 4 oC in PBT-0.1% with the secondary 
antibodies (Table 2.2), then subsequently washed 3 times with PBT-0.1% for 15 min 
and mounted in Vectashield with 4',6-diamidino-2-phenylindole (DAPI; Vectalabs) for 
at least 24 h at 4 oC before imaging using a Zeiss 710 LSM.   
2.15 Immunostaining of cryosections 
Cryosections were processed for immunofluorescence by 2 x 5 min PBS washes to 
remove OCT. The staining area was then outlined with an ImmEdge™ pen (Vector 
Laboratories) before samples were permeabilised with 0.5% Triton X-100 (Sigma) in 
PBS for 5 min. After permeabilisation, sections were blocked for 1 h at room 
temperature with 10% serum (goat or donkey, depending on the species in which the 
primary and/or secondary antibodies were raised, both Sigma), 1% BSA (Sigma) in 0.1% 
Triton X-100/PBS. Incubation with primary antibody, diluted in blocking solution, was 
carried out in a humidified chamber overnight at 4oC. Following 3 x 5 min washes with 
0.1% Triton X-100/PBS, sections were incubated with AlexaFluor secondary antibodies 
(Invitrogen, 1:200) diluted in blocking solution for 1 h  at room temperature. A further 
5 x 5 min PBS washes were performed, the penultimate containing DAPI (Cell Signalling 
Technology) before mounting in 50% glycerol: PBS. Imaging was performed using a 
Leica SP5 confocal microscope. In all experiments, negative controls for each 
secondary antibody (no primary antibody) were included to confirm the specificity of 
the signal. 
2.16 Immunofluorescence of ESC-derived cardiomyocytes 
ESC-derived cardiomyocytes grown on glass coverslips at different stages of 
differentiation or unattached EBs were processed for immunofluorescence by removal 
of growth media, washing in PBS, and fixation in 4% formaldehyde (Sigma) in PBS for 
20 min at room temperature. After fixation ESC samples were rinsed with PBS before 
being permeabilised with 0.1% triton X-100/PBS for 10 min, followed by blocking with 
10% goat serum, 1% BSA in 0.1% Triton X-100/PBS for 1 h. Incubation with primary 
antibodies, diluted in blocking buffer, was carried out overnight at 4 oC.  After 
incubation with primary antibodies samples were washed 3 times for 10 minutes with 
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0.1% Triton X-100/PBS and then incubated with secondary antibodies (Supplementary 
Table 2), diluted in blocking buffer for 1 h at room temperature. After incubation with 
the secondary antibodies, samples were washed 5 times for 5 minutes in PBS. Samples 
were mounted using Vectashield mounting media with DAPI 24 hours before imaging 
using a Zeiss 710 LSM. In all experiments, negative controls for each secondary 
antibody (no primary antibody) were included to confirm the specificity of the signal. 
2.17 RNA extraction using RNAeasy Micro kit 
For ESCs (sample sizes of < 1 x106 cells), E7.5- E8.5 embryos and for hearts from E9.5 – 
E12.5, RNA extraction was performed using the Qiagen RNeasy Plus Micro Kit, as per 
manufacturer’s instructions. Cell or tissue pellets were homogenised in lysis buffer 
containing guanidine-thiocyanate and β-mercaptoethanol, which inactivate RNases, 
using a 21G needle and 1 ml syringe. Homogenate was initially centrifuged through 
gDNA eliminator spin columns to remove genomic DNA from the samples. Lysates, in 
the presence of ethanol, were next loaded onto the spin columns which contained 
RNA binding silicon membranes. Contaminants were then removed in a series of wash 
steps before RNA was eluted into clean Eppendorf tubes using RNase-free water. The 
concentration and purity was determined using a Nanodrop-2000 (Thermo Scientific) 
spectrophotometer, by measuring absorbance at 260, 280 and 230 nm. 
2.18 RNA extraction using Trizol 
For hearts from embryos older than E12.5, RNA extraction was performed using Trizol 
(Invitrogen). RNA extraction from adult hearts required hearts to be powdered using 
liquid nitrogen and a pestle and mortar. 1 ml Trizol was added to the samples before 
using a 21G needle and a 1 ml syringe to homogenise the cell pellet/tissue. To allow 
complete dissociation of nucleoprotein complexes, homogenised samples were left for 
5 min at room temperature. After 5 min, 200 μl chloroform (VWR) was added and the 
samples were vigorously mixed for 15 s before being incubated for 15 min at room 
temperature. The Trizol/Chloroform mix was next centrifuged at 12,000 x g for 15 min 
at 4 oC allowing the aqueous phase (containing the total RNA fraction) to be collected 
and transferred into a clean 1.5 ml tube. RNA was precipitated by the addition and 
mixing of isopropanol and left to proceed overnight at -20 oC. The precipitated RNA 
was pelleted by centrifugation at 12,000 x g for 10 min at 4 oC before removal of the 
45 
 
supernatant. Pellets were then washed in 1 ml 75% ethanol in Diethyl Pyrocarbonate 
(DEPC) treated water to inactive RNases, before being re-pelleted at 7,500 x g for 5 
min at 4 oC, and resuspended in RNase-free water. The concentration and purity of 
RNA was determined by Nanodrop-2000 as above. 
2.19 cDNA synthesis from extracted RNA 
Reverse transcription was performed on samples containing 1 μg total RNA. Initially, a 
pre-cDNA reaction containing 1 μl dNTPs (10 mM of each dNTP; Promega), 0.5 μl 
random primers (Promega), 1 μg RNA and RNase-free water (total reaction volume 
equalled 10 μl) was incubated for 5 min at 65 oC before being cooled to 4 oC. After 
incubation, 4 μl 5 x First Strand Buffer (Invitrogen), 2 μl 0.1 M DTT (Promega), 2 μl 25 
mM MgCl2 and 1 μl RNasin Plus RNase Inhibitor (Promega) was added to each reaction 
and the samples were incubated at 25 oC for 2 min before addition of 1 μl SuperScript 
III Reverse Transcriptase (Invitrogen). Samples were then incubated at 25 oC for 10 min, 
42 oC for 50 min and 70 oC for 15 min, before being cooled to 4 oC. cDNA was then 
diluted in water to a final concentration of 4 ng/μl and stored at -20 oC until use. 
2.20 Real-time PCR 
The expression of mRNAs for genes of interest (Table 2.3), together with endogenous 
controls HPRT and/or GAPDH were measured by quantitative real-time PCR using SYBR 
Green (Applied Biosystems). Each reaction contained: 8 ng cDNA, 0.5 µl of each primer, 
6.5 µl water and 12.5 µl 2 x SYBR Green, made up with H2O to a final volume of 22 µl. 
Primers were either designed using Primer-BLAST (National Center for Biotechnology 
Information, National Institutes of Health) or obtained from PrimerBank 
(http://pga.mgh.harvard.edu/primerbank) or previous publications. Where possible, 
primers were designed to span exon-intron boundaries to prevent any remaining 
genomic DNA from being amplified, have annealing temperatures around 60 oC and 
generate amplicons between 50 bp - 200 bp. The reaction mixture and samples were 
loaded into either a MicroAmp Optical 96-Well Reaction Plates or MicroAmp Fast 
Optical 96-Well Reaction Plates and sealed with Optical Adhesive Films (all Life 
Technologies). Quantification was performed using either an ABI Prism 7000 Sequence 
Detector or a ViiA 7 Detection System (both Applied Biosystems) using a PCR 
programme of 95oC 15 minutes followed by  40 cycles of  (95oC 15 s melting phase and 
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60 oC 1 min annealing and extension).  Amplification of a single amplicon was 
confirmed by obtaining dissociation curve (melt curve) profiles as well as using gel 
electrophoresis to separate the reaction product. Cycle threshold (Ct) values were 
generated using either RQ Manager V1.2 or Viia7 software (both Applied Biosystems). 
Relative gene expression levels were obtained using the ΔΔCt method, in which 
expression of each gene of interest was normalised to Hprt and/or Gapdh (Murphy & 
Polak 2002), and presented as fold change over a reference sample. Non-template 
controls were performed by replacing cDNA with water, to test for non-specific 
amplification.   
 
Figure 2.1: Representative real-time PCR amplification and dissociation curve traces 
Representative plot of SYBR Green flurosecent signal (Rn = Reporter signal normalised to ROX 
dye) during RT-PCR amplification, detailing the increase in reporter singal/amplification as the 
number of PCR cycles increase (*= Non-template control). Insert, representative trace of a 
dissociation curve, highlighting the formation of a single peak and representing the production 
of a single amplicon.  
2.21 Protein extraction from cells 
To prepare protein samples for Western blot analysis, cell culture medium was 
removed and the cells were washed once with PBS. Protein was extracted on ice using 
direct lysis of cells with NP-40 extraction buffer (150 mM NaCl, 1.0% NP-40, 50 mM Tris 
(pH8.0)) and 1x protease and phosphatase inhibitor cocktail (Roche). Lysates were 
collected into pre-cooled 1.5 ml microcentrifuge tubes and incubated on ice for 20 min 
before being centrifuged at 10,000 rpm for 20 min at 4 °C and the supernatant 
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collected and stored at -20 oC. Before freezing a 10 µl aliquot was taken for protein 
quantification. Protein was quantified using the calorimetric DC protein assay which is 
based on the reaction of protein with an alkaline copper tartrate solution and Folin 
reagent (Bio-rad).  
2.22 SDS-PAGE and Western blot analysis 
Protein sample supernatants were prepared for SDS-PAGE analysis by the addition of 
4x Laemmli Buffer containing 5% β-mercaptoethanol and boiling at 95 oC for 5 mins, in 
order to reduce and denature the sample (Laemmli 1970). Samples were quenched 
briefly on ice and then 20 µg of protein was loaded into a pre-cast 4-20% gradient SDS-
PAGE gel (Biorad). A 4-20% gradient gel was used so that a wide range of protein sizes 
could be detected on a single gel. In order to make the protein bands run straight all 
20 µg samples were made up to a maximum volume of 30 µl using 1x Laemmli buffer.  
A Precision Plus Protein Kaleidoscope (Biorad) ladder was included alongside samples 
so that protein size could be assessed. Electrophoresis was performed at 150 V for ~45 
min before being electrotransferred (150 mA, 90 min) onto PVDF membranes pre-
activated in methanol. Efficient transfer was assessed using Ponceau S solution. 
Membranes were then washed in TBS + 0.1% Tween-20 (Sigma; TBS-T)  to remove 
Ponceau S and blocked for 1 h with 5% skimmed dry milk dissolved in TBS-T before 
incubation with primary antibodies diluted in blocking buffer overnight at 4 oC. 
Following 2 x 10 min and 3 x 5 min washes with TBS-T, membranes were incubated 
with HRP-conjugated secondary antibodies (1:2500 in blocking buffer; GE Healthcare) 
for 1 h at room temperature. Following further TBS-T washes, immunodetection was 
performed using the enhanced chemiluminescence kit (ECL, GE Healthcare) and a 
Chemidoc imaging system (BioRad). To re-probe membranes with a second antibody, 
the first antibody was striped for 15 minutes at room temperature using a glycine 
stripping solution (200 mM glycine, 3.5mM SDS, 1% Tween20, pH 7.2) before rinsed 
with TBS-T and re-probed. 
2.23 Image Analysis 
Tissue motion was visually enhanced using an absolute difference image filter in order 
to plot measurements of cardiac contractions in the developing cardiac crescent: 
 (     )   [ (     )              ] where  (     ) is the intensity of a pixel 
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located at position x,y for frame j, and  (         ) is the same intensity of the same 
pixel N frames prior (Chen et al. 2015). In summary, pixel displacement, indicative of 
contractions, was visualized and represented by increasing grey levels within the 
crescent. Change in pixel intensity was assessed in a selected region, to reveal the 
contraction dynamics. To normalize the Ca2+ transients, background signal was 
subtracted from all frames of a given movie using ImageJ.  
2.24 Statistics 
All data involving beat rate and qPCR gene levels were compared using one-way 
ANOVA followed by a Tukey test for multiple comparisons.  In cases where the raw 
data failed to map to a normal distribution with consistent variance, we performed a 
log transformation and tested the assumptions for the transformed data. To compare 
the number of affected embryos upon acute treatments, a Freeman-Halton extension 
of Fisher exact probability test was applied due to a smaller number of samples. To 
compare the effect of different treatments on the number of beating EBs, due to a 
large number of samples, a Chi Square test with a Bonferroni correction for multiple 
comparisons was performed instead. Principal Component Analysis (PCA) was carried 
out to directly compare temporal gene expression data from EBs with that derived 
from embryos, the data of each sample was normalized by assessing the ratio with the 
maximum value of all samples. A log transformation was applied to the normalized 
data and the principal components were calculated using R environment. The 3D 
representation of the PCA was constructed by plotting the 3 first components given 
that these explained more that 95% of the observed variance.  A hierarchical clustering 
analysis was performed using Ward’s minimum variance method (Ward 1963). 
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 2.25: Primary antibodies 
Table 2.1: Primary antibodies 
Applications: WB: western blotting; IF-Fr: immunofluorescence of frozen/cryo-embedded 
sections; ICC: immunocytochemistry; IF-WM: Immunofluorescence of whole-mount tissue. 
  
Antigen Host Species Company Dilution (application) 
Brachyury (C-19) Goat Santa Cruz 1:200 (ICC, IF-WM) 
CamKII (H-300) Rabbit Santa Cruz 1:500 (WB) 
Cardiac α-actinin (EA-53) Mouse Sigma 1:500 (ICC, IF-Fr) 
Cardiac TnT (1C11) Mouse Abcam 1:200 (IF-WM, ICC) 
Cav1.2 (H280) Rabbit Santa Cruz 1:100 (ICC, IF-WM) 
Connexin 43 Rabbit Zymed 1:200 (IF-WM) 
Gapdh (6C5) Mouse Abcam 1:10000 (WB) 
GFP Chicken Abcam 1:1000 (ICC) 
NCX (π-3) Rabbit Swant 1:200 (ICC, IF-FR, IF-WM) 
pCamKII (T286) Rabbit Abcam 1:500 (WB) 
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2.26: Secondary antibodies 
Table 2.2: Secondary antibodies 
  
Antigen Host Species Company Dilution 
Mouse-488 Goat Life Technologies 1:200 
Rabbit-488 Goat Life Technologies 1:200 
Goat-488 Donkey Life Technologies 1:200 
Mouse-555 Donkey Life Technologies 1:200 
Mouse-594 Goat Life Technologies 1:200 
Rabbit-594 Goat Life Technologies 1:200 
Phalloidin Atto-647 N/A Sigma 1:100 
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2.27: Primers for Quantitative RT-PCR 
Table 2.3: qRT-PCR Primer sequences and amplicon length. 
 
Gene  Forward Primer (5’-3’)  Reverse Primer (5’-3’)  Amplicon (bp) 
Gapdh 
Hprt 
Oct-4  
Nanog 
Brachyury  
Gooscoid 
Mesp1 
Gata-4 
Nkx2.5 
Mef2c 
Myh6 
Myh7 
Tnnt2 
Sox17 
Gfap 
Slc8a1 
Slc9a1 
Cacna1c 
Cacna1g 
Ryr2 
Atp2a2 
Atp1a2 
Scn5a 
Itp3r2 
Trpc3 
Stim1 
Orai1 
Tpcn1 
Tpcn2 
Camk2d 
Ppp3ca 
Calm1 
Calm2 
Calm3 
NFAT 
AGGTCGGTGTGAACGGATTTG 
TCAGTCAACGGGGGACATAAA 
TGGAGGAAGCCGACAACAATGAGA 
CCCTTCCCTCGCCATCACACTG 
CATGCTGCCTGTGAGTCATAA 
GAAGCCCTGGAGAACCTCTT 
GTCTGCAGCGGGGTGTCGTG 
CCCTACCCAGCCTACATGG 
CTATGCCCTGTCCCTCAGAT 
ACTGGGAAACCCCAATCTTC 
GCTGGCTGGAAAAGAACAAG 
ACTGTCAACACTAAGAGGGTCA 
CAGAGGAGGCCAACGTAGAAG 
GGAACCTCCAGTAAGCCAGAT 
TGCAAGAGACAGAGGAGTGGT 
GGACCAACAGCTGGAGAGAG 
CGCCATCATCACCGTCATCT 
GGAGGGCGTGCATAAGCATT 
TGTCTCCGCACGGTCTGTAA 
ATTATGAAGGTGGTGCCGTATCA 
TGGGCAAAGTGTATCGACAG 
GAATGGGTTCTACCATCGCG 
CCGCCTTGGACCAAATATGTT 
TCATCATCGCCTTGATTCTG 
TCGACTACCCCAAGCAAATC 
TGACAGGGACTGTACTGAAGATG 
AACGAGCACTCGATGCAGG 
CATGAACTACAGCCGCAAGA 
GAAGCACAGGACCAGGAGAG 
CTGGCACACCTGGGTATCTT 
CTGGCTGCGCTAATGAACCA 
TGCTCCGTTCTTCCTTCCTT 
GGGCGGAGGAGGAGAATTAG 
AGGCCGACATTGATGGAGAT 
TCATCCTGTCCAACACCAAA 
TGTAGACCATGTAGTTGAGGTCA 
GGGGCTGTACTGCTTAACCAG 
TGGCGATGTGAGTGATCTGCTGTA  
GGAAGGGCGAGGAGAGGCAGC 
TGTCTGGGAGCCTGGGGTGAT 
ATCGCTTCTGTCGTCTCCAC 
CGGCGGCGTCCAGGTTTCTA 
ACATATCGAGATTGGGGTGTCT 
CTCCCGGTCCTAGTGTGGAA 
ATCAGACCGCCTGTGTTACC 
TCTTGCCTCCTTTGCCTTTA 
TTGGATGATTTGATCTTCCAGGG 
CTCCATCGGGGATCTTGGGT 
GAGGTGCTGCTCATTGTATCC 
GCGATAGTCGTTAGCTTCGTG 
GGCAAACAGAACCTTCCAGA 
GGTGGTCCAGGAACTGTGTG 
AGGAAGAGATACTCCACTCGTTC 
AGATACCCAAAGCGACCATCTT 
TTCCACTCCACGCGACTCTTA 
CAGCAGGAACTTTGTCACCA 
GCACAGAACCACCACGTGAC 
TGACCAGAGACTCAAAGGTGT 
CAGTTCCCTGGGTCTCATGT 
CTCCTTGCACTCAGACCACA 
TATGCCGAGTCAAGAGAGGAG 
GGGTAGTCATGGTCTGTGTCC 
CCTCGCTCCTCACGATAAAG 
AAAGGCCCGGTTCTGAGTAT 
ATCCCAGAAGGGTGGGTATC 
GGTCTGACCATAGGATGTCACAC 
TTCCTTGGTTGTGATGGTGC 
CTTCAGTCAGTTGGTCAGCC 
AAGAGATCAGGAGAACGGGC 
TCACCCTGGTGTTCTTCCTC 
101 
122 
148 
172 
83 
144 
189 
118 
139 
92 
125 
91 
119 
87 
110 
152 
143 
160 
184 
88 
108 
177 
64 
170 
88 
85 
129 
117 
92 
125 
123 
126 
108 
108 
110 
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3. CHARACTERISATION OF CARDIAC FUNCTION DURING HEART 
DEVELOPMENT 
3.1 Introduction 
It has been well documented that the mammalian heart begins to contract from an 
early stage, raising the important question of how and when the initiation of function 
occurs and to what extent this defines and influences the progression of differentiation 
and subsequent cardiac morphogenesis.  
Formation of the mouse heart begins at around embryonic day (E) 7.5, from 
mesoderm-derived cardiac progenitor cells located in the cardiac crescent, the first 
morphologically recognisable heart structure (Buckingham et al. 2005). From E7.5 
cardiac progenitors migrate to form a linear heart tube, which goes on to develop into 
the mature septated four chambered heart. Cardiac contractions are widely held to 
begin with the formation of the linear heart tube between E8.0 and E8.5 (Navaratnam 
et al. 1986)(Linask et al. 2001)(Nishii & Shibata 2006), but observations from our 
collaborators, the Srinivas lab, have shown that the cardiac crescent is contractile at 
stages earlier than previously documented. Further observations during this 
collaboration revealed single cell slow Ca2+ waves within the cardiac crescent prior to 
the onset of contraction, at around E7.75. In order to study how these early Ca2+ 
transients may influence cardiomyocyte specification and formation, an embryonic 
stem cell (ESC) model of cardiomyocyte differentiation was used, which recapitulated 
heart development in vivo. ESC - derived cardiomyocytes have provided unique 
developmental models for understanding the genetic and epigenetic regulation of 
cardiogenesis and will allow mechanistic insight into the relationship between cardiac 
contractions coincident with cardiomyocyte specification. In terms of cardiac 
differentiation, the stages of cellular specification and commitment have been well 
characterized by the expression of specific genetic markers (Van Vliet et al. 2012). 
Using these well-defined markers it is possible to study and track the induction and 
patterning of mesoderm from pluripotent stem call progenitors as well as the 
specification and maturation of cardiac progenitors.  
In this chapter, I will describe two different models of heart development; In vivo 
formation of the murine cardiac crescent as well as in vitro ESC cardiomyocyte 
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differentiation. Using these models I will characterise and compare formation of the 
cardiac crescent as well as ESC cardiomyocyte differentiation in terms of morphology, 
gene expression and function. Additionally, early calcium dynamics will be investigated 
using confocal imaging of ex vivo embryos and ESC-derived cardiomyocytes.   
3.2 Results 
3.2.1 Morphology and sarcomeric formation during heart development 
In the heart, cardiomyocytes are the contractile cell type which allows it to perform its 
essential function; to supply the body with sufficient oxygen and nutrients. To achieve 
this, cardiomyocytes have a highly defined cellular phenotype and function, which 
becomes established during development.  
To define cardiomyocyte phenotype during development, mouse hearts where imaged 
from the onset of cardiac crescent formation. When trying to assess formation of the 
cardiac crescent it became apparent that conventional staging methods did not 
accurately correlate with specific temporal changes during heart development, instead 
they represented a range of cardiac morphologies. To precisely characterise formation 
of the early heart, a system was established which was independent of conventional 
methods such as somite number or embryonic day. Staging was assessed by measuring 
both the width and the height of the cardiac crescent (Table 3.1). 
 
 
Table 3.1: Staging criteria of early heart development according to formation of the 
cardiac crescent 
  
Stage Width/µm Maximum 
Height/µm 
Width/Height 
Ratio 
Somites Embryonic Day 
0 360 - 390 70 - 80 4.5 - 5.5 0 - 2 E7.5 - E8.0 
1 300 - 370 70 - 95 3.0 - 4.2 1 - 3 E8.0 - E8.25 
2 230 - 280 95 - 120 2.0 - 2.8 2 - 4 E8.0 - E8.5 
3 200 - 230 120 - 140 1.5 - 1.8 3 - 5 E8.25 - E8.5 
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As the crescent matured, the width-to-height ratio decreased with the formation of 
the linear heart tube. This value roughly correlated with ranges in somite number and 
embryonic day. The earliest recognisable cardiac crescent could be located between 
the midline and the head folds at stage 0 (Figure 3.1 a). In terms of size, the stage 0 
cardiac crescent was between 360-390 µm in width and 70-80 µm high, with a large 
width to height ratio around 5. As the heart developed, the height-to-width ratio 
decreases to around 1.65 at stage 3, with the  width of the crescent between 200-230 
µm and height around 120-140 µm. Positive immunostaining for cardiac TnT (cTnT) 
was evident at the earliest stage 0 crescent with expression detected at the cell 
membrane, albeit without corresponding sarcomeric banding (Figure 3.1 a-e). 
Sarcomeres manifested later in discrete regions within stage 1 and 2 crescents, 
indicative of functional cardiomyocytes. Subsequent sarcomere assembly and 
myofibrillar banding became more ordered by stage 3, and increased through to the 
linear heart tube stage, consistent with increased cardiomyocyte maturation (figure 
3.1 g). 
These results revealed that contractile proteins required for cardiac function are 
expressed and organised at the earliest stages of crescent formation and prior to the 
onset of contraction. To more accurately correlate changes during early heart 
development a novel staging method was also defined and characterised. 
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Figure 3.1: Early mouse heart formation and sarcomeric assembly during embryonic 
development 
Maximum intensity projections of cardiac troponin (cTnT) immunostaining revealed 
progressive differentiation and sarcomeric assembly during stages of cardiac crescent through 
to linear heart formation (Stage 0 (a); Stage 1 (b); Stage 2 (c); Stage 3 (d); LHT(e)). Data 
contributed by Antonio A. M. Miranda. Brightfield image of adult mouse heart (f) and 
immunostaining of α-actinin to visualise sarcomere expression in an isolated, adult mouse-
cardiomyocyte (g). Brightfield image of E7.75 embryo (h). cc, cardiac crescent; hf, head folds; 
ml, midline. Scale bars: a-e, top panel 100μm, bottom panel 10μm; f, 500 μm; g, 25μm; h, 
250μm. 
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Figure 3.2: Expression and formation of the sarcomere M-band 
Maximum intensity projections of immunostaining revealed a progressive increase in the M-
band localised protein Myomesin. Myomesin was absent from the stage 0 cardiac crescent 
however became expressed within stage 1 cardiac crescents and revealed the assembly of 
sarcomeres as the cardiac crescent  developed through to linear heart formation (Stage 0 (a); 
Stage 1 (b); Stage 2 (c); Stage 3 (d); LHT(e)). Scale bars: a-e, 100 μm and a’-e’’, 50μm. 
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3.2.2 Onset of cardiac contraction within the developing heart  
It has been documented that rhythmic cellular contractions in mice are evident prior to 
formation of the linear heart tube (Goss 1952). Historical studies in rats have described 
beating even earlier, with pacemaker-like activity observed in lateral regions of the 
embryonic midline (Hirota et al. 1985). Using differential interference contrast (DIC) 
microscopy, our collaborator Shankar Srinivas has observed the onset of beating in 
discrete foci on both the left and right lateral regions of stage 1 cardiac crescents, 
coincident with sarcomeric banding and earlier than previously described (unpublished 
work). The initial rate of contraction at stage 1 was around 30 beats per minute (bpm), 
increasing slightly to 38 bpm by stage 2 with contractions now occurring across the 
whole crescent (Figure 3.3 a). The discrete beating foci observed at stage 1 contracted 
at the same rate, indicative of either synchronisation or a shared intrinsic contractile 
rate (Figure 3.4 a, b). As the cardiac crescent matured towards the linear heart tube 
there was a significant increase in rate of contraction to around 50 bpm at stage 3, 
whilst the linear heart tube was beating around 60 bpm. To further investigate the 
development of cardiac contraction, live-imaging was used to visualise Ca2+ transients 
within the forming cardiac crescent (Figure 3.3 b). In stage 1 cardiac crescents lateral 
propagation of Ca2+ transients, initially from left to right, was observed across the 
embryonic midline and even through regions of non-contractile tissue, despite the 
absence of, Connexin 43 (Cx43) expression (Figure 3.4 c). In the adult, Cx43 electrically 
couples cardiomyocytes via the formation of gap junctions allowing the action 
potential to propagate quickly between cells. To assess the dynamics of these early 
Ca2+ waves, the time to peak (TTP) fluorescent signal and the time to half maximum 
(TT1/2M) signal were measured (Figure 3.3 c). TTP and TT1/2M at stage 1 were around 
0.49±0.02 secs and 0.33±0.02 secs respectively, unsurprisingly in correlation with the 
increase in rate of contraction, there was a significant decrease in the TTP and TT1/2M 
by stage 3 (0.40±0.02 secs; p=0.025 and 0.27±0.01 secs; p=0.025 secs, respectively) 
(Figure 3.3 d, e). 
Overall, these results provided evidence that cardiac contractile function initiates at 
the earliest stages of heart formation with synchronised propagation of calcium 
transits across the cardiac crescent. 
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Figure 3.3: Onset of beating and Ca2+ transients during cardiac crescent formation 
Quantitative analysis from the onset of cardiac contraction at stage 1 of crescent formation to 
formation of the LHT (stage 1, n=12; stage 2, n=8; stage 3, n=10; LHT, n=7), revealed a 
significant increase in heart rate from stages 2 to 3 (a); data courtesy of Antonio A. M. 
Miranda. Maximum intensity projection of normalized Ca2+ signal following Rhod2-AM loading 
of stage 1 embryos revealed lateral propagations of transients across the crescent (b). 
Representative traces of Ca2+ transients at stage 1 and 3 of crescent formation (c). Time to 
peak (TTP) fluorescent signal (d) and time to half maximum (TT1/2M) fluorescence (e), 
showing a significant decrease in both parameters between stage 1 (TTP, 0.49±0.03 secs; 
TT1/M 0.33±0.04 secs.) and stage 3 (TTP, 0.40±0.04 secs; TT1/M 0.27±0.01 secs.), n=5. Scale 
bars: b, 100 μm. All error bars are mean ± standard deviation. Statistics: ANOVA and Tukey test 
for multiple comparisons (* p<0.05; ** p<0.01; *** p<0.001).  
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Figure 3.4: Discrete beating foci on either side of the embryonic midline contract at 
the same rate 
DIC image of a stage 1 embryo with foci of beating highlighted on the left (red arrowhead) and 
right (black arrowhead) of the embryonic midline and cardiac crescent outline highlighted by 
white dashed line (a). Discrete foci on the left and right of lateral region of the crescent beat at 
the equivalent frequency (b), indicative of synchronisation across the midline or intrinsic 
pacing. Immunochemistry revealed a lack of Cx43 expression in the early cardiac crescent (c). 
Scale bar: a, 100μm. 
 
3.2.3 Development of single cell slow Ca2+ waves to propagating fast waves within 
the early cardiac crescent 
Due to the propagation of Ca2+ transients within the stage 1 cardiac crescent, stages 
prior to the onset of contraction were investigated.  Using live-embryo imaging of 
calcium transients in stage 0 non-contractile cardiac crescents stochastic, 
asynchronous slow Ca2+ transients could be observed in single cells (Figure 3.5 a). To 
characterise the dynamics of these calcium transients the TTP and TT1/2M was 
measured using the fluorescent signal from single cells within the crescent (Figure 3.5 
b). Average time TTP (3.41±2.30secs, n=174) and TT1/2M (2.42±1.86secs, n=169) 
showed a large amount of variability with ranges in TTP from 0.79 to 11.93 seconds 
and TT1/2M from 0.39 to 9.66 seconds (Figure 3.5 c, d). Distribution of Ca2+ transient 
rate in terms of TTP (Figure 3.5 e) and TT1/2M (Figure 3.5 f) was positively skewed 
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with the majority of waves having faster dynamics. There was no correlation (R2= 
0.2987) in the TTP and TT1/2M per single cells, with slower waves having a larger 
variation in Ca2+ dynamics (Figure 3.5 g). Therefore, these results highlighted the 
presence of pre-contractile Ca2+ transients within the developing crescent suggesting 
that Ca2+ handling is crucial for the initial stages of murine heart development and the 
onset of cardiac function. 
 
Figure 3.5: Single cell calcium transients precede the onset of contraction within the 
forming cardiac crescent 
Maximum intensity projection of normalised calcium signal following Cal-520 loading of stage 
0 embryos revealed asynchronous, sporadic calcium transients (Ca2+) in individual cells prior to 
beating (a, maximum Cal-520 fluorescence (MaxFluo) and b, highlighted by white arrows).  
Average time to peak (TTP) (3.41±2.30secs, n=174) and time to ½ maximal (TT1/2M) 
(2.42±1.86secs, n=169) fluorescent intensity for stage 0 Ca2+ transients had a large variation (c, 
representative traces shown in d), with a positive skewness towards faster dynamics in terms 
of distribution (e and f). Single cell stage 0 Ca2+ transients varied in TTP and time to ½ maximal 
(TT1/2M) fluorescent intensity (g, n=145), revealing variable Ca2+ wave duration as well as 
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differences in speed of Ca2+ influx and efflux. Scale bars: 100 μm. All error bars are mean ± 
standard deviation. 
3.2.4 Cardiac-specific gene expression profiles during mouse heart development 
To assess cardiomyocyte differentiation cardiac-specific genes were used as stage 
related markers; the profiles of these key genes were investigated throughout 
development using qRT-PCR. To correlate the onset of Ca2+ handling and contraction 
with stage related genes, mRNA form whole embryos at E7.5 (prior to cardiac crescent 
formation (stage 0)), E8.0 (cardiac crescent (stages 0-3) and E8.5 (linear heart tube) 
was used (Figure 3.6a-f).  A significant reduction in the expression of genes required 
for mesoderm formation (Brach-T; E7.5 vs. E8.5; 6 fold; p=<0.001) and mesoderm 
specification (Mesp1; E7.5 vs. E8.5; 76 fold; p=<0.001) was observed, whilst cardiac 
specific genes significantly increased over the same time course (Nkx2.5; E7.5 vs. E8.5; 
11 fold; p=<0.001, Mef2c; E7.5 vs. E8.5; 7 fold; p=<0.001, Tnnt2; E7.5 vs. E8.5; 80 fold; 
p=<0.001, Myh6; E7.5 vs. E8.5; 150 fold; p=<0.001). During the later stages of 
development from E9.5, mature myocyte genes significantly increased in the neonatal 
and adult heart (Myh6; E9.5 vs. Adult; 6 fold; p=0.02), whilst early cardiac genes 
involved in cardiac specification either remained constant (Mef2c) or decreased 
(Nkx2.5; E9.5 vs. Adult; 4 fold; p=0.02) during maturation into the adult (Figure 3.6g-i). 
Of significance, these data are in agreement with previous reports and allows future 
correlation between gene expression profiles with in vitro ESC-derived cardiomyocyte 
differentiation. 
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Figure 3.6: Cardiac specific gene expression changes during mouse heart 
development 
Temporal gene expression profiles were assessed on whole embryos by qRT-PCR, normalised 
to E7.5: down-regulation of mesoderm markers Brachyury (a) and Mesp1 (b) occurred 
between E7.5 to E8.5 whilst cardiac specific markers Nkx2.5 (c), Mef2c (d), Tnnt2 (e) and Myh6 
(f) were significantly up regulated by E8.0 and increased further by E8.5. Expression profiles of 
cardiac specific transcripts during in vivo heart development were assessed on isolated hearts 
using qRT-PCR, normalised to E9.5: whilst Nkx2.5 (g) and Mef2c (h) gene expression remained 
constant from E9.5 onwards, Myh6 (i) showed significant up regulation in postnatal day 0 (P0) 
and adult heart. All error bars are mean ± S.E.M. Statistics: one-way ANOVA and Tukey test for 
multiple comparisons (* p<0.05; ** p<0.01; *** p<0.001). 
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3.2.5 Nkx2.5-GFP ESC model of cardiomyocyte differentiation 
To assess the earliest stages of cardiac specific gene induction and expression a 
hanging drop model of ESC differentiation was utilized, as previously described 
(Boheler et al. 2002)(Figure 3.7b). To form embryoid bodies ~500 ESCs were placed 
into a 20µl drop of differentiation media and cultured for 4 days as hanging drops. 
After 4 days EBs were plated down and allowed to differentiate for a further 10 days 
(Figure 3.7c- d). The advantage of this method is that large quantities of EBs and 
cardiomyocytes can be generated in a reproducible manner. An ESC reporter line 
containing green fluorescent protein (GFP) under the control of the Nkx2.5 promoter 
was used (S. M. Wu et al. 2006), allowing cardiomyocyte differentiation to be easily 
assessed (Figure 3.7a). At around day 6-7 of differentiation EBs began to express GFP, 
indicating the formation of Nkx2.5 positive cardiac progenitor cells. Consequently, by 
~day 8 weak rhythmic contractions could be seen in small GFP positive regions. This 
developed further until strong synchronous beating was observed in large GFP positive 
regions by ~day 10, as shown in (Figure 3.7e-f). To assess whether beating regions 
contained muscle-specific cytoskeletal structures, immunohistochemistry was used to 
determine sarcomeric alpha-actinin localisation. By day 14, striated expression of 
alpha-actinin was observed in regions containing Nkx2.5-GFP expressing cells, 
indicating sarcomere formation (Figure 3.8a-b). 
qRT-PCR was used to assess the temporal expression of key transcription factors 
implicated in the transition of pluripotent ESCs to a cardiac committed fate (Van Vliet 
et al. 2012). Figure 3.9 demonstrates the expression profiles of specific genes 
throughout the differentiation timecourse. Expression of the pluripotent marker Oct-4 
and Nanog decreased from day 0, as would be expected. Genes regulating the 
specification and patterning of the primitive streak such as Brachyury and Mesp1 were 
strongly up-regulated at around day 4 of differentiation before being rapidly down-
regulated by day 7. Key cardiac transcription factors such as Nkx2.5 and Mef2c began 
to be expressed at day 7, and peaked at around day 10. mRNA expression of 
cardiomyocyte structural proteins, such as alpha-MHC (Myh6) and cardiac troponin t 
(cTnT), began at day 7 and increased further thereafter, in accordance with the 
observed contractile phenotype of these cells. The changes in gene expression 
between day 4 and 14 of ESC differentiation correlated with those observed during 
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formation of the cardiac crescent in vivo (Figure 3.6), therefore helping to validate the 
model. 
 
Figure 3.7: Nkx2.5-GFP ESC model of cardiomyocyte differentiation 
Construct diagram for the Nkx2.5 cardiac enchancer-eGFP plasmid used to create the Nkx2.5-
GFP reporter ESC line (Wu et al., 2006) (a). Cardiomyocyte differentiation was achieved using a 
“hanging drop” method of ESC differentiation (b). Brightfield images show the formation of 
embryoid bodies (EBs) at day 4 (c) with a large amount of outgrowth occurring by day 7 (d). 
The Nkx2.5-GFP was used to visualise the formation of cardiac progenitors in both EBs (e) and 
plated-down cultures at day 14 (f). Scale bars: b, c, e, 250μm; d, 100μm. 
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Figure 3.8: Formation of sarcomeres during Nkx2.5-GFP ESC cardiomyocyte differentiation 
Immunocytochemistry revealed the expression of α-actinin in Nkx2.5-GFP positive regions, 
indicating formation of ESC-derived cardiomyocytes (a); higher magnification images of α-
actinin filaments revealed the formation of sarcomeres (b). Arrowheads indicate Nkx2.5-GFP 
positive cells with sarcomeres. Scale bars: a, 100μm; b, 25μm. 
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Figure 3.9: Expression of genetic markers during Nkx2.5-GFP ESC cardiomyocyte 
differentiation 
Temporal gene expression profiles were assessed during ESC cardiomyocyte differentiation by 
qRT-PCR and normalised to day 0. Pluripotent marker Oct-4 decreased throughout the 
differentiation timecourse (a). Mesoderm markers Brachyury (b) and Mesp1 (c) were 
significantly up regulated at day 4 of differentiation before being down regulated thereafter. 
Cardiac specific markers Nkx2.5 (e), Mef2c (f), Tnnt2 (g), Myh6 (h) increased throughout 
differentiation from day 7 whilst Gata-4 (d) was first up regulated by day 4. N= 5 independent 
differentiation experiments. All error bars are mean ± S.E.M. Statistics: one-way ANOVA and 
Tukey test for multiple comparisons (* p<0.05; ** p<0.01; *** p<0.001). 
 
3.2.6 Eomes-GFP ESC model of cardiomyocyte differentiation 
To further characterise the hanging drop model of ESC cardiomyocyte differentiation a 
second ESC cell line was used. This ESC reporter line contained GFP under the control 
of the Eomes promoter which is known to be expressed by cardiogenic mesoderm and 
therefore would be useful when trying to identify cardiac progenitors prior to the 
expression of Nkx2.5 (Arnold et al. 2009)(Figure 3.10a). At around day 4 of 
differentiation there was strong expression of the Eomes-GFP reporter in EBs, 
indicating formation of cardiogenic mesoderm (Figure 3.10b). By day 7 the levels of 
GFP had decreased with GFP only being observed in a very small population of cells at 
day 14, suggesting that cells had undergone differentiation and no longer expressed 
Eomes (Figure 3.10c-d). As a result of this differentiation, beating was observed 
between day 6 and 7 within small foci, with strong synchronous beating occurring 
across large regions by day 14. To assess whether beating regions contained muscle 
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specific cytoskeletal structures, immunohistochemistry was employed to determine 
sarcomeric alpha-actinin localisation. Results revealed clear striated expression of 
alpha-actinin in small regions at day 7, indicative of sarcomere formation and 
correlating with the onset of beating (Figure 3.10e). Beating rate was assessed using 
bright field movies. At day 7 of differentiation small regions of ESC derived 
cardiomyocytes were beating at 32.5±1.1 bpm, increasing to 36.0±1.3 bpm by day 14 
(Figure 3.11a). Further analysis using Ca2+ reporter dyes showed large propagating 
calcium waves occurring between cells (Figure 3.11b) as well as slow calcium waves 
occurring within single cells (Figure 3.11c), similar to that observed in the early embryo 
(Figure 3.5b). 
qRT-PCR was again used to assess the temporal expression of key transcription factors 
implicated in the transition of pluripotent ESCs to a cardiac committed fate. Figure 
3.12 demonstrates the gene expression profiles throughout the differentiation 
timecourse. Pluripotent markers (Oct-4) decreased as expected throughout the 
differentiation protocol. Genes regulating the specification and patterning of the 
primitive streak such as Eomes, and Brachyury had increased by day 3 before being 
rapidly down regulated whilst Mesp1 was strongly up regulated at day 4. Key cardiac 
transcription factors such as Nkx2.5 and Mef2c began to be expressed at day 5, with 
Gata-4 already being up-regulated by day 4. mRNA expression of Myh6 and cTnT, 
initially began at day 5 and 6 respectively and increased further thereafter, correlating 
with both the observed contractile phenotype as well as the gene expression changes 
in the early embryo (Figure 3.6). 
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Figure 3.10: Eomes-GFP ESC model of cardiomyocyte differentiation 
Strategy to introduce eGFP into the first coding Exon 1 of the Eomes locus by homologous 
recombination in ES cells (a). An EGFP.pA cassette was placed into the transcriptional start site 
of the endogenous Eomes locus, followed by a removable, LoxP-flanked (blue arrows) selection 
cassette (PGK.neo). Brightfield and epi-fluorescence images of Eomes-GFP expression in day 4 
embryoid bodies (b) and day 7 (c) and 14 (d) plated EBs, revealing a decrease in Eomes 
expression during cardiomyocyte differentiation. Immunostaining of day 7 plated EBs revealed 
the striated expression of cardiac Troponin T and the formation of ESC derived cardiomyocytes 
with nuclear staining (blue; d, left panel); higher magnification of cTnT filaments revealed the 
formation of sarcomeres (e, right panel). Scale bars: a, b, c 250μm; d, left panel 100μm, right 
panel 25μm. 
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Figure 3.11: Onset of beating and Ca2+ transients during Eomes-GFP ESC 
cardiomyocyte differentiation 
Beating was first observed in day 7 (D7) Eomes-GFP ESC-derived cardiomyocytes. Rate of 
beating was assessed using bright field movies and calculated at day 7 (n=176 EBs) and day 14 
(n=180 EBs), revealing a significant increase between the two time points (a). Cal520 calcium 
imaging of day 7 ESC-derived cardiomyocytes revealed large fast propagating Ca2+ waves (b) as 
well as slow Ca2+ transients in single cells (c). Representative Cal-520 traces for the time series 
shown in figure 3.11b (d) and 3.10c (e).  Scale bars: b, 100μm; c, 10μm. All error bars are mean 
± standard deviation. Statistics: ANOVA and Tukey test for comparisons (* p<0.05). 
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Figure 3.12: Expression of genetic markers during Eomes-GFP ESC cardiomyocyte 
differentiation  
Temporal gene expression profiles were assessed during ESC cardiomyocyte differentiation by 
qRT-PCR and normalised to day 0. Pluripotent marker Oct-4 decreased throughout the 
differentiation timecourse (a). Early mesoderm markers Eomes (b) and Brachyury (c) were 
significantly unregulated at day 3 of differentiation whilst Mesp1 (d) increased at day 4 before 
beginning down regulated thereafter. Cardiac progenitor marker Gata-4 (e) was first up 
regulated at day 4 of differentiation whilst other progenitor markers such as Nkx2.5 (f), Mef2c 
(g) increased from day 5. Mature cardiomyocyte markers increased from day 5 (Tnnt2) and day 
6 (Myh6) with further increases throughout differentiation. N= 5 independent differentiation 
experiments. All error bars are mean ± S.E.M. Statistics: one-way ANOVA and Tukey test for 
multiple comparisons (* p<0.05; ** p<0.01; *** p<0.001). 
 
3.2.7 Comparison of ESC differentiation and in vivo gene profiles 
In order to map the gene expression changes that occurred during ESC differentiation 
onto those occurring during in vivo heart development a principal component analysis 
and cluster analysis of qRT-PCR data was performed (Figure 3.13). The expression 
profiles of 12 cardiac related genes (Brachyury, Mesp1, Gata-4, Nkx2.5, Mef2c, Tnnt2, 
Myh6, Cacna1c, Slc8a1, Ryr2, Ppp3ca, Camk2d) were used to compare embryonic 
stages E7.5 to E8.5 with Eomes-GFP ESC-derived cardiomyocytes from days 0-7 
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inclusive and day 14 of differentiation. This analysis revealed no clustering between 
days 0-3 of ESC differentiation, which would be predicted to represent a significantly 
earlier developmental stage than E7.5. In contrast, there was correlation between the 
expression profiles of ESC days 6 and 7 with E8.0, when beating was established in 
both ESC-derived cardiomyocytes and the embryonic heart proper. The most mature 
phenotypes, day 14 and E8.5, also correlated strongly together. Thus, gene expression 
profiles during the onset of contraction in both embryos and ESC cardiomyocyte 
formation correlated, and appropriately reflected stages of cardiac progenitor 
specification and differentiation, allowing comparison of both models in parallel.  
 
 
Figure 3.13: Principle component analysis comparing the gene expression during in 
vivo heart development and ESC-cardiomyocyte differentiation 
Principal component analysis (PCA) was conducted using 12 different genes (Brachyury, 
Mesp1, Gata-4, Nkx2.5, Mef2c, Tnnt2, Myh6, Cacna1c, Slc8a1, Ryr2, Ppp3ca, Camk2d) to 
compare embryonic stages E7.5 to E8.5 (chapter 3) with days 0-14 of ESC induced 
cardiomyocyte differentiation. Groups were calculated by hierarchical clustering: E7.5 embryos 
clustered weakly with day 4/5 EBs, E8.0 embryos clustered with day 6/7 EBs and E8.5 embryos 
clustered with day 14 EBs representing mature cardiomyocytes within each model (a). 
Experiments conducted by R.Tyser, data analysed by A.M. Miranda. 
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3.3 Discussion 
Studies of mammalian heart development have historically focused on the origin and 
spatio-temporal allocation of cardiac progenitors and cardiovascular lineage 
determination. Whilst studies into the identification and regulation of cardiac cell 
types are important for improved understanding of congenital heart disease, insight 
into the initiation and development of cardiac function is crucial to investigate the 
impact of function on subsequent cardiac development in terms of differentiation, 
maturation and organogenesis. In this chapter, a method for the precise staging of 
early morphological changes in the cardiac crescent has been established and 
correlated with the onset of contractile function by using live imaging. In parallel, two 
different ESC lines have been used to assess cardiomyocyte specification and 
differentiation, as evidenced by GFP expression, visible contraction, and cardiac 
specific gene expression, which closely mimicked those seen in vivo. 
3.3.1 Methods to stage heart development in the mouse embryo 
Dynamic changes were observed in both morphology and function during cardiac 
crescent formation, which required accurate and precise staging. Current methods for 
staging embryos include somite number and embryonic day/days post coitum, 
however, these did not directly correlate with heart morphology or function (Kaufman 
& Navaratnam 1981). During dissections, it became apparent that there was a large 
variation in the age (embryonic day) of embryos within a single litter as well as in the 
crescent morphology relative to somite number, suggesting current staging methods 
do not accurately represent early heart development. 
Somites are bilateral-paired blocks of mesoderm, which develop to form skeletal 
components such as bone, cartilage and muscle. Somitogenesis produces somites at 
regular intervals from around E7.5-8.5 of development. In chick, these intervals occur 
regularly (every 90 minutes), however, in mice the interval between somite formation 
varies (Tam 1981).  Although somite number is widely used to stage embryos at early 
developmental time points, previous studies have noted that heart development is not 
strictly synchronous with other developmental processes including that of somite 
formation (Biben & Harvey 1997).  
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To determine embryonic day, mice were mated in the evening, and the morning of 
vaginal plug formation was counted as 0.5 days post-coitum (embryonic day), making 
the assumption that conception occurred in the middle of the night. This method 
works well for later stages of gestation, when the developmental processes are less 
dynamic and embryos within a litter have become more uniform. However, at earlier 
stages of embryonic development the large variation between individual embryos per 
litter make this approach inappropriate and sub-optimal. Therefore, hearts were 
grouped based on width and height measurements, enabling the precise 
characterisation of the onset and changes in cardiac function during early 
development.  
3.3.2 Initiation of the first heartbeat 
Formation and organisation of sarcomeres was investigated using 
immunofluorescence to detect the striated myofilament pattern associated with the 
overlapping of thick (myosin) and thin (actin) filaments. In the developing heart at 
stage 1 striated cTnT expression clearly revealed the formation of sarcomeres, 
suggesting that immature cardiomyocytes had the ability to contract. However, in 
stage 0 crescents it was apparent that despite expression of cTnT, myofilaments had 
not become organised into sarcomeres. At this time-point, cTnT expression was 
localised to the cell membrane, previously shown to be the site of cardiac myofibril 
assembly. Myofibrils originate, as fibrillar bundles of actin filaments with closely 
spaced Z-bodies before maturing into sarcomeres with regularly spaced z-lines (Clark 
et al. 2002). This data reveals that formation of the contractile apparatus occurs during 
the transition between stage 0 and stage 1 and indirectly implies that contraction 
could be occurring within stage 1 of the cardiac crescent. Although contractile 
apparatus was detected at the protein level by immunostaining it does not allow the 
onset of contraction to be determined. For function to occur, immature 
cardiomyocytes would also need the ability to raise intracellular Ca2+ concentrations to 
stimulate the contractile machinery.  
The difficulty when trying to determine when cardiac contraction is first established is 
that previous studies have used conventional staging methods, making comparisons 
difficult due to reasons previously discussed. Using this new staging the earliest 
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observed contractions in the developing cardiac crescent could be precisely 
characterised. In these experiments, the mouse strains used were C57Bl/6 males 
crossed with CD-1 females, to ensure large litter sizes. On average C57Bl/6 females 
have 6-8 pups per litter whilst CD-1 females have around 12 (data not shown). In these 
mice with mixed background, contractile function began at stage 1 of crescent 
formation, correlating with the appearance of sarcomeres. To confirm these findings  
along with rule out any strain dependent variation, a number of different mouse 
strains were assessed, including; pure bred CD-1, C57Bl/6 and a Hex-GFP transgenic 
line (mixed CBA/J and C57BL6 background)(data not shown). Although slight 
differences were observed in the rate of embryo development, onset of beating 
occurred at the same stage of cardiac crescent formation in all strains examined. 
Early contractile activity correlated with obvious, propagating Ca2+ transients from 
stage 1. These initially propagated across the symmetric cardiac crescent from left to 
right, which suggests that there is a functional break in left-right symmetry prior to the 
appearance of morphological left-right differences. This early synchronisation suggests 
connectivity across the cardiac crescent, as well as the formation of a pacemaker 
region from which Ca2+ waves propagate. Cardiomyocytes are electrically coupled by 
gap junctions - clusters of channels composed of connexins. In the heart, there are 
three major subtypes: Connexin-40 (Cx-40), Connexin-43 (Cx-43) and Connexin-45 (Cx-
45) (Jansen et al. 2010). In the developing cardiac crescent, expression of Cx-43 by 
immunohistochemistry was not detected, suggesting connectivity is occurring via Cx-
40 or Cx-45 or does not require coupling via gap junctions. It have previously been 
reported that Cx-45 is the predominant gap junction prior to chamber formation 
(Kumai et al. 2000) and therefore would be important to characterise. 
The basis for the cardiac pacemaker activity in the adult is a controversial and much 
debated subject with two different hypotheses proposed (Lakatta & DiFrancesco 
2009). The “funny current” hypothesis proposes that regularly repeating changes in 
inward membrane Na+ current (If) are responsible for pacemaker activity (Brown et al. 
1979). In opposition, the “calcium clock” hypothesis proposes that intracellular 
changes in Ca2+ concentration determine pacemaker activity (Bogdanov et al. 2001). 
Applying these two hypotheses to the early heart, which lacks a defined pace making 
region, pace making could be initiated by either a distinct population of cells within the 
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cardiac crescent which have an HCN4 derived If “funny” current or by cells simply 
gaining the ability to generate intracellular calcium transients to produce contraction. 
Previous studies have shown that mouse embryos lacking HCN4 contract rhythmically 
and survive to adulthood despite a heart rate that is reduced by ~50% (Stieber et al. 
2003), blockade of HCN4 in E8.5 cardiomyocytes resulted in a reduced action potential 
frequency, but did not prevent action potential generation (Liang et al. 2010). 
Together, this data would suggest that If is not essential for initiating cardiac 
contraction. However, since it is also known that HCN4 is expressed in the early heart, 
and has recently been suggested to label a population of cardiac progenitor cells (Liang 
et al. 2013)(Spater et al. 2013), and therefore the role of HCN4 and If cannot be ruled 
out. In contrast, genetic knock out or pharmacological inhibition of calcium handling 
proteins such as Cav1.2, RyR2 or NCX in mice leads to a lack of heart beat along with 
embryonic lethality (Seisenberger et al. 2000)(Takeshima et al. 1998) (Wakimoto et al. 
2000), suggesting that Ca2+ channels are fundamentally required for cardiac 
development. However, determining whether this phenotype is due to an inability to 
initiate contraction or simply a loss of pace maker activity has yet to be determined.  
3.3.3 Calcium transients precede function in the developing heart 
When examining embryos at stage 0 of development, it was evident that single cell 
Ca2+ transients preceded the onset of contraction. This finding raises the questions as 
to the role of Ca2+ transients in the initiation of contraction and development of 
cardiac function. It also suggests that Ca2+ handling is fundamental to the initial 
formation of the heart, with signalling pathways independent of mechanical force 
regulating early cardiomyocyte differentiation. The role of Ca2+ signalling pathways in 
the heart is not a new concept; it has been clearly shown in the adult heart that Ca2+ 
signalling has a key role in regulating gene expression during pathological hypertrophy 
and remodelling (Molkentin 2006). One of the major challenges in the field is 
separating direct Ca2+ signalling pathways from indirect mechanical force pathways 
induced by regular contraction. 
The influence of mechanical force on cardiomyocyte formation and maturation has 
been well studied, however mechanotransduction signalling is extremely complex. 
Stretch is known to directly affect the activity and expression of several ion channels 
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and gap junctions (Jacot et al. 2010), and has a role in cardiomyocyte maturation 
(Granados-Riveron & Brook 2012), but its role in cardiomyocyte specification and early 
formation is more difficult to assess. In one study, applying stretch to embryonic stem 
cells was shown to promote differentiation by increasing expression of cardiac specific 
genes such as Mef2c and ACTN2 (encodes the protein α-sarcomeric actinin) (Schmelter 
et al. 2006), although in a second study using human embryonic stem cells, direct 
stretch was shown to reduce differentiation (Saha et al. 2006). By investigating the role 
of Ca2+ transients prior to contraction it may be possible to elucidate distinct roles for 
direct Ca2+ versus mechanical signalling pathways on cardiomyocyte differentiation.  
TTP and TT1/2P measurements were employed to quantify the speed at which 
intracellular Ca2+ increased and decreased (Lindner et al. 2002). These measurements 
are used in mature cardiomyocytes to assess Ca2+ transients due to the fast upstroke 
and slow decay in Ca2+ levels during contraction. The Ca2+ waves observed at stage 0 
were significantly slower than the propagating waves observed at stage 1, as 
determined by time to peak (TTP) and time to half maximum (TT1/2M). This raises the 
question as to how the rate of propagation changes between stages 0/1 as well as how 
co-ordination of single cell Ca2+ transients becomes established. After completing TTP 
and TT1/2M analysis at stage 0, the rate of Ca2+ influx and efflux showed significantly 
different dynamics compared to the adult. Due to the slow rise in Ca2+ levels, in future 
it may be better to use a more comparable measure of Ca2+ rise and decay, such as 
time from 50% max to peak compared with TT1/2M or comparing the increase and 
decrease from 10% to 90% fluorescence, although this could be debated. 
Ca2+ transients at stage 0 had a large variation in both their TTP and TT1/2M. The 
underlying basis for this variation is most likely due to differences in the expression of 
proteins which regulate cellular electrophysiology and Ca2+ handling, such as channels 
and exchangers. The increase in the correlation between the TTP and TT1/2M as Ca2+ 
transient speed increased may suggest that differences in the cells’ electrochemical 
properties and related protein expression become more uniform as development 
progresses. Two possibilities might explain the variation observed in Ca2+ transients at 
stage 0. First, the differences seen reflect the stage of cardiomyocyte differentiation 
with direct correlation between cellular electrophysiology and the expression of 
specific genes which control  cardiomyocyte lineage, suggesting each cell follows a 
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predetermined pattern of cardiac Ca2+ handling protein expression. Alternatively the 
electrophysiology and expression of Ca2+ handling proteins fluctuates within individual 
cells in the stage 0 cardiac crescent until a required function/physiology is reached, 
similar to that seen during the formation of the neuromuscular junction (Prieto-Godino 
et al. 2012), where cellular physiology acts as signalling entity to feedback and control 
gene transcription. Further studies will be needed to make any conclusions as to the 
mechanisms by which these early Ca2+ transients are both initiated and regulated.  
3.3.4 Technical limitations of using Ca2+ dyes to image transients in ex vivo embryos 
Although the use of dyes allowed the assessment of live calcium dynamics within the 
developing heart for the first time, this approach has a number of drawbacks which are 
important to address. The advantage of the Ca2+ dye Rhod-2 is that the wavelength of 
light it emits is around 580 nm allowing it to be combined with other fluorescent 
reporters such as GFP, however, it also loads to mitochondria and has a relatively high 
Kd value (570 nM) (Paredes et al. 2008). The Kd value determines how tightly Ca2+ 
binds to the indicator, the high Kd of Rhod-2, therefore, means it may be less sensitive 
than other Ca2+ dyes. Cal-520 is a novel Ca2+ dye which has a lower Kd value (320 nM) 
as well as a better signal-to-noise ratio and does not load to mitochondria (Tada et al. 
2014). Using Cal-520, better dye loading and brighter Ca2+ signals could be achieved 
making its use preferable to Rhod-2. The problem with high affinity Ca2+ dyes is that, 
although they have brighter signals, their strong Ca2+ buffering capacity may affect 
physiological Ca2+ dynamics and signalling. Unfortunately Cal-520 is not a ratiometric 
dye and as such the concentration of Ca2+ within the cell as well as the efficiency of dye 
loading has not been assessed. 
A second caveat with the use of Ca2+ dyes is the degree of tissue penetration. To allow 
penetration and loading in this case, the overlying endoderm had to be removed, 
disrupting the cardiac environment and preventing long-term culture. If the endoderm 
is not removed it takes up the dye and the fluorescent Ca2+ signal from the heart is 
blocked. Surgical removal of endoderm to gain access to the myocardium for ex vivo 
Ca2+ imaging could, therefore, influence the contractile activity of the cardiac crescent. 
Endoderm is known to promote the specification of mesoderm to cardiomyocytes 
(Murry & Keller 2008) by controlling extracellular signalling molecules, which directly 
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influence transcription, leading to lineage specific differentiation (Cai et al. 2013). 
Endoderm has also been shown to have a role in the left-right patterning of cardiac 
mesoderm (Viotti et al. 2012). Although the endoderm and mesoderm are known to 
interact, the influence of the endoderm on early cardiac function has not been 
investigated. To date, our initial observations made at stages 1-3 of crescent formation 
using DIC imaging suggested that accidental perturbations of the endoderm (made 
during dissection) affected function, however, further experiments are required to 
confirm this observation.  
An approach which may circumvent the problem of dyes would be to use transgenic 
mice which express genetically encoded calcium indicators (GECI). GECIs were 
developed over the last decade to image Ca2+ dynamics in vivo, mainly in the mouse 
brain to assess neuronal activity (Tian et al. 2009). One type of GECI is GCaMP, which is 
based on the calmodulin Ca2+ sensing domain and the fluorophore EGFP to assess Ca2+ 
levels. The most recently developed variant GCaMP6f has properties similar to Cal-520 
in terms of kinetics, making it suitable for early embryo imaging (Chen et al. 2013). 
Using a Cre dependent GECI would make it possible to express the Ca2+ reporter 
specifically within the cardiac crescent and image transients without removing the 
endoderm.  A potential Cre line to drive GECI expression would be the Mesp1-Cre 
transgenic mouse line, as it is one of the earliest cardiovascular markers (Saga et al. 
1999). 
3.3.5 ESC model of cardiomyocyte differentiation 
ESCs have provided an in vitro model to study both normal and pathological 
development in early mouse and human embryos. The pluripotent nature of ESCs gives 
them the ability to form any embryonic cell type (Beddington & Robertson 1989), 
making them an important tool when investigating the delineation of early cell fate 
decisions such as mesendoderm segregation into endoderm and mesoderm. 
Attempting to study these early cell fate decisions in vivo is difficult due the embryonic 
lethality associated with early knockout (KO) of genes. Working with ESCs, therefore, 
makes it possible to carry out fine mechanistic studies on pure cell populations which 
have proved difficult when conducting genetic/epigenetic studies in the embryo. 
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Using ESCs as a model also has a number of limitations, including a lack of cross-talk 
between tissues, loss of germ layer spatial organisation, variation in the extent of 
different cell lineages formed and difficulty in controlling extracellular stimuli. In vitro 
differentiation of ESCs is limited in terms of studying morphogenetic events, such as 
the spatial organisation of germ layers and the interactions between different tissue 
types, such as the role of overlying endoderm in cardiac crescent formation. This also 
means it is difficult to mimic morphogen gradients or reveal true morphogenetic 
actions of growth factors such as BMP2, a key growth factor involved in cardiogenic 
mesoderm specification (Schultheiss et al. 1997). The pluripotent nature of ESCs can 
also lead to misleading results as non-physiologically relevant differentiation can occur 
due to the plasticity of these cells.  
The hanging drop method of cardiomyocyte differentiation allowed reproducible 
formation of contractile cardiomyocytes in around 70% of embryoid bodies. Although 
all experiments followed the same sequence of gene marker expression there was a 
significant degree of variation in the relative mRNA levels between experiments. This 
variation could be due to a number of different variables, including the levels of 
growth factors and signalling molecules within the culture media. Using the hanging 
drop method of differentiation EBs contained a mixed population of cells, representing 
multiple differentiation pathways. The cell type heterogeneity within the EBs will lead 
to variations in the growth factors and signalling molecules released by different cell 
types and, therefore, influence cardiogenic specification and maturation. Another 
variable affecting the levels of growth factors is the serum used, therefore, serum 
batch variation may affect EB cell heterogeneity and cardiomyocyte formation. Other 
methods which may be more appropriate in terms of reducing the variation in 
cardiomyocyte differentiation and producing a purer population of cardiomyocytes 
include models of directed differentiation using chemically defined media, as well as 
small molecules to promote cardiomyocyte formation and reduce the myriad of other 
potential cell types (Kattman et al. 2011). 
3.3.6 Comparisons between the Nkx2.5-GFP and Eomes-GFP ESC lines 
Although both ESC models (Nkx2.5-GFP and Eomes-GFP) led to the production of 
beating cardiomyocytes it is interesting to note the differences observed between the 
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two. Overall the Eomes-GFP cell line was the more reliable model in terms of 
cardiomyocyte formation and temporal onset of beating relative to the Nkx2.5-GFP 
ESC line, however, the Nkx2.5-GFP model had stronger cardiac gene expression and 
provided an easy fluorescent read-out of cardiomyocyte differentiation. 
The main difference between the models was in the speed at which differentiation 
occurred. Using the Nkx2.5-GFP ESCs beating was observed at around day 8 of 
differentiation whilst Eomes ESCs had already started to contract around day 6/7, 
comparable with the differences observed in formation of sarcomeres. It is difficult to 
compare the two ESC models directly in terms of temporal gene expression profiles, 
due to differences in the time-points when samples were collected, although both 
followed similar trends. However, there were clear differences in the overall level of 
gene expression relative to day 0. Despite the Nkx2.5-GFP cell line taking longer to 
form functional cardiomyocytes, the maximum expression for each gene was much 
greater in this model compared to the Eomes-GFP Esc line. Expression of mesoderm 
genes, such as Brachyury and Mesp1, were greater in the Nkx2.5-GFP model compared 
to the Eomes-GFP model at day 4 (Brachyury ~2.7x and Mesp1 ~5.3x); cardiac 
progenitor genes such as Nkx2.5 and Mef2c were ~10.9 and ~5.0 fold greater in the 
Nkx2.5-GFP model respectively, at day 14, whilst the mature marker Myh6 was ~32.0 
fold higher. The differences between the two models as differentiation proceeded 
suggests that mesoderm specification is greater in the Nkx2.5-GFP model leading to 
more cardiomyocyte differentiation due to an increased number of cardiac 
progenitors.  
The most likely reasons for the variation seen between the Eomes-GFP and Nkx2.5-GFP 
ESCs during differentiation are due to differences in the original cell line used, the 
method used to make each, the effect of the inserted transgene and how each had 
been previously maintained (Fedorov et al. 1997). The Nkx2.5-GFP ESC line was 
created by injecting CJ7 ES cells with a vector containing eGFP under the control of a 
murine Nkx2.5 promoter and a regulatory region (S. M. Wu et al. 2006)(Lien et al. 
1999). This is in contrast to the knock in Eomes-GFP ESC line which used a CCE ES line 
(Robertson et al. 1986) to insert a eGFP reporter cassette into the translational start 
site of the endogenous Eomes gene leading to the deletion of 500bp within exon 1 
(Arnold et al. 2009). The difference in starting cell line as well as the method of eGFP 
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reporter insertion is likely to significantly influence downstream gene expression and 
cardiomyocyte differentiation. 
The RT-PCR method used for these studies measured relative changes in gene 
expression compared to a calibrator. The calibrator chosen for the timecourse 
experiments was the undifferentiated day 0 ESCs, meaning that all changes in gene 
expression are relative to the starting population of cells and are not an absolute 
quantification. Using day 0 as the calibrator, therefore, means that any differences in 
the starting population of cells would affect the relative quantification of gene 
expression at later stages of differentiation. Although every effort was made to keep 
the starting populations of ESCs pluripotent, any difference in the number of 
pluripotent versus committed cells would not only affect differentiation but would also 
affect the relative analyse of gene expression.  
Overall, both models followed similar trends and led to the production of ESC-derived 
cardiomyocytes, however, it is important to take into consideration the different levels 
of gene expression when making conclusions in future experiments.  
3.3.7 Formation of cardiomyocytes 
Both ESC lines led to the production of beating cardiomyocytes with gene expression 
profiles following the well documented stage-specific timecourse of ESC differentiation 
from the pluripotent state to defined cardiomyocytes as determined using established 
markers (Van Vliet et al. 2012)(Li et al. 2015). In terms of validation, it was striking to 
see that the initial rate of beating in both the ESC model and the embryonic cardiac 
crescent were similar at around 30 bpm, refer to Figure 4.5 a, suggesting that the in 
vivo and in vitro models of cardiomyocyte development correlate in terms of function. 
This observation further suggests that immature developing cardiomyocytes have an 
intrinsic rate at which they initially start beating as discussed previously. There was 
also a significant increase in the rate of beating as ESC-derived cardiomyocytes 
matured between day 7 and day 14 which suggests increases in contractile rate 
underlie cardiomyocyte maturation independent of external cues and pacemaker 
activity.  
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Another important finding which again validated the ESC model and was consistent 
with observations in vivo was the identification of individual differentiating ESC cells 
which were able to generate Ca2+ transients prior to contraction. At day 7 these were 
located in close proximity to small contractile regions, despite not being contractile 
themselves. Ca2+ dye imaging, revealed Ca2+ oscillations within  single cells which had 
slow dynamics in terms of transient wave duration, again suggesting a potentially 
fundamental role for Ca2+ handling in cardiomyocyte differentiation. When observing 
these cells it was clear to see that they had a small and round morphology suggestive 
of a more undifferentiated phenotype. To further characterise these cells it would be 
important to investigate stages earlier than day 7, whilst also using a cell line which 
would permit identification of the origin prior to contraction such, as a Mesp1-GFP ESC 
line (Bondue et al. 2011). The ability of cells to handle Ca2+ prior to contraction 
suggests that calcium signalling has a key role in the regulation of cardiac specific 
genes. ESC models will therefore allow mechanistic insight into this regulation. 
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3.4 Summary 
In this chapter, crescent morphology, cardiac function and gene expression changes 
have been examined during the early stages of heart formation allowing the 
correlation of form and function in the developing cardiac crescent. Along with this 
characterisation, Ca2+ transients were observed in single cells within the cardiac 
crescent prior to the onset of contraction, suggesting that Ca2+ signalling could be 
acting as an independent signalling entity to contraction during early heart 
development. This chapter has also described the formation and differentiation of 
cardiomyocytes using two different ESC lines. Correlation of these findings with in vivo 
results has validated the ESC differentiation and generated a stage matched model of 
ESC cardiomyocyte formation, allowing the mechanisms involved in heart 
development to be more reliably investigated in vitro. In the following chapters, the 
regulation of early cardiac function will be investigated as well as the downstream 
influence Ca2+ transients have on gene expression, cardiomyocyte differentiation and 
heart development. 
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4. CHARACTERISATION OF POTENTIAL CHANNELS AND EXCHANGERS 
REQUIRED FOR Ca2+ TRANSIENTS DURING FORMATION OF THE HEART 
4.1 Introduction 
In the adult heart, coordinated electrical excitation is coupled to physical contraction 
in a process termed excitation contraction coupling (ECC). ECC relies on the second 
messenger Ca2+, which binds to cardiac myofilaments resulting in contraction and 
creating the force needed to pump blood around the body (Bers 2002). Although this 
mechanism of contraction has been well described in the adult, this study aimed to 
investigate how Ca2+ handling occurs during formation of the cardiac crescent. 
Targeted disruption of genes encoding ECC proteins has shown that prior to E13.5, 
contraction can occur without the need for ECC, via a non-defined mechanism. Whilst 
the functional significance of the SR in immature cardiomyocytes is debated it is widely 
excepted that sarcolemmal Ca2+ flux is a predominant source of Ca2+ required to 
generate early contractile activity. Whilst characterising the development and 
initiation of cardiac function, large changes were observed in Ca2+ transient dynamics 
during the onset of contraction (Chapter 3). We, therefore, sought to understand the 
potential mechanisms which may be regulating the concentration of intracellular Ca2+. 
 This chapter will examine both the in vivo and in vitro expression of genes and 
proteins involved in cardiomyocyte Ca2+ handling and signalling, focusing on the 
earliest stages of cardiomyocyte differentiation. It will also assess the functional role of 
sarcolemmal channels and exchangers using acute pharmacological inhibition during 
both early murine heart development (cardiac crescent formation) and ESC- derived 
cardiomyocyte differentiation. 
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4.2 Results 
4.2.1 Temporal variability in the expression of Ca2+ related genes during late heart 
development 
To characterise the expression of ECC genes as well as other Ca2+ related genes during 
maturation of the developing heart, mRNA expression was measured using qRT-PCR 
and correlated with key stage specific transcription factors implicated in cardiac 
differentiation as described in chapter 1. During maturation of the heart key ECC genes 
were significantly elevated in the postnatal (Cacna1c; 16.0 fold ±1.1; p=0.002; Ryr2; 8.3 
fold ±1.1; p≤0.001; Atp2a2; 3.7 fold ±0.3; p=0.004; Figure 4.1b-d) and adult heart 
samples (Cacna1c; 11.5 fold ±3.0; p=0.008; Ryr2; 12.0 fold ±1.1; p≤0.001; Atp2a2; 8.0 
fold ±1.9; p≤0.001) compared to the embryonic heart at E9.5. In contrast to Cacna1c 
and SR related ECC genes, Slc8a1 (encoding NCX1) did not change from E9.5, 
suggesting that Slc8a1 was maximally expressed in the heart by E9.5 (Figure 4.1 a) 
(Reppel, Sasse, et al. 2007). A number of other Ca2+ related genes were also assessed. 
Scn5a, the main Na+ channel involved in cardiomyocyte depolarisation (Haufe et al. 
2005) was significantly elevated in the P0 (3.8 fold ±0.3; p=0.007; Figure 4.1 e) and 
adult heart (4.3 fold ±0.7; p=0.005) compared to E12.5. Itp3r2, encoding IP3R, a 
channel known to be involved in Ca2+ release from the endoplasmic reticulum (Perez et 
al. 1997) was significantly increased in the postnatal (6.9 fold ±0.2; p=0.002; Figure 4.1 
f) and adult heart (4.1 fold ±0.2; p=0.002) compared to the E9.5 heart. The final 
calcium channels studied were the two pore channels 1 and 2 (TPC1/2), encoded by 
Tpcn1 and Tpcn2, known to release calcium from lysosomal stores (Calcraft et al. 2009; 
Brailoiu et al. 2009), which remained unchanged between E9.5 and the adult stages 
(Figure 4.1 g, h). Together these results reveal that whilst mature ECC genes increase 
from E9.5 into the adult, expression of the NCX1 encoding gene, Slc8a1, remains 
unchanged throughout the later stages of heart development suggesting NCX1 is 
maximally expressed by E9.5.   
In order to investigate NCX1 protein expression and localisation, 
immunohistochemistry was performed on E12.5 heart cryosections. Cardiomyocytes 
were labelled using alpha-actinin staining and examined by confocal microscopy. NCX1 
was expressed in both the ventricle and atria and exhibited an anticipated membrane 
localisation as shown in Figure 4.2. Overall these findings indicate that NCX1 is strongly 
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expressed in the heart by E9.5 and that the level of gene expression is maintained 
throughout development, this was in contrast to other cardiac specific Ca2+ handling 
genes which increased in a similar manner to mature cardiomyocyte markers such as 
α-MHC (Figure 3.7). 
 
Figure 4.1: Temporal expression patterns of Ca2+ genes during in vivo cardiomyocyte 
maturation 
Gene expression was assessed during maturation of the heart from E9.5 using qRT-PCR on 
isolated mouse heart samples. ECC genes including Cacna1c (b), Ryr2 (c), Atp2a2 (d) as well as 
Scn5a (e) and Itp3r2 (f) significantly increased in the postnatal day 0 and adult hearts samples, 
whilst Slc8a1 (a), Tpcn 1 (g) and 2 (h) remained constant from E9.5. All error bars are mean ± 
S.E.M. Statistics: one-way ANOVA and Tukey test for multiple comparisons (* p<0.05; ** 
p<0.01; *** p<0.001). 
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Figure 4.2: Localised expression of NCX1 in E12.5 mouse hearts 
Immunocytochemistry imaging revealed the expression of NCX1 in α-actinin positive E12.5 
mouse hearts (a); higher magnification images revealed membrane localised expression of 
NCX1 (b). Arrows highlight membrane localised expression. Scale bars: a, 100μm; b, 15μm. 
 
4.2.2 Expression of NCX1 and LTCC during cardiac crescent formation 
Due to the early expression of Slc8a1 (which encodes NCX1) at E9.5 and the findings, in 
chapter 3, on function within the cardiac crescent it was important to study time 
points earlier than E9.5. Using immunohistochemistry the expression of the main 
sarcolemmal ECC proteins NCX1 and Cav1.2 was assessed. In the late stage2/3 cardiac 
crescent, expression and localisation of both NCX1 and Cav1.2 was detected and 
corresponded with cTnT expression (Figure 4.3a, b).  However, whilst NCX1 was clearly 
detectable within the early cardiac crescent at stage 0, Cav1.2 was absent (Figure 4.4 
e, f). To identify a transcriptional difference that could explain the difference in protein 
levels, RNA was collected and analysed from whole embryos at E7.5 (prior to crescent 
formation), E8.0 (cardiac crescent) and E8.5 (linear heart tube). At these early time 
points there was a significant increase in Slc8a1 expression between days E7.5 and 
E8.0 (2.2 fold ±0.3; p≤0.001; Figure 4.4 a) whilst Cacna1c (which encodes Cav1.2) 
expression was unchanged (Figure 4.4 b). By E8.5 there was significant up regulation in 
both Slc8a1 (12.1 fold ±0.5; p≤0.001) and Cacna1c (3.7 fold ±0.9; p≤0.01). The early 
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expression of membrane localised NCX1 expression within the stage 0 cardiac crescent 
therefore correlates with the increase in Slc8a1, between E7.5 and E8.0.   
RyR2 and HCN4 mRNA levels were also studied because of their role in adult cardiac 
physiology. RyR2 is responsible for Ca2+ release from the SR and is fundamental for 
contraction within the mature heart (Bround et al. 2012), however, its role in early 
cardiac function is debated (Rapila et al. 2008). HCN4 is functionally required for the 
spontaneous pacemaker activity of the heart (Difrancesco 2010) although the 
mechanism for pacemaker activity in the developing cardiac crescent is unknown. 
HCN4 has also been reported to demarcate a source of cardiac progenitors during 
formation of the heart. RyR2 and Hcn4 were found to be significantly up-regulated 
between E7.5 and E8.5 (Ryr2; 9.4 fold ±1.5; p≤0.001; Hcn4; 4.8 fold ±0.5; p=0.001 
Figure 4.4 c, d). At E8.0 Ryr2 was significantly up regulated compared to E7.5 (3.1 fold 
±0.1; p=0.003), whilst Hcn4 was unchanged. Therefore, during formation of the cardiac 
crescent and transition to the linear heart tube both RyR2 and HCN4 increase, 
potentially resulting in changes in cardiac physiology. 
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Figure 4.3: Membrane localised expression of NCX1 and Cav1.2 in stage 2 cardiac 
crescent 
Using whole mount immunohistochemistry and confocal imaging of embryos  it was possible 
to detect the expression of both NCX1 and Cav1.2 within stage 2 cardiac crescents, as 
demarcated by cTnT expression. Scale bars: 100μm. 
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Figure 4.4: Temporal expression patterns of NCX1 and Cav1.2 during formation of the 
cardiac crescent 
Temporal gene expression profiles were assessed on whole embryos by qRT-PCR, normalised 
to E7.5: significant up-regulation of both Slc8a1 and RyR2 occurred by E8.0 increasing further 
at E8.5, whilst Cacna1c and Hcn4 didn’t significantly increase until E8.5. Immunostaining 
revealed the expression of NCX1 (arrows, e) but not Cav1.2 (f) in the cardiac crescent at stage 
0 as marked by the expression of cTnT. All error bars are mean ± S.E.M. Statistics: ANOVA and 
Tukey test for multiple comparisons (* p<0.05; ** p<0.01; *** p<0.001). Scale bars: 50μm. 
 
4.2.3 Temporal variability in the expression of genes related to Ca2+ regulation during 
Nkx2.5-GFP ESC differentiation 
To enable the identification of potential proteins involved in the regulation of the 
earliest Ca2+ transients and heart function, gene expression profiles of functionally 
relevant channels and exchangers were initially investigated using Nkx2.5-GFP ESC 
cardiomyocyte differentiation. Figure 4.5 Shows that apart from Atp2a2 (encoding 
SERC2a) which was unchanged (Figure 4.5 d), there was a significant up regulation in 
the main ECC Ca2+ handling genes over the 14 day timecourse (Slc8a1; 373.1 fold 
±111.6; p≤0.001; Cacna1c; 76.1 fold ±10.9; p≤0.001; Ryr2; 5.6 fold ±1.4; p=0.025; 
Figure 4.5 a, b, c). NCX1 mRNA was significantly up regulated by day 4 of 
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differentiation, compared to levels at day 0 (5.7 fold ±0.9; p=0.011), however, there 
was no change in the mRNA levels of the sarcolemmal Ca2+ channel, Cav1.2, or the SR 
Ca2+ channel, RyR2, over the same timescale. Other channels involved in adult heart 
function included Nav1.5 and Cav3.1 (encoded by Scn5a and Cacna1g, respectively). 
Nav1.5 is responsible for the depolarisation of cardiomyocytes upon electrical 
excitation and therefore has a key role in triggering Ca2+ influx and generating 
contraction. Cav3.1 is a T-type sarcolemmal Ca2+ channel reported to be involved in 
pace maker activity and Ca2+ influx during early heart development. Following 
formation of embryoid bodies, Scn5a was up-regulated by day 2 of differentiation (8.7 
fold ±2.6; p=0.001; Figure 4.5 e), increasing further at day 14 (13.8 fold ±4.0; p≤0.001), 
whilst Cacna1g was not up regulated until day 14 (19.0 fold ±13.5; p=0.021; Figure 4.5 
i). The lysosomal Ca2+ channels TPC1 and TPC2 (encoded by Tpcn1 and Tpcn2) had 
different expression profiles during ESC differentiation, Tpcn1 was significantly 
elevated at day 7 (Tpcn1; 3.5 fold ±0.5; p=0.005), whilst Tpcn2 expression remained 
constant throughout (Figure 4.5 g, h). Other Ca2+ channels investigated included the 
Transient receptor potential channel 3 (TRPC3 encoded by Trpc3), the IP3R channel 
(encoded by Itp3r2) and the store-operated related channels Stim1 and Orai1 
(encoded by Stim1 and Orai1) which have been reported to be involved in the 
regulation of pacemaker activity, pathological Ca2+ influx and signalling during cardiac 
hypertrophy as well as ESC cardiomyocyte differentiation (Bush et al. 2006) (Arantes et 
al. 2012) (Voelkers et al. 2010). Over the 14 day protocol, Trpc3 expression was 
elevated at day 7 of differentiation (Trpc3; 28.9 fold ±11.5; p=0.016; Figure 4.5 j), 
whilst, Itp3r2 did not significantly increase until day 10 (18.4 fold ±5.0; p=0.037; Figure 
4.5 f). Stim1 and Orai1 remained constant throughout the differentiation protocol 
(Figure 4.5 k, l). Overall this data reveals a gene expression timecourse for certain 
channels and exchangers involved in cardiomyocyte physiology and highlights the early 
expression of NCX1 prior to mature cardiomyocyte marker expression (Figure 4.3). 
Immunohistochemistry was used to investigate NCX1 protein expression and 
localisation. NCX1 was observed in Nkx2.5-positive cells and localised to the 
membrane at day 7 (Figure 4.6 b). NCX1 membrane expression was also present in 
cells that did not express Nkx2.5-GFP. By day 14, it was observed that all Nkx2.5-GFP 
positive ESC derived cardiomyocytes strongly expressed membrane localised NCX1 
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protein, whist regions which were Nkx2.5-GFP negative did not express NCX1 (Figure 
4.6 a). This data confirms the expression of NCX1 protein during ESC differentiation 
and reveals a heterogeneity in the cell types which express membrane localised NCX1. 
 
Figure 4.5: Temporal expression patterns of Ca2+ genes during Nkx2.5-GFP ESC 
cardiomyocyte differentiation 
Gene expression was assessed during ESC cardiomyocyte differentiation using qRT-PCR. ECC 
genes including Slc8a1 (a), Cacna1c (b) and Ryr2 (c) increased throughout differentiation from 
between day 4 and 7 whilst Atp2a2 (d) remained constant. Scn5a (e) became significantly up-
regulated by day 2 of differentiation, with expression levels remaining constant throughout 
the rest of differentiation. Itp3r2 (f), Tpcn1 (g), Cacna1g (i) and Trpc3 (j) all increased as 
differentiation progressed towards day 14. Tpcn2 (h), Stim1 (k) and Orai1 (l) remained 
constant through Esc cardiomyocyte differentiation. All error bars are mean ± S.E.M. Statistics: 
one-way ANOVA and Tukey test for multiple comparisons (* p<0.05; ** p<0.01; *** p<0.001). 
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Figure 4.6: Membrane localised expression of NCX1 during Nkx2.5-GFP 
cardiomyocyte differentiation 
Immunocytochemistry revealed the expression of NCX1 (red) in Nkx2.5 -GFP (green) positive 
regions at day 14 (a). By day 7 membrane localised expression of NCX1 was observed in cells 
which expressed Nkx2.5-GFP but also in cells which were Nkx2.5-GFP negative (arrows) (b). 
Scale bars: a, 50μm; b, 25μm. 
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4.2.4 Temporal variability in the expression of Ca2+ related gene expression during 
EOMEs-GFP ESC differentiation 
To confirm the results gathered from the Nkx2.5-GFP ESC line and to investigate with 
higher temporal resolution the expression changes of Ca2+ handling genes occurring 
during ESC differentiation experiments were repeated using the Eomes-GFP ESC line. 
During differentiation both Slc8a1 and Cacna1c were up-regulated by day 14 (Slc8a1; 
373.4 fold ±40.0; p≤0.001; Cacna1c; 124.4 fold ±21.0; p≤0.001; Figure 4.7 a, d), 
however, there was a significant increase in Slc8a1 by day 2 (4.0 fold ±0.8; p=0.004; 
Figure 4.7 b) whilst Cacna1c was not up-regulated until day 4 of differentiation (5.9 
fold ±1.9; p=0.009; Figure 4.7 e). Ryr2 expression was significantly up-regulated by day 
14 of differentiation compared to day 0 (6.1 fold ±1.3; p=0.043; Figure 4.7 c), in 
contrast to Atp2a2 (encoding SERC2a) remained unchanged throughout differentiation 
(Figure 4.7 f). Other genes related to cardiomyocyte physiology included Scn5a 
(encoding Nav1.5) and Cacna1g (encoding Cav3.1) which were both significantly up-
regulated by day 2 (Scn5a; 4.6 fold ±0.9; p≤0.001; Cacna1g; 4.7 fold ±1.2; p≤0.001; 
Figure 4.7 h, i), whilst Scn5a stayed relatively constant throughout subsequent 
differentiation, Cacna1g became significantly up-regulated at day 14 compared to day 
7 (91.2 fold ±10.5; p≤0.001; Figure 4.7 g). Atp1a2 (encoding Na+/K+ATPaseα2) was first 
up-regulated at day 4 (6.8 fold ±2.2; p=0.014; Figure 4.7 k) before increasing further at 
day 14 (45.7 fold ±16.4; p≤0.001; Figure 4.7 j ), in contrast Slc9a1 (encoding NHE1) 
remained constant throughout differentiation from day 0-4 before increasing at day 14 
(2.8 fold ±0.5; p=0.003; Figure 4.7 l). 
Overall this data reveals that NCX1, Cav3.1 and Nav1.5 gene expression is up regulated 
prior to the onset of contraction and formation of cardiomyocytes and significantly 
earlier than other cardiomyocyte related channels and exchangers. 
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Figure 4.7: Temporal expression patterns of Ca2+ genes during Eomes-GFP ESC 
cardiomyocyte differentiation 
Gene expression was assessed during ESC cardiomyocyte differentiation using qRT-PCR. Slc8a1 
(a, b), Scn5a (i) and Cacna1g (g,h) genes were significantly up-regulated by day of 
differentiation, with both Slc8a1 and Cacna1g increasing again at later time points. Cacna1c (d, 
e) and Atp1a2 (j, k) mRNA levels became significantly elevated by day 4 of differentiation 
compared to day 0. The gene Atp2a2 (f) remained constant throughout differentiation whilst 
Ryr2(c) and Slc9a1 (I) became up-regulated by day 5 and 6, respectively, before increasing 
further at day 14. All error bars are mean ± S.E.M. Statistics: one-way ANOVA and Tukey test 
for multiple comparisons (* p<0.05; ** p<0.01; *** p<0.001). 
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4.2.5 Expression of NCX1 and Cav1.2 during Eomes-GFP cardiomyocyte 
differentiation 
Although relative mRNA levels give an approximate indication about protein levels, it 
was important to directly measure and localise protein expression. In Eomes-GFP ESCs 
at day 7 of differentiation, both NCX1 and Cav1.2 were expressed, but whilst NCX1 was 
consistently co-expressed with cTnT (Figure 4.8 a), there were clear cTnT+ve foci which 
were negative for Cav1.2 (Figure 4.8 b). Further immunohistochemical analysis showed 
that whilst Brachyury positive cells did not express NCX1, the latter was found in close 
proximity to Brachyury positive cells at day 7 (Figure 4.9). At day 4 there was clear 
expression of Brachyury when imaging whole mount EBs as well as distinct puncta of 
NCX1 which looked to be expressed at the membrane and were not detectable in 
secondary antibody negative controls (Figure 4.10). 
 
Figure 4.8: Expression of NCX1 and Cav1.2 at day 7 of Eomes-GFP ESC cardiomyocyte 
differentiation 
Immunocytochemistry at day 7 of ESC-cardiomyocyte differentiation revealed the complete 
overlap of NCX1 (green) and cTnT (red) expression (a), whereas Cav1.2 (green) expression 
overlapped in certain regions with cTnT (red) but not all regions expressed both Cav1.2 and 
cTnT (b) as seen with NCX1. Scale bars: 50μm. 
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Figure 4.9: Expression of NCX1 and Brachyury at day 7 of Eomes-GFP ESC 
cardiomyocyte differentiation 
At day 7, immunocytochemistry of ESC-cardiomyocytes revealed NCX1 (red) expressing cells 
sitting adjacent to Brachyury positive cells (green) suggesting a potential interaction between 
the two cell types. Scale bars: 100μm. 
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Figure 4.10: Expression of NCX1 and Brachyury at day 4 of Eomes-GFP ESC 
cardiomyocyte differentiation 
Immunostaining of day 4 embryoid bodies revealed the expression of Brachyury (green) 
positive cells as well as discrete puncta of NCX1 (red) expression (a, b),  which were not 
detected when secondary antibodies were added alone as a negative control (c).  Scale bars: a, 
c, 100μm; b, 50μm. 
 
4.2.6 NCX1 & Cav1.2 are required for Ca2+ influx during cardiac crescent maturation 
To directly investigate the role of NCX1 and Cav1.2 in establishing and maintaining 
cardiac contractions, pharmacological blockade using the specific inhibitors CB-DMB or 
KB-R7943 to block NCX1 activity was employed (Secondo et al. 2009)(Kimura et al. 
1999) and nifedipine to inhibit Cav1.2 (McDonald et al. 1994), on embryos maintained 
ex-vivo. Embryos were isolated and imaged for contractile activity by differential 
interference contrast imaging (DIC) whilst Ca2+ transients were assessed in parallel 
with confocal imaging of the Ca2+ dye Cal-520. Acute treatment (5, 15 and 30 min) with 
either NCX1 inhibitors (CB-DMB and KBR7943) or the L-type Ca2+ channel inhibitor 
(Nifedipine), affected the embryos in a stage dependent-manner when compared to 
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baseline recordings (Figure 4.11a, Figure 4.11b). Inhibition of either NCX1 or Cav1.2 
prevented Ca2+ transients at stage 1/2, when contraction  was first established, 
however, at later stages only Cav1.2 inhibition prevented Ca2+ transients (3 and LHT). 
Inhibition of both NCX1 and Cav1.2 led to an initial confinement of Ca2+ transients to 
the right-side of the crescent (within approximately 5 min which persisted through to 
15 min) followed shortly afterwards by complete loss of Ca2+ signal (Figure 4.11c, 
Figure 4.11d). At stage 3 and later, only Cav1.2 was required for Ca2+ transients and 
contractile activity, since NCX1 inhibition no longer had any effect. 
This data highlights a stage dependent role for NCX1 and Cav1.2 in the generation of 
Ca2+ transients and contraction during formation of the cardiac crescent, thus 
providing a novel mechanism by which early Ca2+ influx is regulated.  
 
Figure 4.11: NCX1 and Cav1.2 inhibition prevents Ca2+ transients in a stage 
dependent manner during cardiac crescent maturation 
Inhibition of Ca2+ transients occurred upon treatment of embryos between stage 1 and LHT 
with either NCX1 inhibitors CB-DMB, KB-R7943 or the Cav1.2 inhibitor Nifedipine, relative to 
DMSO control (a, b). Inhibition of NCX1 with either CB-DMB (20 μM) or KB-R7943 (30 μM) 
affected only stage 1 and 2 embryos(a), whereas inhibition of Cav1.2 with nifedipine (10 μM) 
effected both stages 1 and 2 and the later stage 3/LHT (b; stage1/2: DMSO, n=5; CB-DMB, n=7; 
KB-R7943, n=6; nifedipine, n=6;stage3/LHT: DMSO, n=5; CB-DMB, n=14; KB-R7943, n=7; 
nifedipine, n=8). Stage1-2 embryo time series of calcium transients at different time points of 
either CB-DMB or Nifedipine treatment, revealed a confinement to the right side of the 
embryo prior to complete block (c, d). All scale bars 100μm. Statistics: Freeman-Halton 
extension of Fisher exact probability test (* p<0.05; ** p<0.01;*** p<0.001). 
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4.2.7 Inhibition of NCX1 & Cav1.2 prevents Ca2+ transients during EOMEs-GFP ESC 
cardiomyocyte differentiation 
To determine whether NCX1 or Cav1.2 are involved in ESC derived cardiomyocyte Ca2+ 
influx, pharmacological inhibitor experiments were performed at day 7 and day 14 of 
ESC differentiation. ESC derived cardiomyocytes were treated for 30 minutes with CB-
DMB, KB-R7943 or Nifedipine. Similar to observations made in the embryo, NCX1 
inhibition affected ESC-derived cardiomyocytes in a stage dependent manner whilst 
Cav1.2 was required for contractile function at all stages examined (Figure 4.12a, 
Figure 4.12b). Inhibition of NCX1 at day 7 with CB-DMB or KB-R7934 blocked beating in 
ESC-derived cardiomyocytes, however, by day 14 of cardiomyocyte differentiation 
acute administration of CB-DMB had no effect on beating whilst inhibition with KB-
R7943 was significantly reduced. This was in contrast to inhibition of Cav1.2 with 
Nifedipine which prevented beating at both day 7 and 14. Consistent with these 
findings both CB-DMB and Nifedipine restricted the propagation of Ca2+ waves at day 7 
of differentiation after 5 minutes of treatment before completely preventing wave 
propagation after 30 minutes (Figure 4.12c, Figure 4.12d). 
Overall the relative effects of CB-DMB, KB-R7943 and Nifedipine were consistent with 
those observed in the developing cardiac crescent and suggest that both NCX1 and 
Cav1.2 have stage-dependent roles in Ca2+ influx during cardiomyocyte differentiation. 
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Figure 4.12: NCX1 and Cav1.2 inhibition prevents Ca2+ transients in a stage 
dependent manner during ESC-derived cardiomyocyte differentiation 
Contraction was assessed in ESC-derived cardiomyocytes at different days of differentiation 
after treatment with the same channel blockers as used in the mouse embryo. Inhibition of 
NCX1 with CB-DMB (10 μM) significantly reduced contractions only in day 7 cardiomyocytes 
(a), whereas KB-R7943 (30 μM) affected cardiomyocytes at both day 7 and 14 (a, b). Inhibition 
of LTCC with nifedipine (10 μM) significantly reduced contractions in both day 7 and 14 
cardiomyocytes and to a much greater extent than KB-R7943 at the later stage (b; day 7: 
DMSO, n=38; CB-DMB, n=36; KB-R7943, n=7; nifedipine, n=10; day 14: DMSO, n=25; CB-DMB, 
n=36; KB-R7943, n=15; nifedipine, n=15). Time series of day 7 ESC-derived cardiomyocyte 
calcium transients at different time points of either CB-DMB or Nifedipine treatment, revealed 
confinement of Ca2+ transients prior to complete block (c, d), equivalent to that observed in 
the treated embryos (Figure 4.11). All scale bars100μm. Statistics: Freeman-Halton extension 
of Fisher exact probability test (* p<0.05; ** p<0.01;*** p<0.001). 
 
4.2.8 Ca2+ influx via NCX1 is required for single cell Ca2+ transients at stage 0 of 
crescent formation 
Taking into account the earlier expression of NCX1 relative to Cav1.2 at stage 0, the 
possibility that NCX1 might be pivotal in generating the single-cell, slow Ca2+ transients 
observed at stage 0 of crescent formation was tested. Treatment of stage 0 embryos, 
prior to the onset of contraction for 15 min with CB-DMB to inhibit NCX1 resulted in a 
significant inhibition of slow Ca2+ transients compared to application of DMSO or 
inhibition of Cav1.2 with Nifedipine (DMSO, 32% ± 6% n=8; CB-DMB, 87% ± 8% n= 6; 
nifedipine, 43% ± 10% n=8 embryos per treatment; p≤0.01; Figure 4.13a, Figure 4.13b, 
Figure 4.13c). 
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This data suggests that NCX1 is the predominant mechanism for Ca2+ influx in pre-
contractile cardiomyocytes at stage 0 of cardiac crescent formation and suggests that 
NCX1 function is required for the establishment of cardiac function during formation of 
the heart. 
 
Figure 4.13: NCX1 activity is required for Ca2+ transients prior to the onset of 
contraction in the murine stage 0 cardiac crescent 
Treatment of stage 0 embryos prior to the onset of beating with CB-DMB (20 μM) resulted in 
inhibition of slow asynchronous Ca2+ transients (a, b) whereas treatment with nifedipine (10 
μM) had no discernible effect on the slow transients compared to DMSO (a, c; DMSO, n=8; CB-
DMB, n=6; Nifedipine, n=8), supporting the earlier role for NCX1 in initiating Ca2+ handling prior 
to beating. cc, cardiac crescent. All scale bars100μm. Statistics: ANOVA and Tukey test for 
multiple comparisons (** p<0.01). 
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4.3 Discussion 
Due to the early function observed in both in vivo and in vitro models it was important 
to assess the potential mechanisms by which Ca2+ could be regulated in immature 
cardiomyocytes. Previous studies in both the adult and E8.5+ embryonic heart have 
described and characterised a number of Ca2+ handling proteins which have multiple 
roles in function, signalling and gene expression (Liang et al. 2010)(Sabourin et al. 
2011)(Méry et al. 2005). These studies were the basis for initial investigations into the 
Ca2+ handling proteins involved in early heart development specifically cardiac crescent 
formation and function. Studies into the mechanisms of embryonic heart function 
have typically focused on stages from the linear heart tube (E8.5) onwards. This thesis 
has shown that cardiac contraction is established prior to that described in previous 
studies, with single cell Ca2+ transients preceding contraction in the developing cardiac 
crescent. Therefore to further characterise these observations it was important to 
address the potential mechanisms which may be involved in regulating early function 
and Ca2+ transients. Using published studies as well as our own expression analysis, 
NCX1 and Cav1.2 represent potential sarcolemmal proteins involved in early cardiac 
function. This chapter has shown that both NCX1 and Cav1.2 have a dynamic role in 
regulating Ca2+ influx. Although these experiments have focused on NCX1 and Cav1.2 it 
is important to note that other channels could potentially contribute to early Ca2+ 
transient dynamics including T-type calcium channels, SR Ca2+ channels such as 
ryanodine receptors or  IP3receptors and lysosomal Ca
2+ channels, however studying all 
of the potential channel-based mechanisms that might influence early heart function 
in the embryo was beyond the scope of this PhD. 
4.3.1 Maturation of cardiomyocyte function 
During cardiomyocyte maturation a large number of genetic, phenotypic and 
functional changes occur, including increases in the number of mitochondria 
(Khryapenkova et al. 2008)(Kasahara et al. 2013) as well as the formation of t-tubules 
(Brette & Orchard 2003). In terms of function, the embryonic mouse heart at E10.5 has 
been reported to beat at ~127bpm, increasing to 300bpm at neonatal stages, whilst 
the adult heart beats at over 500bpm (Keller et al. 1996). In the neonatal and adult 
heart, the mRNA expression of ECCs proteins such as RyR2, SERCA2a, Nav1.5 and 
Cav1.2 became elevated, corresponding with increases in heart function. This 
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correlation would suggest that in order to raise heart rate, increases in ECC protein 
expression need to occur. The maturational changes observed in both function and 
ECC gene expression also correlated with the expression of mature structural 
cardiomyocyte markers (Figure 3.7). Whether changes in these Ca2+ handling proteins 
are a downstream consequence of differentiation or whether they can directly 
regulate gene expression and maturation is still open for debate. In terms of ECC 
maturation, knockout studies have suggested that functional ECC develops around 
E10.5-11.5, however the exact timing of embryonic lethality varies depending on the 
specific ECC gene knockout. Homozygous RyR2 gene inactivation in transgenic mice 
causes embryonic lethality between E10.5-11.5 (Takeshima et al. 1998). Embryos with 
homozygous Cav1.2 gene inactivation developed normally until E12.5, however, no 
viable embryos were detected at E14.5 (Seisenberger et al. 2000), whilst homozygous 
NCX1 gene inactivation led to lethality at ~E9.5 ((Wakimoto et al. 2000)(Cho et al. 
2000)(Koushik et al. 2001)). During embryonic heart development (E9.5 – E14.5), there 
were no changes detected in the mRNA expression of RyR2, Cav1.2 or NCX1. Due to 
the embryonic lethality associated with the disruption of these genes, this data would 
suggest that RyR2, Cav1.2 and NCX1 are already expressed prior to E9.5, however, it is 
likely that they may individually be able to trigger contraction independent of ECC and 
therefore allowing embryos survive past E9.5. These experiments highlight a significant 
role for ECC during the later stages of heart development, although, they suggest that 
in the early heart, contraction occurs via a different mechanism.  
4.3.2 Expression of NCX1 occurs during early cardiomyocyte differentiation 
In the adult heart, NCX1 is one of the major Ca2+ removal pathways allowing relaxation 
of adult cardiomyocytes after contraction (Reuter & Seitz 1968)(Nicoll et al. 1990).  
Slc8a1, the gene which encodes NCX1, was expressed at similar levels throughout 
development of the heart from E9.5, suggesting that increases in Slc8a1 were not 
required during maturation within the post natal and adult heart and that initiation of 
expression occurred at the earliest stages of heart development. This observation fits 
with previous studies which have shown the functional expression of NCX1 in E8.5 
cardiomyocytes (Reppel, Sasse, et al. 2007). By analysing whole embryos, it was 
observed that Slc8a1 mRNA first became elevated at E8.0 compared to E7.5. This up 
regulation in Slc8a1 was further supported by the membrane-localised expression of 
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NCX1 within the stage 0 cardiac crescent. In the ESC model of differentiation NCX1 was 
also the first ECC gene to be up regulated at around day 2 of differentiation. 
Unsurprisingly at day 7 all cTnT +ve ESC-derived cardiomyocytes expressed localised 
NCX1 corresponding with a mature phenotype and supporting the early expression of 
NCX1. Together this data suggests that NCX1 is one of the first sarcolemmal Ca2+ 
handling proteins to be expressed during differentiation and may be required for the 
earliest observed pre-contractile Ca2+ transients.  
Whilst using the Nkx2.5-GFP reporter line it was possible at day 7 to observe NCX1 +ve 
regions which didn’t express Nkx2.5-GFP. This would suggest that during 
differentiation, NCX1 is expressed in cells prior to cardiac commitment (Nkx2.5-GFP 
expression) and may have a role in the specification of mesoderm into cardiac 
progenitors. Alternatively, NCX1 may be expressed in other cells types within the ESC 
culture. However, due to the juxtaposition of the NCX1 +ve Nkx2.5-GFP -ve cells and 
NCX1 +ve Nkx2.5-GFP +ve cells, it seems likely that they originate from a common 
progenitor and are not derived from other lineages (ectoderm or endoderm) (Z. Wang 
et al. 2012). At earlier stages of differentiation (day 4) prior to Nkx2.5-GFP, punctated 
expression of NCX1 could be observed within EBs, potentially at the cell membrane. 
This would suggest that NCX1 expression, although not yet distributed throughout the 
entire membrane, is expressed prior to cardiomyocyte specification. Whether these 
NCX1 puncta are functional and represent discrete membrane signalling domains 
(Schulze et al. 2003) or whether NCX1 is none-functional and is still being trafficked to 
the membrane is unclear (Feldmann et al. 2009).  
To attempt to determine the earliest cardiac progenitor population which expressed 
NCX1, a Brachyury antibody was used to locate cells of the mesoderm lineage. 
Although Brachyury +ve cells did not express membrane localised NCX1 it was 
interesting to note that NCX1 +ve cells could be found adjacent to Brachyury +ve cells, 
potentially suggesting communication between the two different cell types. 
Communication between different cell types during differentiation can have both feed 
forward positive effects, enhancing and promoting cardiomyocyte differentiation 
(Lavine et al. 2005), or alternatively it can repress mesoderm gene expression in 
progenitor cells (Mercola et al. 2011)(Lian et al. 2013). To be able to determine the 
earliest population of cardiac progenitors which express NCX1 it would be important to 
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try other markers such as Mesp1 or Gata-4, since their mRNA expression profiles 
corresponded with the increase in NCX1 expression (Table 3.8 and 3.11).  
4.3.3 Cav1.2 expression during cardiomyocyte differentiation 
In the adult heart, Cav1.2 is the main sarcolemmal Ca2+ influx pathway required for 
ECC. During cardiac crescent formation, the up regulation of Cacna1c (the gene which 
encodes Cav1.2) did not occur until E8.5 (after the increase in NCX1) with mRNA levels 
remaining unchanged between E7.5 and E8.0. This mRNA expression analysis was 
supported by immunohistochemical of whole mount embryos which showed that 
Cav1.2 was expressed within cardiac crescent at stage 2, but was absent at stage 0. 
Together this data revealed that the expression of Cav1.2 is preceded by NCX1 within 
the developing cardiac crescent. This difference in expression suggests that NCX1 is the 
main sarcolemmal protein responsible for the Ca2+ influx required to generate Ca2+ 
transients prior to contraction within the stage 0 heart. Whilst at later stages of cardiac 
crescent formation both Cav1.2 and NCX1 have a functional role in sarcolemmal Ca2+ 
flux and contraction. Although this data provides an insight into the dynamics of 
sarcolemmal ECC gene expression, levels of both channel and exchanger mRNA and 
protein do not directly correlate with function. Channels are known to have a greater 
rate of ion flux in comparison to exchangers meaning even with reduced expression 
Cav1.2 could perform a similar amount of Ca2+ flux compared to NCX1 (Gadsby 2009). 
To definitively understand the mechanisms for function, electrophysiological 
recordings of direct channel and exchange function would be needed. 
To investigate further the expression of Cav1.2 especially in relation to NCX1, temporal 
changes in mRNA expression and protein localization during ESC cardiomyocyte 
differentiation were examined. Expression of Cacna1c did not increase until day 4 of 
differentiation in the Eomes-GFP model, 2 days later than the initial increase in Slc8a1. 
Expression of Cav1.2 protein by immunohistochemical analysis could be observed in 
cTnT+ve cells at day 7 of differentiation however there was also a population of 
cTnT+ve cells which did not express Cav1.2. This difference could be due to the 
maturity of the ESC-derived cardiomyocytes. Previous data has shown Cav1.2 
expression occurs later than other functionally related cardiac genes such as NCX1 and 
suggests that these cTnT +ve Cav1.2 –ve cells represent less terminally differentiated 
107 
 
cells. Alternatively the variation in expression could be due to differences in 
cardiomyocyte cell type within cTnT+ve regions. In the adult heart there are multiple 
subtypes of cardiomyocytes (ventricular and atrial) which express different levels of 
various Ca2+ channels. In ventricular cardiomyocytes L-type channels are the main 
sarcolemmal Ca2+ channel subtype, however in the atria another Ca2+ channel (T-Type) 
is suggested to be more predominant. The role of other Ca2+ channels in heart function 
during development has also been described (Ferron et al. 2002)(Sabourin et al. 
2011)(Méry et al. 2005). These findings suggest that cTnT+ve cells which do not 
express Cav1.2 may express other types of Ca2+ channels allowing Ca2+ influx and 
contraction to occur and suggest that the cTnT+ve regions of cells is heterogonous in 
terms of Ca2+ influx mechanisms. 
4.3.4 The role of sarcolemmal Ca2+ release during cardiomyocyte differentiation 
The mechanism by which Ca2+ transients are generated prior to the development of 
ECC is poorly understood, with debate surrounding the relative contribution of Ca2+ 
from internal sarcoplasmic stores (Sasse et al. 2007)(Rapila et al. 2008). Previous 
immunofluorescence showed that both the sarcolemmal ECC proteins NCX1 and 
Cav1.2 are expressed within the cardiac crescent. To begin to investigate the role of 
the SR during cardiomyocyte differentiation, the expression of ECC genes responsible 
for SR Ca2+ regulation was assessed. During early development of the heart, Ryr2 
(encoding the ryanodine receptor – RyR2) expression was elevated during formation of 
the cardiac crescent (E8.0) and further increased during progression to the linear heart 
tube (E8.5). The increases in Ryr2 expression suggest that the SR is capable of releasing 
Ca2+ within the cardiac crescent. However, during ESC cardiomyocyte differentiation, 
Ryr2 expression did not increase until later stages of differentiation and, although 
significant, these changes were relatively small suggesting SR Ca2+ release via RyR2 was 
less fundamental during ESC cardiomyocyte differentiation. The development of a 
functional SR from the rough endoplasmic reticulum is poorly understood. Cytosolic 
Ca2+ oscillations originating from the SR have been observed in isolated E8.5 
cardiomyocytes (Sasse et al. 2007), providing support for the role of SR Ca2+ release in 
early contractile activity. However, contrary to these observations, treatment of 
control myocytes between E9.5 and E11.5 with ryanodine, a compound which locks 
the RyR2 in an open state, did not exert a major effect on spontaneous Ca2+ transients 
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(Takeshima et al. 1998). The observation that RyR2 KO transgenic mice have beating 
linear heart tubes at E9.5 again suggests SR Ca2+ release is not required for early 
contractile function. The late onset of Ryr2 expression in the ESC model would suggest 
that SR Ca2+ release does not influence early cardiomyocyte differentiation, however, 
this data cannot unequivocally exclude a role for RyR2 mediated Ca2+ release within 
the cardiac crescent until further functional studies are conducted. The relativity low 
level and late expression of Ryr2 in the ESC models compared to the embryo would 
suggest that the functional relevance of SR Ca2+ stores and RyR2 mediated Ca2+ release 
is  different in vitro compared to in vivo. This difference could either be due to the 
relative immaturity of ESC-derived cardiomyocytes (Li et al. 2015) and that RyR2 
expression correlates with maturity, alternatively the mechanism by which ESC-derived 
cardiomyocytes and embryonic hearts regulate contraction may be fundamentally 
different. 
4.3.5 Sodium regulation during cardiomyocyte differentiation 
In adult cardiomyocytes, ECC couples electrical depolarization with contraction. 
Depolarisation is initiated by the sodium channel, Nav1.5 (encoded by the gene Scn5a), 
which, once open, leads to Na+ influx which in a feed-forward manner further 
depolarises the membrane (Bers et al. 2003)(Aronsen et al. 2013). Although not 
directly involved in Ca2+ regulation it was interesting to investigate Nav1.5 gene 
expression to understand the electrophysical properties of the early heart and how 
other ions may be regulated. Unsurprisingly, as observed with the ECC components, 
Nav1.5 mRNA expression increased during postnatal and adult stages correlating with 
the maturation of cardiomyocytes. In terms of ESC cardiomyocyte differentiation, 
Nav1.5 was one of the first genes to be up regulated at around day 2 and had a 
dynamic expression profile during differentiation, as also observed in the embryo from 
E9.5 (Domínguez et al. 2008), suggesting a potential role for Nav1.5 and Na+ influx 
during early differentiation. Nav1.5 is known to have a role in heart development, as 
shown in Nav1.5 KO embryos which die around E10.5 with restricted ventricle 
development (Papadatos et al. 2002). Studies in zebrafish have shown that knock 
down of Nav1.5 leads to defects in specification of pre-cardiac mesoderm (Chopra et 
al. 2010) and a reduction in cardiomyocyte number, implying that proliferation of 
embryonic cardiomyocytes requires Nav1.5 activity (Bennett et al. 2013).  
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The correlation between the expression profiles of different channels and exchangers 
during differentiation, suggests that multiple ion fluxes may interact to regulate 
function. In guinea pig ventricular cardiomyocytes, the local accumulation of Na+ via 
Nav1.5 can trigger reverse mode NCX1 activity leading to Ca2+ induced Ca2+ release 
from the SR (Leblanc & Hume 1990). In the Eomes-GFP model of cardiomyocyte 
differentiation, increases in Nav1.5 mRNA corresponded with increases in NCX1 mRNA 
at day 2, suggesting an interaction between the two proteins and that early Na+ influx 
via Nav1.5 may be capable of regulating NCX1 activity. Together this data suggests a 
complex mechanism by which multiple proteins and exchangers can indirectly regulate 
different intracellular ions to effect downstream function and signalling. Na+ is also 
known to activate transcription and gene expression via its ability to activate salt-
inducible kinase 1 (Popov et al. 2012) suggesting a direct mechanism by which early 
Na+ influx could regulate differentiation.  
The early expression of both Scn5a and NCX1 suggests early increases in the 
concentration of intracellular Na+, we, therefore, wanted to investigate whether other 
proteins involved in Na+ removal were regulated during differentiation such as Na+/K+ 
ATPase. The Na+/K+ATPaseα2 is a ATP-dependent exchanger which removes Na+ from 
the cell whilst bringing in K+. Overexpression of Na+/K+ATPaseα2 has been shown to 
attenuate pathological cardiac hypertrophy in the adult by regulating intracellular Na+ 
and Ca2+ levels (Correll et al. 2014). During ESC differentiation, Atp1a2 (encoding 
Na+/K+ATPaseα2) was first up regulated at day 4 of differentiation before increasing 
further by day 14. This finding would fit with the hypothesis that the concentration of 
intracellular Na+ becomes elevated between day 2 and 4, increasing the requirement 
for Na+ removal. Another Na+-related gene studied was Slc9a1 which encodes Na+/H+ 
exchanger (NHE1), a regulator of intracellular pH which functions to transport protons 
out of the cell and bring Na+ in. NHE1 activity has also been reported to mediate Ca2+ 
oscillation via acidification and increases in the concentration of intracellular Na+ 
(Nakamura et al. 2012). As Ca2+ transients are initiated and function develops, an 
increase in metabolism would occur in order supply the cardiomyocytes with enough 
energy for contraction to occur (Abel & Doenst 2011). Increases in metabolism and 
ATP production are known to decrease intracellular pH (Poole-Wilson 1982), therefore 
NHE1 may be require to regulate these changes in pH. Initially the expression of NHE1 
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in the Eomes-GFP ESC model of differentiation was examined and a small increase in 
expression was observed between day 3 and 6 with a further increase at day 14. This 
relatively minor increase in expression suggests that NHE1 does not play a major role 
in cardiomyocyte formation although a role for NHE1 cannot be excluded as protein 
expression or activity has not been assessed. 
4.3.6 T-Type Calcium channel 
Although Cav1.2 is the predominant calcium channel in cardiomyocytes contributing to 
most of the Ca2+ required for ECC, other sarcolemmal Ca2+ channels are expressed in 
the heart, for example T-type Ca2+ channels (Cav3.1 and Cav3.2), are reported to have 
a role in pacemaker activity (Hagiwara et al. 1988)(Zhou & Lipsius 1994). T-type Ca2+ 
channels have also been suggested to have a role in heart development as they are 
observed at higher densities in embryonic (Mizuta et al. 2010)(Ferron et al. 2002) and 
neonatal myocytes (Nuss & Marban 1994)(Leuranguer et al. 2000) than in mature 
ventricular myocytes. It has been suggested that Ca2+ entry via T-type Ca2+ channels 
may serve as a current injector to initiate depolarisation during heart development 
(Zhang et al. 2003)(Schroder et al. 2006).  This study focused on the expression of 
Cacna1g, the gene known to encode the α1g subunit of Cav3.1. In the Nkx2.5-GFP 
cells, significant up regulation of Cacna1g occurred at day 14 of differentiation, 
although there was also a small increase at day 2 which did not reach significance. In 
the Eomes-GFP model, the expression profile of Cav3.1 was similar, with a large 
increase at day 14, although in this model Cacna1g was also significantly up regulated 
at day 2 of differentiation. This data suggests that Cav3.1 may be expressed at very 
early stages of ESC differentiation and is consistent with a previous study that 
demonstrated the functional expression of Cav3.1 in ESC-derived cardiomyocytes 
(Zhang et al. 2003). Together this could suggest that T-type Ca2+ channels may be 
involved in linking spontaneous electrical activity and Ca2+ handling with 
transcriptional activity during cardiac differentiation, as observed in neonatal 
cardiomyocytes (Ruchon et al. 2012). 
4.3.7 Inositol trisphosphate receptor type 2 (IP3R2) 
The main mechanism for Ca2+ release from the SR in the adult heart is via RyR2 
channels, however, IP3 receptors can also release Ca
2+ from the SR in a number of 
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different cell types including cardiomyocytes (Berridge 2009). IP3R-mediated Ca
2+ 
oscillations are some of the first signals known to occur during development, essential 
in activating unfertilized oocytes (Ciapa & Chiri 2000). Although the functional role of 
IP3R receptors in regulating heart rate is controversial, accumulating evidence suggests 
they may be involved in the rhythm control of non-cardiac pacemaker tissue as well as 
in the embryonic heart (Méry et al. 2005)(Ju et al. 2012). IP3R-dependent nuclear 
calcium signalling is also an important mechanism involved in cardiomyocyte 
excitation-transcription coupling, both in the adult heart during cardiac hypertrophy 
(X. Wu et al. 2006)(Nakayama et al. 2010) and in neonatal cardiomyocytes (Arantes et 
al. 2012)(Ibarra et al. 2013). ESC-derived cardiomyocyte studies have shown that 
application of Xestospongin-C or 2-amino-ethoxydiphenyl borate (2-APB), IP3-receptor 
antagonists, prevented spontaneous beating (Ferreira-Martins et al. 2009). In single 
E9.5 cardiomyocytes, IP3 receptors have been shown to regulate the frequency of SR 
Ca2+ oscillations and thus heartbeats (Sasse et al. 2007). 
We first examined IP3R gene expression during the later stages of embryonic 
development from E9.5 and found elevated Itp3r2, which encodes the main cardiac 
isoform of IP3R channels, within the P0 and adult heart. In the Nkx2.5-GFP ESC model 
of cardiomyocyte differentiation Itp3r2 was up regulated at around day 7 of 
differentiation, however, the increase was not statistically significant until around day 
10. Although this data does not exclude a role for Itp3r2 in the earliest calcium 
transients, the IP3R gene expression profile in comparison to other Ca
2+ channels and 
cardiomyocyte markers suggests that other Ca2+ handling proteins may be more 
important for early embryonic heart function. 
4.3.8 NAADP, Two-pore channels and lysosomal calcium stores 
NAADP is the most potent Ca2+-releasing second messenger known. Extensive studies 
have demonstrated that NAADP can stimulate Ca2+ release from lysosomes via Two-
pore channels 1 and 2 (TPC1 and TPC2). TPC1/2 were first cloned in 2000 (Ishibashi et 
al. 2000) and displayed significant sequence similarity to voltage-gated Ca2+ and Na2+ 
channels. Both TPC1 and 2 localize to the endo-lysosomal system which is known to 
contain high levels of Ca2+ (Brailoiu et al. 2009). More recently NAADP has been shown 
to be involved in atrial cardiomyocyte contraction and arrhythmias (Collins et al. 
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2011)(Nebel et al. 2013). Therefore it is a potential source of Ca2+ that has not been 
investigated to-date in cardiac development. NAADP signalling was therefore 
investigated as a potentially novel regulator of early Ca2+ signalling during ESC 
differentiation. NAADP levels were not quantified during ESC differentiation due to 
difficulties with assaying this nucleotide (Graeff & Lee 2002), instead TPC1 and 2 
expression was assessed. 
Throughout heart development, gene expression of Tpcn1 and Tpcn2 (encoding TPC1 
and TPC2) was maintained from E9.5, suggesting both early expression and a potential 
physiological role throughout development. In terms of ESC differentiation, Tpcn1 
expression began to increase from day 4 whilst levels of Tpcn2 remained constant 
throughout differentiation. The specific localisation and function of TPC1 and TPC2 are 
reported to be slightly different. TPC1 is primarily located in endolysosomes and 
believed to cause localised Ca2+ transients whereas TPC2 localises solely within 
lysosomes and triggers globalised Ca2+ transients (Patel et al. 2011). This may indicate 
that TPC1 and TPC2 are regulated in a cell-type specific manner as previously 
mentioned, which may account for the variation in mRNA levels during development. 
Although absolute gene expression levels were not quantified, Ct values for TPCs in 
both the in vivo heart samples and ESCs were very similar (TPC1; in vivo = ~25cts, in 
vitro = ~25cts. TPC2; in vivo = ~28cts, in vitro = ~29cts.), suggesting similar mRNA 
expression levels and hence cellular requirement. To determine protein levels, western 
blots and immunohistochemistry needs to be performed however currently available 
TPC antibodies are of low quality, rendering this difficult.  
Whilst, TPC1 and TPC2 have been strongly reported to be involved in Ca2+ release from 
acidic stores, recent studies have suggested that TPC1 and TPC2 are actually Na+ 
selective (X. Wang et al. 2012), although this is strongly debated (Marchant & Patel 
2013). If TPC1 and TPC2 were Na+-selective channels they could potentially regulate 
cardiomyocyte differentiation via direct Na+ related signalling pathways or indirectly by 
activating other Na+ regulated exchangers such as NCX, similar to the potential 
function of Nav1.5. 
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4.3.9 Store operated calcium release 
Transient receptor potential channels (TRPC) are store-operated sarcolemmal Ca2+ 
channels that can be activated by signalling molecules, internal Ca2+ store depletion 
and membrane stretch. Studies in chick hearts have shown that TRPCs can regulate 
both contractility and pacemaker activity during development (Sabourin et al. 2011). 
TRPC3 is a cardiac-specific isoform, shown to be up regulated in murine hypertrophy 
(Bush et al. 2006). Inhibition of TRPC3 with the specific inhibitors, GSK2332255B and 
GSK2833503A , inhibited the onset and progression of pathological hypertrophy in 
mice (Seo et al. 2014). Expression of TRPC3 increased at day 7 of ES cardiomyocyte 
differentiation correlating with the expression of mature cardiac specific markers 
suggesting TRPC3 may not be essential for cardiomyocyte formation and early function 
in this model, but may play a role in maturation. This would fit with the observation 
that TRPC3 global KO mice survive to adulthood (Hartmann et al. 2008).  
Another important stored-operated Ca2+ channel is Orai1, which is activated upon 
decreases in the concentration of Ca2+ in the endoplasmic via an interacting protein 
Stim1. Stim1 and Orai1 have been shown to regulate hypertrophic growth in 
cardiomyocytes (Voelkers et al. 2010) as well as having a role in regulating 
cardiomyocyte function (Collins et al. 2013). In the Eomes-GFP ESC model stim1 and 
orai1 were not up regulated during cardiomyocyte differentiation, suggesting that they 
do not play a role in heart formation. This is further supported by Stim1 (Oh-Hora et al. 
2008) and Orai1 (Gwack et al. 2008) KO mice surviving until at least the late stages of 
embryonic development. 
4.3.10 Cav1.2 is required for cardiomyocyte contraction during cardiac crescent 
development 
Cav1.2, a voltage-dependent Ca2+ channel, is activated by membrane depolarisation 
allowing Ca2+ to cross the sarcolemmal membrane via an electrochemical gradient. In 
the adult heart, Cav1.2 is the predominant source of Ca2+ influx, triggering SR Ca2+ 
release and contraction (Reuter 1979)(Lederer et al. 1990) (Ertel et al. 2000). In these 
current studies, Cav1.2 was found to have a fundamental role in generating Ca2+ 
transients from the onset of contraction, although it was not involved at the earliest 
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stages exemplified by the pre-contractile Ca2+ transients observed during cardiac 
crescent formation. 
In adult cardiomyocytes, Cav1.2 is activated during action potential depolarisation, at a 
membrane potential of -40mV, allowing Ca2+ influx until repolarisation occurs. In 
cardiomyocytes at E10.5 the resting membrane potential is reported to be around -
40mV, which is significantly greater than that in adult cardiomyocytes and suggests 
constant Cav1.2 activation or that smaller depolarisation currents are sufficient to 
trigger activity and Ca2+ influx. In addition to the membrane potential, a number of 
other factors can affect Cav1.2 activity, including intracellular Ca2+ levels, auxiliary 
channel subunit composition as well as regulation by different signalling molecules 
including calmodulin kinase II and A-kinase anchoring proteins (AKAPs) (for review see 
(Harvey & Hell 2013)). Due to the dynamic regulation of Cav1.2 it is difficult to assess 
the kinetics of this channel within the stage 1 cardiac crescent, however, it is likely that 
the properties of this channel in the embryonic heart are significantly different from 
that in the adult.   
To generate contraction, Ca2+ must bind and activate myofilaments; this activation is 
facilitated by rapid increases in the concentration of intracellular Ca2+ (Bers 2000)(De 
Tombe 2003). In intact adult cardiomyocytes, the concentration of free intracellular 
Ca2+ required for half-maximal myofilament activation is around 600 nM, however due 
to Ca2+ buffering, greater levels of Ca2+ influx are required in order for free cytosolic 
Ca2+ to reach the threshold for contraction (Berlin et al. 1994)(Trafford et al. 1999). 
Ca2+ is buffered by a number of different intracellular moieties which compete with 
troponin to bind Ca2+ (Gao et al. 1994). Studies have shown that to raise intracellular 
Ca2+ concentrations from around 100 nM to peak systolic levels of around 1 µM, the 
actual Ca2+ concentration needs to increase by over 100 µM due to Ca2+ buffering 
(Trafford et al. 1999). This suggests that Cav1.2 is fundamentally required to generate 
the large Ca2+ fluxes required for contraction in adult cardiomyocytes. In embryonic 
cardiomyocytes, however, the concentration of Ca2+ required for contraction may be 
reduced due to a number of different cellular properties including; cell size, the 
expression of Ca2+ buffering proteins as well as altered sensitivity of myofilaments to 
Ca2+. These differences may potentially allow Cav1.2-mediated Ca2+ influx to initiate 
contraction independently of SR activity. The functional impact of Cav1.2 inhibition 
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correlated with an increased time-to-peak (TTP) observed between stage 0 and stage 1 
(chapter 3) and would suggest increased Cav1.2 kinetics, in terms of rate of flux, were 
responsible for the increased rate of Ca2+ transients. This embryo-adult difference 
suggests that Cav1.2 expression facilitated contraction by enabling a greater 
concentration of Ca2+ to enter the cell, therefore, raising the intracellular Ca2+ 
concentration to a level capable of triggering myofilament activation.  
Overall this data reveals that Ca2+ channel activity is fundamental for contraction at 
stage 1 of cardiac crescent development and suggests that Cav1.2 is essential for the 
generation of the large inward Ca2+ fluxes in order to raise intracellular Ca2+ levels 
sufficiently to active myofilaments and generate contraction. 
4.3.11 Directionality of NCX1 activity 
In the adult heart NCX1 is the main Ca2+ efflux pathway, working in combination with 
SERCA to remove Ca2+, after contraction. Although NCX1 works predominantly in 
“forward mode” (Ca2+ efflux), it can also work in “reverse mode” (Ca2+ influx), due to 
its electrogenic nature and sarcolemmal ionic gradients, resulting in Ca2+ influx 
(Blaustein & Lederer 1999)(Leblanc & Hume 1990). These results reveal that NCX1 is 
fundamental for the generation of Ca2+ transients prior to contraction in early 
developing cardiomyocytes and suggests that in the stage 0 cardiac crescent NCX1 
functions in reverse mode to trigger Ca2+ influx. In mature cardiomyocytes, the 
importance of NCX1-mediated Ca2+ influx is widely debated, although studies have 
shown that Ca2+ entry via “reverse mode” NCX, triggered by sodium influx during an 
action potential, can work synergistically with Cav1.2 to trigger Ca2+ release from the 
SR (Larbig et al. 2010). In the developing heart (~E8.5), however, “forward mode” 
NCX1 has a predominant role in action potential generation (Liang et al. 2010) as well 
as potentially contributing to early Ca2+ influx by working in “reverse mode” (Reppel, 
Reuter, et al. 2007). Previous studies have characterised the functional expression of 
NCX1 from E8.5-E9.5 (post-linear heart tube formation) in mouse (Linask et al. 
2001)(Reppel, Sasse, et al. 2007)(Liang et al. 2010), coincident with cardiac looping 
morphogenesis, which is later than the stages in which onset of NCX1 expression and 
associated cardiac function is observed.  
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The directionality of NCX1 activity is dependent on the concentration gradient of intra- 
and extra-cellular Ca2+ and Na+ in addition to the membrane potential (Reppel, Reuter, 
et al. 2007). The reversal potential determines the membrane potential at which NCX1 
activity is balanced and varies depending on the intra and extracellular concentrations 
of Na+ and Ca2+. Under normal physiological conditions, the concentration of 
intracellular Na+ is ~8 mM whilst Ca2+ is ~100 nM (Bers et al. 2003), which is 
significantly lower than the extracellular concentrations (Na+ = ~140mM; Ca2+ = 
~1.5mM). As a result the reversal potential, calculated using the Nernst equation, for 
NCX1 is around -26mV. In terms of NCX1 function this means that, if the membrane 
potential was lower than -26mV, “forward mode” activity (Ca2+ efflux) would occur, 
however at membrane potentials above -26mV “reverse-mode” activity(Ca2+ influx) 
would predominate.  
Adult cardiomyocytes have a resting membrane potential of around -85mV, which 
favours “forward-mode” NCX1 activity and the removal of Ca2+, however, during 
development the resting membrane potential of immature cardiomyocytes is known 
to be significantly higher. Embryonic cardiomyocytes at around E10.5 have been 
shown to have a resting membrane potential of around -40mV (Sasse et al. 
2007)(Rapila et al. 2008), which would increase the likelihood and potential functional 
relevance of “reverse mode” NCX1 activity. The conditions that favour reverse mode 
NCX1 activity include less depolarised membrane potentials as well as a high 
concentration of intracellular Na+, which are likely to be present in immature 
cardiomyocytes. Although the membrane potential of stage 0 cardiomyocytes has not 
been measured, it can be assumed to be greater than -40mV meaning NCX1 activity 
would be more susceptible to changes in the concentration of intracellular Ca2+ and 
Na+. Collectively this suggests that within the developing heart the directionality of 
NCX1 activity will be highly variable due to electrochemical properties of immature 
cardiomyocytes and the dynamic ionic fluxes occurring during formation of the cardiac 
crescent. 
4.3.12 The role of NCX1 in cardiomyocyte function  
Inhibition of NCX1 function with either CB-DMB or KB-R7943 blocked single–cell, slow 
Ca2+ transients in pre-contractile cells at stage 0, suggesting that “reverse mode” NCX1 
117 
 
activity was prevented due to an inhibition in Ca2+ influx. It has been reported that KB-
R9743 preferentially blocks “reverse mode” NCX1 activity (Hoyt et al. 1998)(Iwamoto 
2004) further supporting a role for NCX1 in Ca2+ influx, although the ability of 
pharmacological NCX1 inhibitors to block specific modes of NCX1 function is debated. 
One possibility was that the inhibition of spontaneous Ca2+ transients was due to 
cytosolic Ca2+ overload occurring secondary to the inhibition of NCX1 acting in its 
forward mode of operation and transporting Ca2+ out of the cell. However, arguing 
against this is the fact that there were no changes observed in the baseline Cal-520 
signal over the imaging timecourse. This may further support a role for “reverse mode” 
NCX1 function in early Ca2+ transients.   
Although NCX1 inhibition directly blocked Ca2+ transients suggesting NCX1 mediated 
Ca2+ influx was inhibited, it could also be suggested that this phenotype was 
alternatively due to forward mode activity. It is widely accepted that “forward mode” 
NCX1 function removes one Ca2+ in exchange for three Na2+ (Blaustein & Lederer 
1999), overall resulting in one extra positive charge entering the cell leading to 
production of a net inward current. In the adult, the NCX1-derived, inward current can 
trigger ectopic action potentials leading to arrhythmias such as delayed after 
depolarisations, whilst at ~E8.5 NCX1-derived, inward current has been suggested to 
contribute to depolarisation and action potential generation (Liang et al. 2010). This 
suggests that inhibition of NCX1 could block Ca2+ transients by preventing action 
potential generation and depolarisation resulting in the inhibition of Ca2+ influx via 
other Ca2+ channels. This mode of inhibition is most likely to occur in the stage 1 
cardiac crescent when both CB-DMB and nifedipine inhibited Ca2+ transient 
generation, since “forward mode” NCX1 activity could trigger the opening of Cav1.2. In 
the stage 0 cardiac crescent, however, nifedipine did not affect Ca2+ transient activity, 
further supporting a role for “reverse mode” NCX1 Ca2+ influx triggering Ca2+ 
transients. Alternately at stage 0 “forward mode” NCX1 activity could still generate 
action potentials and depolarisation but may activate unidentified Ca2+ channels 
however due to the slow Ca2+ dynamics observed at this stage this is unlikely. A third 
possibility in terms of NCX1 function is that within the stage 0 cardiac crescent NCX1 
could be responsible for both the Ca2+ influx and efflux, correlating with the slow 
dynamics of stage 0 Ca2+ transients. It was shown in chapter 5 that the Na2+ channel 
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Nav1.5 was expressed at the earliest stages of cardiomyocyte differentiation and could 
act as a potential mechanism for increasing intracellular Na+ concentrations and 
driving initial NCX1-mediated Ca2+ transients. As “reverse mode” NCX1 activity triggers 
Ca2+ influx the intracellular concentration of Ca2+ would increase raising the reversal 
potential of NCX1 and triggering Ca2+ efflux via “forward mode” activity. This “forward 
mode” NCX1 activity may also go on to regulate the next Ca2+ transient by activating 
Nav1.5 and triggering further Na+ influx. 
4.3.13 Dynamic requirement for NCX1 and Cav1.2 during cardiac crescent formation 
During formation of the heart from the pre-contractile cardiac crescent (stage 0) to the 
linear heart tube stage-dependent changes in the role of both NCX1 and Cav1.2 were 
revealed. Similar differences were also observed in the ESC cardiomyocyte 
differentiation model between days 7 and 14. These findings correlate with the 
increases in rate of contraction and changes in Ca2+ transient dynamics during 
formation of the cardiac crescent (chapter 3) as well as the increased expression of 
NCX1 prior to Cav1.2. The influence of NCX1 and Cav1.2 on Ca2+ transients occurs in a 
dynamic way, with the transition from cardiac crescent to LHT taking around 12 hours 
suggesting that changes in NCX1 activity occur very rapidly. These differences are most 
likely due to the stage-dependent gene expression of NCX1 and Cav1.2 as discussed in 
chapter 5, however a number of other factors are likely to determine the functional 
significance of NCX1 and Cav1.2 during initiation of cardiac function. 
One of the main factors regulating Cav1.2 and NCX1 function is the difference in 
kinetics of channels and exchangers. Typically channels have around a 1000-fold 
greater rate of ion flux compared to exchangers (Bers 2001). At stage 0 of crescent 
formation inhibition of Cav1.2 had no effect on pre-contractile Ca2+ transients whilst 
NCX1 was required for their initiation.  The ability of CB-DMB to inhibit pre-contractile 
Ca2+ waves suggests that the slow dynamics of these stage 0 Ca2+ transients are due to 
the slow kinetics of NCX1 activity. The lack of contraction at stage 0 may be due to two 
different reasons. One possibility is that the lack of sarcomere formation at stage 0 
may prevent contraction, meaning NCX1 derived Ca2+ transients cannot trigger 
contraction due to the immature contractile apparatus. Alternatively, NCX1-derived 
Ca2+ transients may not be sufficient to raise intracellular Ca2+ levels and trigger 
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activation of myofilaments. The inability of NCX1 mediated Ca2+ transients to generate 
contraction may be exacerbated by Ca2+-binding proteins buffering free Ca2+ during 
initial Ca2+ influx and could suggest that intracellular Ca2+ has to reach a threshold 
before contraction can occur.  
As the cardiac crescent matured from stage 1 to the linear heart a number of changes 
were observed including, the onset and increase in rate of contraction (chapter 3), the 
expression of Cav1.2 along with a loss in ability of NCX1 blockade to prevent Ca2+ 
transients.  The onset and increase in contraction correlate with the kinetics of Cav1.2 
and its increased expression as previously discussed, however the loss of “reverse-
mode” NCX1 activity and Ca2+ influx may be due to a number of interlinked factors.   As 
cardiomyocytes mature their resting membrane potential decreases leading to a 
change in NCX1 activity (Reppel, Sasse, et al. 2007). Between stage 0 and stage 3 there 
is likely a reduction in resting membrane potential sufficient to prevent “reverse-
mode” NCX1 activity and therefore Ca2+ influx. The loss of NCX-mediated Ca2+ influx 
may also be due to the role of NCX1 in Ca2+ homeostasis. The increased expression and 
function of Cav1.2 would trigger greater Ca2+ influx, therefore, raising intracellular Ca2+ 
concentration leading to increased “forward–mode” NCX1 activity in order to prevent 
Ca2+ overload. NCX1-mediated Ca2+ efflux may be more fundamentally relevant in the 
embryonic setting compared to the adult due to the lack of a mature sarcoplasmic 
reticulum, making the balance between Cav1.2 mediated Ca2+ influx and NCX1 Ca2+ 
efflux critical. Elevated Ca2+ removal via NCX1 could also result in an increased rate of 
contraction due to the inward depolarising current generated by “forward-mode” 
NCX1 activity having a pacemaker like function. In terms of pacemaker activity it is 
likely that the role of NCX1 in action potential generation is superseded by the 
expression of HCN4 along with decreases in the membrane potential as 
cardiomyocytes mature. 
In conclusion, NCX1 appears to be fundamental to the initiation of pre-contractile slow 
Ca2+ transients, however, its role becomes superseded by Cav1.2 during crescent 
maturation and as contraction rate increases. In order to determine the mechanisms 
underlying these functional changes, further electrophysiological studies would be 
required.  
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4.3.14 Restriction of Ca2+ wave propagation in the cardiac crescent 
Whilst assessing the effect of pharmacological inhibition on wave propagation in the 
cardiac crescent at stages 1-3, a confinement of Ca2+ transients was observed after 5 
min of drug application before complete inhibition. CB-DMB, KB-R7943 and Nifedipine 
all caused a similar effect in confining Ca2+ waves to the right side of the embryo. This 
would suggest a cellular heterogeneity across the cardiac crescent in terms Ca2+ 
transient generation. This heterogeneity could represent cardiomyocyte maturity or 
lineage specific differences. As cardiomyocytes mature, the role of pace maker 
currents such as the If HCN4 derived “funny current” and the T-type type current 
become more predominant in controlling the rate of contraction. This non-inhibited 
region may, therefore, represent a population of cells which have matured so that Ca2+ 
transient generation is more resistant to inhibition. Alternatively, this observation 
could be explained by the cardiac crescent being made up of different cardiomyocyte 
sub-populations which have different electrochemical properties. In the adult, 
different regions of the heart have different electrophysical properties due to the 
channels and exchangers they express. For example, HCN4 and T-type Ca2+ channels 
are expressed at greater levels in the atria compared to the ventricles. It has been 
shown that during first and second heart field formation both lineages express the 
cardiogenic mesoderm marker, Mesp1, however, these cells are already committed to 
form distinct populations of cardiomyocytes which give rise to different regions of the 
heart. In contrast, differences in channel expression between the two ventricles or the 
two atria may be due to left-right signalling as confinement of Ca2+ transients occurring 
in an asymmetrical manner. Expression of genes involved in left-right patterning such 
as Pitx2 may control the expression of genes responsible for the electrophysiological 
heterogeneity and left-right differences. Pitx2 plays a crucial role in morphology of the 
forming heart as well as being shown to control cardiac transcription factors such as 
Mef2c and Gata-4 but also ion channels including HCN4 and repolarising  potassium 
channels such as Kcna1, Kcnk2 (Wang et al. 2010).  In addition to a role in heart 
development, Pitx2 has also been implicated as causative of atrial fibrillation in the 
adult (Sinner et al. 2011), highlighting a potential role for left-right patterning in 
manifesting via the electrophysiological properties across the adult heart. 
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Overall, this data reveals that in the stage 1 cardiac crescent, the response to 
pharmacological inhibition is not uniform, with confinement of Ca2+ waves to a specific 
region. This observation would suggest that across the symmetrical cardiac crescent 
there is heterogeneous ion channel and exchanger expression, however what 
determines this electrophysiological asymmetry is still unknown. 
4.3.15 Pharmacological and technical limitations when assessing NCX1 and Cav1.2 
function 
Whilst CB-DMB, KB-R7943 and nifedipine have been reported as specific inhibitors to 
NCX1 and L-type Ca2+ channels respectively caution must be taken when interpreting 
this data in regards to off-target effects. To reduce the chance of off-target effects 
when using NCX1 inhibitors two different specific inhibitors of NCX1 were used. Both 
CB-DMB and KB-R7943 have been shown to directly inhibit NCX1 function, however, it 
has been published that at high concentrations they can inhibit L-type Ca2+ channel 
activity (Secondo et al. 2009). Using the whole embryo in order to image Ca2+ 
transients in the forming heart prevented the precise concentration of inhibitor 
reaching the cardiac crescent from being known, although the concentration is likely to 
be significantly lower than that calculated in the media due to mounting of the 
embryos, the tissue surrounding the heart and diffusion of the media.  These 
observations revealed that both KB-R7943 and CB-DMB had the same stage-
dependent effect on Ca2+ transients; with no inhibition observed at the late stages of 
cardiac crescent formation, in contrast to application of nifedipine which continued to 
inhibit Ca2+ transients at the later stages of development. Together this data would 
strongly support the specific nature of both CB-DMB and KB-R7943 when inhibiting 
NCX1 function, especially in ruling out off-target inhibition of L-type Ca2+ channels. 
Nifedipine is widely used as a specific L-type Ca2+ channel inhibitor, however, it could 
also inhibit other L-type Ca2+ channels such as Cav1.1. Although the focus of these 
studies was on the L-type channel Cav1.2, other L-type Ca2+ channels, such as Cav1.3, 
may also influence Ca2+ transients and contraction within the cardiac crescent, 
however, this was not addressed in this study.  
When analysing Ca2+ transients at stage 0 application of DMSO, as a vehicle control, 
inhibited Ca2+ transients, whilst from stage 1 onwards it had no effect. The inhibition 
observed at this stage under control conditions (DMSO) is most likely due to the model 
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used and the technical difficulties associated with Ca2+ dye loading, fine dissection and 
removal of the endoderm as previously discussed. The fact that application of DMSO 
resulted in a decrease in the number of cells with Ca2+ transients would suggest that 
the endoderm has a role in maintaining early Ca2+ transients. This again highlights the 
need for a new approach when trying to investigate the initiation of Ca2+ transients 
during heart development such as transgenic Ca2+ reporter lines which would allow 
Ca2+ imaging to be conducted without removing the overlying endoderm. 
4.4 Summary 
In this chapter the expression of a number of different Ca2+ related channels and 
exchangers during cardiomyocyte differentiation and heart formation has been 
characterised. The aim of this study was to try and identify potential Ca2+ handling 
mechanisms which may have a role in both cardiac function as well as influencing 
downstream signalling pathways required for cardiac gene expression and 
cardiomyocyte differentiation. This chapter has focused on the sarcolemmal protein 
NCX1 as having a major role in pre-contractile Ca2+ transients due to its early 
expression and previously reported role in embryonic cardiomyocyte function. The 
functional significance of NCX1 and Cav1.2 has been investigated during the initiation 
of cardiac function with similar roles for NCX1 and Cav1.2 observed in both the mouse 
embryo and ESC-derived cardiomyocytes. These results revealed that NCX1 is 
responsible for Ca2+ influx in stage 0 Ca2+ transients whilst its role is superseded by 
Cav1.2 as cardiomyocytes mature, highlighting a dynamic role for these proteins 
during the initiation of heart function. In the following chapters, how these early Ca2+ 
influx pathways may regulate cardiomyocyte gene expression and differentiation to 
feedback onto early heart development will be investigated. 
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5. CHRONIC INHIBITION OF NCX1, CAV1.2 AND TPC1/2 INHIBITS 
CARDIOMYOCYTE DIFFERENTIATION 
5.1 Introduction 
During formation of the cardiac crescent dynamic changes were observed in cardiac 
function, the expression of Ca2+ handling proteins and the mechanism by which Ca2+ 
transients are initiated. NCX1 was found to be a predominant mechanism for 
sarcolemmal Ca2+ influx and transient generation prior to contraction a role 
superseded by Cav1.2 as the cardiac crescent matured. Whilst transgenic models of 
NCX1 and Cav1.2 loss of function have shown that these proteins are required for 
viable embryo development they have not revealed how early Ca2+ handling via NCX1 
or Cav1.2 effects cardiomyocyte differentiation. In this chapter we will examine how 
pharmacological inhibition of NCX1 and Cav1.2 effects cardiomyocyte differentiation 
using both ESC cardiomyocyte differentiation and embryo culture models.  
5.2 Results 
5.2.1 CB-DMB and nifedipine have half-lives suitable for long term culture 
experiments 
To assess the role of NCX1 and Cav1.2 mediated Ca2+ influx pharmacological inhibition 
was used during ESC cardiomyocyte differentiation and embryo culture. To determine 
the most suitable inhibitors for long-term culture, it was important to determine the 
activity of CB-DMB, KB-R7943 and nifedipine over extended periods of culture, due to 
the differentiation protocol requiring up to 4 days without a media change. To 
determine the most stable NCX1 and Cav1.2 inhibitors, drug activity was measured by 
assessing the percentage of beating EBs at day 7 after 30mins of application. Inhibitors 
were either freshly made or maintained in solution at 37oC for 2 or 4 days. The 
inhibitory effect of CB-DMB, nifedipine and DMSO was unchanged when either 2 day 
or 4 day old drug-containing-media was added, compared to fresh drug containing 
media (Figure 5.1a & b, Figure 5.1d). This was in contrast to KB-R7943 which when 
made fresh inhibited contraction but had no effect after 4 days at 37oC (Figure 5.1c). 
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Overall this data suggests that for long-term culture the most suitable NCX1 and 
Cav1.2 inhibitors would be CB-DMB and nifedipine respectively based on their stability 
and continued inhibition after 4 days in culture. 
 
Figure 5.1: Pharmacological activity of CB-DMB and nifedipine is maintained after 4-days in 
culture 
Contraction was assessed in ESC-derived cardiomyocytes at day 7 of differentiation after 
30mins culture with NCX1 and Cav1.2 channel blockers cultured for different lengths of time. 
Application of DMSO did not inhibit contraction when using fresh, 2-day old and 4-day old 
media (a, fresh, n=42; 2-day=2; 4-day n=9). Inhibition of NCX1 with CB-DMB (10 μM) reduced 
contractions when fresh, 2-day old and 4-day old drug containing media was added (b, fresh, 
n=37; 2-day=5; 4-day n=6), whereas fresh KB-R7943 (30 μM) completely inhibited contraction 
but its ability to inhibit contraction was reduced when 2-day old drug containing media was 
added and had no effect when 4-day old drug was applied (c, fresh, n=10; 2-day=3; 4-day n=3). 
Inhibition of LTCC with nifedipine (10 μM) significantly reduced contractions when fresh, 2-day 
old and 4-day old drug containing media was added (d, fresh, n=15; 2-day=2; 4-day n=6). 
 
5.2.2 Inhibition of NCX1 prevents Nkx2.5-GFP ESC cardiomyocyte differentiation 
Pharmacological inhibition was used to establish the role of NCX1 and Cav1.2 in 
cardiomyocyte specification and differentiation. For these experiments, Nkx2.5-GFP 
EBs were plated at day 4 of differentiation on gelatin-coated 12 well plates. In cells 
treated throughout differentiation with 1 µM CB-DMB, expression of Nkx2.5 was 
significantly reduced as assessed by number of GFP positive cells present at day 14 
(Figure 5.2e-h). In terms of phenotype, the inhibition of NCX1 had no effect on the 
formation of EBs or cell outgrowth, although at day 14 the morphology of original EBs 
was more defined compared to the DMSO control. To establish the stage at which 
NCX1 inhibition affects cardiac differentiation mRNA expression of stage specific 
markers was measured. Cells treated with 1 µm CB-DMB, a concentration known to 
inhibit the NCX1 function (Secondo et al. 2009), from day 0-14 exhibited significantly 
reduced expression of the myocyte markers Myh6 and Tnnt2 (Cooper & Ordahl 
1984)(Nakao et al. 1997)(Myh6; 0.031 ±0.02; p≤0.001; Tnnt2; 0.122 ±0.04; p≤0.001; 
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Figure 5.3a, Figure 5.3b) as well as inhibiting expression of the early cardiac progenitor 
markers Nkx2.5 and Mef2c (Edmondson et al. 1994)(Lien et al. 1999)(Nkx2.5; 0.242 
±0.04; p≤0.001; Mef2c; 0.278 ±0.11; p=0.006; Figure 5.3c, Figure 5.3d). The endoderm 
marker Sox17 was also down regulated (0.268 ±0.10; p=0.04; Figure 5.3j) whilst GFAP 
and Goosecoid were unchanged (Eglitis & Mezey 1997)(Gaunt et al. 1993)(Figure 5.3i, 
Figure 5.3k).  In contrast, NCX1 inhibition significantly increased the expression of the 
mesoderm marker Brachyury (Wilkinson et al. 1990)(7.30 ±2.27; p≤0.001; Figure 5.3f). 
Although the cardiogenic mesoderm marker Mesp1 was up-regulated this was not 
significant (Saga et al. 1999)(3.35 ±1.03; Figure 5.3e). Pluripotent markers Oct-4 and 
Nanog (Niwa et al. 2005) (Mitsui et al. 2003) were also both up-regulated (Oct-4; 3.60 
±1.04; p≤0.001; Nanog; 2.75 ±0.34; p=0.003; Figure 5.3g, Figure 5.3h) compared to the 
DMSO control.  These findings indicate that NCX1 inhibition may be playing a role in 
the specification of mesoderm to cardiac progenitors.  
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Figure 5.2: Nkx2.5-GFP ESC derived cardiomyocyte formation is reduced at day 14 after 
culture with 1 µM CB-DMB and 30 µM Ned-k throughout differentiation, but was not 
affected by 500 nM nifedipine 
At day 14 control Nkx2.5-GFP cardiomyocyte differentiation revealed extensive GFP+ 
expression after culture with DMSO from day 0-14 (a-d) as compared to a loss of GFP+ cells 
when treated from day 0-14 with CB-DMB (day 0-14) to inhibit NCX1 (e-h) or Ned-K to inhibit 
NAADP signalling (i-l). Inhibition of Cav1.2 with 500 nM nifedipine had no effect on Nkx2.5-GFP 
expression at after 14 days of differentiation (m-p). Fluorescence (a, c-e, g-i, k-m, o, p) and 
bright field (b, f, j, n) images shown for each treatment group; bright field confirmed the 
cultures were grossly unaffected by treatment. Scale bar: a-c, e-g, i-k, m-o = 500 µm; d, h, l, p = 
200 µm. 
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In order to determine the time point at which NCX1 inhibition was repressing 
differentiation, ESCs were treated from day 0-4 with 1µm CB-DMB before being 
cultured in normal control media from day 4 to 14. This treatment regime led to a 
reduced number of Nkx2.5-GFP positive cells forming, although there were more in 
total when compared to treatment from day 0-14 (Figure 5.4e-h). Expression of Myh6, 
Tnnt2 and Nkx2.5 mRNA was found to be significantly decreased by day 14 when 
compared to DMSO treatment (Myh6; 0.086 ±0.04; p=0.019; Tnnt2; 0.215 ±0.04; 
p=0.001; Nkx2.5; 0.328 ±0.06; p≤0.001; Figure 5.3a-b, Figure 5.3d), although to a lesser 
extent than observed when ESC where treated with 1 µm CB-DMB throughout 
differentiation. In contrast, Mef2c expression was not significantly reduced at day 14 
when treated from day 0-4 with 1 µm CB-DMB (Figure 5.3c). In terms of early markers 
at day 14, Mesp1, Brachyury, Oct-4 and Nanog expression were significantly up-
regulated compared to DMSO control (Mesp1; 4.86 ±0.43; p=0.018; Brachyury; 3.62 
±0.55; p=0.012; Oct-4; 2.19 ±0.21; p=0.002; Nanog; 2.21 ±0.34; p=0.02; Figure 5.3e-h), 
although Brachyury, Oct-4 and Nanog were not elevated to the same extent as 1 µm 
CB-DMB treatment from day 0-14. There were significant differences at day 14 in the 
expression levels of Myh6, Mef2c and Nanog compared to day 0-14 1 µm CB-DMB 
treatment (Myh6; p=0.031; Mef2c; p=0.035; Nanog; p=0.008; Figure 5.3a, Figure 5.3c, 
Figure 5.3h). Therefore, whilst blocking early NCX1 function during mesoderm 
pattering and cardiomyocyte specification (day 0-4) reduced cardiomyocyte 
differentiation it did not completely prevent it, as demonstrated by the increases in 
cardiomyocyte-specific mRNA levels and the expression of Nk2.5-GFP at day 14. This 
highlights a potential early role for NCX1 in mesoderm to cardiomyocyte specification. 
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Figure 5.3: Inhibition of NCX1 with 1 µM CB-DMB prevents cardiomyocyte specific gene 
expression and promotes early ESC markers at day 14 of Nkx2.5-GFP ESC differentiation 
Following chronic exposure of Nkx2.5-GFP ESC for 14 days to CB-DMB (1 μM) there was a 
significant decreases in the cardiac genes Myh6 (a), Tnnt2 (b), Mef2c (c) and Nkx2.5(d), whilst 
early ESC genes Brachyury (f), Oct-4 (g) and Nanog (h) were up regulated compared to DMSO 
control.  The endoderm marker Sox17 was also down regulated (j), whereas Mesp1 (e), GSC (i) 
and GFAP (k) were not significantly different. Treatment from day 0-4 with CB-DMB and 
subsequent culture in control media until day 14 resulted in the same effect on gene 
expression as that observed with treatment from day 0-14 although there was a significant 
increase in the expression of Myh6 (a) and Mef2c (c) compared to treatment from day 0-14. 
Whilst most genes showed a similar expression pattern at day 14 when treated from day 0-4 
compared when treated throughout the mesoderm gene Mesp1 (e) became significantly up 
regulated. All error bars are mean ± S.E.M (n=5). Statistics: one-way ANOVA and Tukey test for 
multiple comparisons (* p<0.05; ** p<0.01; *** p<0.001). 
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Figure 5.4: Nkx2.5-GFP ESC derived cardiomyocyte formation is reduced at day 14 after 
culture with 1 µM CB-DMB and 30 µM Ned-k from day 0-4, but was not affected by 500 nM 
nifedipine 
Nkx2.5-GFP cardiomyocyte differentiation revealed extensive GFP+ expression after treatment 
with DMSO from day 0-4 (a-d) before culture for 10 days in control media, as compared to a 
significant reduction in GFP+ cells when treated from day 0-4 with CB-DMB (maintained in 
control media from day 4-14) to inhibit NCX1 (e-h) or Ned-K to inhibit NAADP signalling (i-l). 
Inhibition of Cav1.2 with 500 nM nifedipine had no effect on Nkx2.5-GFP expression after 14 
days of differentiation (m-p). Fluorescence (a, c-e, g-i, k-m, o, p) and bright field (b, f, j, n) 
images shown for each treatment group; bright field confirmed the cultures were grossly 
unaffected by treatment. Scale bar: a-c, e-g, i-k, m-o = 500 µm; d, h, l, p = 200 µm. 
 
5.2.3 Low dose inhibition of Cav1.2 has no effect on Nkx2.5-GFP cardiomyocyte 
differentiation 
Inhibition of Ca2+ influx by nifedipine was used to assess the role of Cav1.2 in myocyte 
differentiation. Treatment of Nkx2.5-GFP ESCs with 500 nM nifedipine, a concentration 
previously shown to inhibit Cav1.2 function (Thiel et al. 2008), from either day 0 to 14 
or day 0 to 4 had no effect on the levels of GFP positive cells compared to vehicle 
control at day 14 (Figure 5.2m-p, Figure 5.4m-p). Treatment with nifedipine did not 
prevent either the formation of EBs or the outgrowth of cells. Furthermore, application 
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of nifedipine had no effect on expression of the stage-specific markers when compared 
to control (Figure 5.5). Together these results indicate that Cav1.2 inhibition with 500 
nM nifedipine has no effect on cardiomyocyte differentiation in this model. 
 
Figure 5.5: Inhibition of Cav1.2 with 500 nM nifedipine did not affect cardiomyocyte gene 
expression or effect early ESC markers at day 14 of Nkx2.5-GFP ESC differentiation 
Chronic exposure of Nkx2.5-GFP ESC from day 0-14 and day 0-4 with nifedipine (500 nM) did 
not affect the expression of cardiomyocyte genes Myh6 (a), Tnnt2 (b), Mef2c (c) and Nkx2.5(d)  
or early ESC genes  including Brachyury (e) and Oct-4 (f) compared to DMSO control at day 14.  
All error bars are mean ± S.E.M (n=5). Statistics: one-way ANOVA (all results showed no 
significance). 
 
5.2.4 Inhibition of NAADP signalling prevents Nkx2.5-GFP ESC cardiomyocyte 
differentiation 
To assess the requirement for NAADP-stimulated release of lysosomal Ca2+ stores via 
TPCs during cardiomyocyte differentiation the inhibitor Ned-K was employed (Calcraft 
et al. 2009). Ned-K is based on the inhibitor Ned-19, which inhibits TPC function by 
blocking both Ca2+ release and NAADP binding (Naylor et al. 2009). Application of Ned-
K from day 0-14 of Nkx2.5-GFP ESC differentiation reduced the expression of GFP 
positive cells in comparison to DMSO treated control samples (Figure 5.2i-l). Treating 
cultures with Ned-K from day 0-14 significantly reduced expression of the mature 
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cardiomyocyte markers Myh6 and Tnnt2 (Myh6; 0.014 ±0.01; p≤0.001; Tnnt2; 0.063 
±0.02; p≤0.001; Figure 5.6a-b), as well as significantly inhibiting the cardiac progenitor 
markers Nkx2.5 (0.20 ±0.05; p=0.001; Figure 5.6d) and Mef2c (0.18 ±0.064; p≤0.001; 
Figure 5.6c). Inhibition of NAADP signalling had no significant effect on Mesp1, 
Brachyury, Goosecoid and GFAP mRNA levels (Figure 5.6e-f, Figure 5.6i, Figure 5.6k) 
whilst Sox17 was significantly down regulated (0.36 ±0.13; p=0.033; Figure 5.6j). In 
contrast pluripotent markers Oct-4 and Nanog were significantly up-regulated at day 
14 (Oct-4; 2.86 fold ±0.60; p=0.004; Nanog; 2.21 ±0.31; p=0.002; Figure 5.6g-h). In 
terms of phenotype, inhibition of NAADP signalling had no effect on the formation of 
EBs or cell outgrowth. Treatment of ESCs with Ned-K from day 0-4 inhibited the 
number of GFP-positive cells, although these numbers were greater than when Ned-K 
was present throughout days 0-14 (Figure 5.4i-l). Similarly, mRNA levels of Myh6, 
Tnnt2 and Nkx2.5 and were significantly reduced when Ned-K was present from day 0-
4 (Myh6; 0.058 ±0.03; p=0.014; Tnnt2; 0.185 ±0.03; p=0.002; Nkx2.5; 0.288 ±0.05; 
p=0.006; Figure 5.6a-b, Figure 5.6d), although expression was significantly greater than 
that observed when ESC were treated from day 0-14 with Ned-K (Myh6; p=0.01; Tnnt2; 
p=0.004; Mef2c; p=0.013; Nkx2.5; p=0.032. Figure 5.6a-d). Day 0-4 inhibition of TPC1/2 
significantly up-regulated mRNA levels of early ESC genes including Brachyury (3.69 
±1.2; p=0.021; Figure 5.6f), Mesp1 (5.04 ±0.4; p=0.028; Figure 5.6e), Oct-4 (2.21 ±0.3; 
p=0.018; Figure 5.6g) and Nanog (1.71 ±0.1; p=0.018; Figure 5.6h), although the level 
of Nanog expression was significantly reduced compared to treatment throughout 
differentiation (p=0.012). Overall these results reveal that TPC1/2 inhibition prevented 
cardiomyocyte formation, suggesting a novel role for NAADP signalling and lysosomal 
Ca2+ release during differentiation. 
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Figure 5.6: Inhibition of NAADP signalling with 30 µM Ned-K prevents cardiomyocyte gene 
expression and promotes early ESC markers at day 14 of Nkx2.5-GFP ESC differentiation 
Exposure of Nkx2.5-GFP ESC to Ned-K (30 μM) for 14 days resulted in a significant decrease in 
cardiac genes Myh6 (a), Tnnt2 (b), Mef2c (c) and Nkx2.5(d), whilst early ESC genes, Oct-4 (g) 
and Nanog (h) were up regulated compared to DMSO control.  The endoderm marker Sox17 
was also down regulated (j), whereas Brachyury (f), Mesp1 (e), Gsc (i) and GFAP (k) were not 
significantly different from the DMSO control samples. Treatment from day 0-4 with Ned-K 
before subsequent culture in control media until day 14 resulted in similar overall effect on 
gene expression when treated throughout although there were significant increases in the 
expression of Myh6 (a), Tnnt2 (b), Mef2c (c) and Nkx2.5 (d) as well as a decrease in Nanog 
expression (h) when compared to treatment from day 0-14. Whilst most genes showed a 
similar expression pattern at day 14 when treated from day 0-4 compared to treatment 
throughout the mesoderm genes Mesp1 (e) and Brachyury (f) became significantly up 
regulated. All error bars are mean ± S.E.M (n=5). Statistics: one-way ANOVA and Tukey test for 
multiple comparisons (* p<0.05; ** p<0.01; *** p<0.001). 
 
5.2.5 Inhibition of NCX1 prevents Eomes-GFP ESC cardiomyocyte differentiation 
To confirm the above observations made using the Nkx2.5-GFP cell line experiments 
were repeated using the Eomes-GFP ESC line. Due to the absence of cardiomyocyte 
specific GFP reporter readout in this model it was not possible to directly asses 
cardiomyocyte formation using GFP expression, instead the percentage of 
spontaneously beating EBs was measured after drug removal. Inhibition of NCX1 led to 
a significant decrease in the number of beating EBs compared to DMSO at both day 7 
(10% vs. 68%; p≤0.001; Figure 5.7a) and day 14 (22% vs. 77%; p≤0.001; Figure 5.7b) 
and was consistent with the inhibition observed in the Nkx2.5-GFP ESC line. The 
133 
 
difference in percentage of beating EBs corresponded with differences in gene 
expression. In terms of phenotype, the inhibition of NCX1 had no effect on the 
formation of EBs or cell outgrowth (Figure 5.8e-h) and the number of cells was not 
significantly different from DMSO treated EBs at day 4 (Figure 5.8m) and 7 (Figure 
5.8n). Mature cardiomyocyte markers Myh6, Myh7 and Tnnt2 were all significantly 
down regulated at both day 7 (Myh6; 0.485 ±0.15; p=0.003; Tnnt2; 0.624 ±0.16; 
p=0.039; Figure 5.9a-c) and day 14 of differentiation (Myh6; 0.585 ±0.08; p=0.002; 
Myh7; 0.445 ±0.05; p=0.002; Tnnt2; 0.571 ±0.06; p≤0.001; Figure 5.9a-c). Cardiac 
progenitor markers Mef2c and Nkx2.5 were significantly down regulated at day 14 of 
differentiation (Mef2c; 0.600 ±0.05; p≤0.001; Nkx2.5; 0.807 ±0.09; p=0.039; Figure 
5.9d and Figure 5.9e), whilst Gata-4 expression was unchanged at both day 7 and day 
14 (Figure 5.9f). Mesoderm markers Mesp1 and Brachyury showed no difference at 
day 7 or day 14 except for Brachyury which was significantly up-regulated at day 14 
(3.75 ±1.78; p=0.04; Figure 5.9h), whilst the pluripotent marker Oct-4 was unchanged 
(Figure 5.9i). Gene expression of Ca2+ handling proteins NCX1 (Slc8a1) and Cav1.2 
(Canca1c) were significantly down regulated at day 7 (Slc8a1; 0.503 ±0.13; p=0.001; 
Canca1c; 0.809 ±0.09; p≤0.001; Figure 5.9j and Figure 5.9k) and day 14 of 
differentiation (Slc8a1; 0.764 ±0.09; p=0.037; Canca1c; 0.780 ±0.05; p=0.003; Figure 
5.9j and Figure 5.9k), most likely representing the decrease in cardiomyocyte 
formation.  
To assess further the role of NCX1 during early differentiation in Eomes-GFP ESCs, EBs 
were treated with CB-DMB from day 0-4 before being cultured in control media until 
day 14. At day 7, the percentage of day 0-4 CB-DMB treated EBs was significantly 
reduced compared to DMSO (CB-DMB 25%; DMSO 66%; p≤0.001; Figure 5.7a), whilst 
at day 14 there was no difference between treated and control ESCs (CB-DMB 48%; 
DMSO 59%; Figure 5.7b). Thus, removal of NCX1 inhibition allowed differentiation to 
proceed normally and cardiomyocytes could form after 10 days in normal media. 
Overall these results recapitulate the effect of CB-DMB treatment when using the 
Nkx2.5-GFP ESCs and confirm the role of NCX1 in ESC cardiomyocyte differentiation 
using two different ESC lines. 
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Figure 5.7: Inhibition of NCX1 with 1 µM CB-DMB and Cav1.2 with 10 µM nifedipine reduced 
the formation of Eomes-GFP ESC derived cardiomyocyte at day 4 and 7 
Chronic exposure of embryoid bodies to CB-DMB (1 μM) or nifedipine (10 μM) resulted in a 
significant decrease in the incidence of beating EBs at both day 7 (Control, 64% (n=233); 
DMSO, 68% (n=603); CB-DMB, 10% (n=363); nifedipine, 0% (n=83) and day 14 (Control, 68% 
(n=183); DMSO, 80% (n=196); CB-DMB, 22% (n=152); nifedipine, 52% (n=71)) although at day 
14 there was significantly greater percentage of beating EBs when treated with nifedipine 
compared to CB-DMB (a). Initial treatment from day 0-4 with CB-DMB resulted in a decreased 
number of beating EBs compared to DMSO at day 7 (Day 0-4 DMSO 66%, (n=105); Day 0-4 CB-
DMB 25%, (n=102)) however there were significantly more beating EBs compared to treatment 
from day 0-7 (a). By day 14, treatment from day 0-4 with both CB-DMB and nifedipine had no 
effect on the percentage of beating EBs compared to the DMSO control (DMSO, 59% (n=207); 
CB-DMB, 48% (n=172); nifedipine, 60% (n=33)) as well as there being a significant increase in 
the percentage of beating EBs when comparing EBs treated with CB-DMB from day 0-4 B to 
treatment throughout. Statistics: Fisher’s exact test with a Bonferroni correction for multiple 
comparisons. (* p<0.05; ** p<0.01; *** p<0.001). 
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Figure 5.8: Inhibition of NCX1 with 1 µM CB-DMB and Cav1.2 with 10 µM nifedipine did not 
effect embryoid body formation or cell outgrowth during Eomes-GFP ESC differentiation 
Treatment of Eomes-GFP ESCs with 1 µm CB-DMB or 10 µm nifedipine did not prevent EB 
formation or cell outgrowth.  Bright field images confirmed that cultures were grossly 
unaffected by CB-DMB or nifedipine at all stages of differentiation as was the number of cells 
per EB at both day 4 (m, DMSO, 20744 cells/EB (n=9); CB-DMB, 19184 cells/EB (n=7); 
nifedipine, 26359 cells/EB (n=3)) and day 7 (n, DMSO, 46800 cells/EB (n=10); CB-DMB, 44922 
cells/EB (n=8); nifedipine, 50761 cells/EB (n=3)). Scale bars: 500μm. All error bars are mean ± 
S.E.M. Statistics: one-way ANOVA and Tukey test for multiple comparisons (* p<0.05; ** 
p<0.01; *** p<0.001). 
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Figure 5.9: Inhibition of NCX1 with 1 µM CB-DMB prevents cardiomyocyte specific gene 
expression during Eomes-GFP ESC differentiation 
Treatment of Eomes-GFP ESCs throughout differentiation with CB-DMB (1 μM) resulted in a 
down regulation of cardiac genes Myh6 (a, day 7, n=6; day 14, n=9), Tnnt2 (c, day 7, n=4; day 
14, n=9), Slc8a1 (j, day 7, n=4; day 14, n=9) and Cacna1c (k, day 7, n=4; day 14, n=9) at both 
day 7 and 14 of differentiation compared to the DMSO control whilst Myh7 (b, day 14, n=5), 
Mef2c (d, day 7, n=4; day 14, n=9), Nkx2.5 (e, day 7, n=6; day 14, n=9) where significantly 
reduced by day 14. The cardiac progenitor gene, Gata-4 (f, day 7, n=4; day 14, n=6), cardiac 
mesoderm marker, Mesp1 (g, day 7, n=4; day 14, n=9) and pluripotent maker, Oct-4 (i, day 7, 
n=4; day 14, n=9) were unaffected by treatment with CB-DMB at both day 7 and 14 although 
the early mesoderm marker Brachyury was significantly up-regulated by day 14 (h, day 7, n=6; 
day 14, n=8). All error bars are mean ± S.E.M. Statistics: Student’s paired t-test (* p<0.05; ** 
p<0.01; *** p<0.001). 
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5.2.6 Inhibition of Cav1.2 reduces differentiation of Eomes-GFP ESC cardiomyocyte 
Although experiments using 500 nM nifedipine did not reveal an effect on 
cardiomyocyte differentiation in the Nkx2.5-GFP model, recently published work 
suggested that Cav1.2 does have a role in ESC cardiomyocyte differentiation (Nguemo 
et al. 2013). In this study, the authors used a higher concentration (10 μm) than 
previously tested in this study (500 nM), therefore to further asses the role of Cav1.2 
experiments repeated using 10μm nifedipine. Treatment of EBs with nifedipine 
prevented the appearance of beating EBs at day 7 (nifedipine 0%; DMSO; 68%; 
p≤0.001; Figure 5.7a), with a significant reduction in the number of beating EBs at day 
14 compared to DMSO (nifedipine 52%; DMSO; 76%; p≤0.001; Figure 5.7b), although 
there were still significantly more beating EBs at day 14 compared to CB-DMB 
treatment (nifedipine 52%; CB-DMB 22%; p≤0.001). In terms of phenotype, there was 
no difference in EB formation, cell outgrowth (Figure 5.8i-l) or cell number per EB at 
day 4 or day 7 (Figure 5.8m-n). The expression of cardiomyocyte marker genes (Myh6, 
Tnnt2, Mef2c, Nkx2.5, Slc8a1, Cacna1c) were unaffected at both day 7 and day 14 of 
treatment (Figure 5.10a, Figure 5.10c-e & Figure 5.10j-k) whilst Myh7 and Gata-4 were 
significantly down-regulated at day 14 (Myh7; 0.425 ±0.06; p=0.002; Gata-4; 0.652 
±0.12; p=0.037; Figure 5.10b and Figure 5.10f). Mesoderm marker, Brachyury, and 
pluripotent marker, Oct-4, were also unaffected (Figure 5.10h-i) whilst Mesp1 was 
significantly down-regulated by day 14 (0.550 ±0.12; p=0.043; Figure 5.10g), although 
unchanged at day 7. Overall 10μm nifedipine led to delayed cardiomyocyte formation 
but did not inhibit differentiation to the same extent as NCX1 inhibition. 
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Figure 5.10: Inhibition of Cav1.2 with 10 µM nifedipine prevents cardiomyocyte specific gene 
expression during Nkx2.5-GFP ESC differentiation 
Nifedipine treatment of Eomes-GFP ESCs throughout differentiation had no effect on the 
expression of Myh6 (a), Tnnt2 (c), Mef2c (d), Nkx2.5 (e), Brachyury (h), Oct-4 (i), Slc8a1 (j) or 
Cacna1c (k) compared to DMSO control at day 7 or 14. In contrast Myh7 (b), Gata-4 (f) and 
Mesp1 (g) were all significantly down regulated by day 14 of differentiation although these 
genes were still unaffected by treatment with nifedipine at day 7. All error bars are mean ± 
S.E.M (n=5). Statistics: Student’s paired t-test (* p<0.05; ** p<0.01; *** p<0.001). 
 
5.2.7 Inhibition of NCX1 and Cav1.2 during cardiac crescent formation ex vivo 
To characterise the effect of drug inhibition in the embryo proper, ex vivo culture was 
used. Embryos were collected at E7.25 prior to the formation of the cardiac crescent 
and cultured in their yolk sacs using rolling culture. During 12 h culture with DMSO, 
cells arising from the lateral plate mesoderm coalesced into a distinct crescent 
structure with respect to the overlying neural ectoderm (head folds) and endoderm 
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(Figure 5.11a). When embryos were treated with 3 µm CB-DMB cells failed to coalesce 
into distinct cardiac crescent structures as observed by actin staining (Figure 5.11c). 
After culture, embryos were collected and gene expression was assessed. Inhibition of 
NCX1 with CB-DMB led to a significant down-regulation in Tnnt2, Mef2c, Nkx2.5, 
Slc8a1 (Tnnt2; 0.54 ±0.11; p=0.038; Mef2c; 0.74 ±0.05; p=0.012; Nkx2.5; 0.48 ±0.08; 
p=0.004; Slc8a1; 0.77 ±0.04; p=0.043; Figure 5.12b-e), whilst Myh6 and Cacna1c were 
not significantly affected (Figure 5.12a & Figure 5.12f). Thus overall the down-
regulation in cardiac gene expression correlated with the morphological differences 
observed and the failed crescent formation following NCX1 inhibition. This was is in 
contrast to treatment with 10 µm nifedipine, in which the crescent developed 
normally and progressed to the equivalent stage as untreated embryos at E8.0 (Figure 
5.11b). This was further supported by the gene expression profile of treated embryos 
which showed no differences when compared to embryos treated with DMSO (Figure 
5.12g-l).  
 
Figure 5.11: Inhibition of NCX1 with CB-DMB prevents formation of the cardiac crescent 
during embryo culture from E7.25 
E7.25 embryos were dissected and cultured for 12 hours in media containing either DMSO, 
nifedipine (10 μM) or CB-DMB (3 μM) and stained for actin (a-c). Embryos developed normally 
in culture, as indicated by head fold formation, coalescence of the cardiac crescent (a-c) and 
addition of somites (not shown) relative to dissected stage-matched control embryos at E8.0 
(d). Embryos cultured in CB-DMB were delayed in terms of cardiac crescent formation (c) 
compared to either DMSO alone (a), nifedipine-treated (b) or E8.0 dissected embryos (P). 
White dashed line highlights cardiac crescent. cc, cardiac crescent; hf, headfolds. All scale bars 
50μm. 
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Figure 5.12: Inhibition of NCX1 with CB-DMB prevents cardiomyocyte specific gene 
expression during formation of the cardiac crescent from E7.25 
Cultured E7.25 embryos in the presence of either CB-DMB or nifedipine for 12 hours, revealed 
that CB-DMB significantly down-regulated the expression of both late TnnT2 (b) and early 
Mef2c (c) and Nkx2.5 (d) cardiac genes as well as Slc8a1 (e) which encode NCX1, coincident 
with impaired cardiac crescent formation, whilst Myh6 (a) and Cacna1c (f) were unaffected. 
Whereas, nifedipine treatment did not affect cardiac gene expression after 12 hours of culture 
(g-l). All error bars are mean ± S.E.M (n=5). Statistics: Student’s paired t-test (* p<0.05; ** 
p<0.01; *** p<0.001).  
 
5.3 Discussion 
We have previously shown that both NCX1 and Cav1.2 are expressed within the 
developing heart and are required for Ca2+ transients and contraction during formation 
of the cardiac crescent. The early expression and function of these proteins would 
suggest that not only are they crucial for contraction, but that they may have 
downstream effects in terms of gene expression and differentiation. In this chapter, I 
have shown that NCX1, Cav1.2 and NAADP signalling via TPCs are required for the 
specification and functional differentiation of cardiomyocytes suggesting these 
channels and exchangers are fundamentally required for cardiomyocyte development. 
5.3.1 Inhibition of NCX1 prevents the formation of cardiomyocytes 
NCX1 is one of the first ECC proteins to be expressed during development; becoming 
up-regulated prior to RyR2 and Cav1.2 as well as being required for Ca2+ transients 
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prior to contraction during cardiac crescent formation.  Using long-term 
pharmacological inhibition with CB-DMB we assessed the role of NCX1 during ESC-
derived cardiomyocyte differentiation in two different ESC lines (Nkx2.5-GFP and 
Eomes-GFP). By assessing the expression Nkx2.5-GFP as well as the percentage of 
beating EBs we observed a significant reduction in the formation of cardiomyocytes 
when NCX1 was inhibited from day 0-14. Between day 7 and day 14 further increases 
in the percentage of beating EBs were modest when treated with DMSO (~1.1 fold 
increase) or CB-DMB (~2.2 fold increase) treatment, suggesting that by day 7 the 
maximal number of EBs had undergone cardiomyocyte differentiation, however, the 
size of beating regions continued to increase. In terms of NCX1 inhibition this would 
suggest that cardiomyocyte differentiation was completely prevented by day 7, rather 
than being delayed. The decrease in cardiomyocyte differentiation by NCX1 was also 
reflected in the down regulation of cardiac progenitor and cardiomyocyte specific 
genes. Overall these findings suggested that NCX1 is required for cardiomyocyte 
specification and differentiation. Alternatively, the decrease in cardiomyocyte 
formation could be due to inhibition of cell growth, decrease in proliferation or cell 
death. Culture with CB-DMB throughout differentiation did not reduce the number of 
cells per EB, nor did it affect the gross morphology of EBs or inhibit cell out growth, this 
suggests that proliferation and cell viability were not affected by CB-DMB treatment. 
Furthermore, we did not observe increases in intracellular Ca2+ during acute 
treatment, suggesting that there was no Ca2+ overload secondary to NCX1 inhibition. 
To conclusively rule out increased cell death as a mechanism for reduced 
cardiomyocyte formation it would be important to perform TUNEL staining to assess 
levels of apoptosis, especially within GFP-positive cardiac progenitors.   
Although cardiomyocyte differentiation was significantly reduced at both day 7 and 14, 
the formation of cardiomyocytes was not completely inhibited as demonstrated by the 
observation of GFP+ cells within the cultures as well as the small percentage of beating 
regions which developed during CB-DMB treatment. The residual development of 
some cardiomyocytes would also explain why cardiac marker gene expression was not 
more strongly down-regulated in comparison to the decrease in the percentage of 
beating EBs. The inability of CB-DMB to completely inhibit cardiomyocyte 
differentiation may suggest incomplete inhibition of NCX1 activity with 1 µm CB-DMB 
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or that a specific sub-cardiac lineage does not require NCX1 for cardiomyocyte 
differentiation. Published studies which directly measured NCX1 generated current 
have shown that 1μm CB-DMB inhibits around 80% of NCX1 activity (Secondo et al. 
2009), suggesting some cells may escape inhibition and go on to differentiate, which 
would correlate with the 20% of beating EBs observed at day 14. An alternative reason 
could be that certain genes required for cardiomyocyte differentiation are not 
regulated by NCX1 function or that heterogeneity in the expression of Ca2+ handling 
proteins within cardiac progenitors may compensate for a loss in NCX1 function.  
Our observations that NCX1 inhibition leads to reduced cardiomyocyte differentiation 
is consistent with the early embryonic lethality observed in NCX1 transgenic mice 
around E9.5-11 (Cho et al. 2000)(Wakimoto et al. 2000)(Koushik et al. 2001). Mouse 
transgenic lines in which NCX1 is disrupted have shown that NCX1 is required for heart 
development however it is difficult to make conclusions about the role of NCX1 with 
certainty due to the large variation in the cardiac phenotype observed between 
different transgenic lines despite them having used the same targeting strategy. The 
first transgenic model published showed that disruption of NCX1 resulted in embryonic 
lethality between E9.5-10.5 (Wakimoto et al. 2000). At E9.5, hearts had reduced 
ventricular wall thickness due to fewer cardiomyocytes and increased apoptosis. In 
addition, whilst 70% of NCX1 knock out hearts lacked a heartbeat, the remaining 30% 
were able to contract with slow arrhythmic heartbeats. In comparison, another 
transgenic NCX1 knockout mouse survived until E11.0 with normal heart 
morphogenesis, although these mice lacked a heartbeat and had disorganised 
myofibril assembly (Koushik et al. 2001). Although the early embryonic lethality 
associated with a lack of NCX1 supports these findings, transgenic models may not be 
the most suitable model for examining the early role of NCX1 due to the variable 
penetrance and consequently in the observed cardiac phenotype. These differences 
may be due to other Ca2+ channels or different NCX1 isoforms compensating for the 
loss of NCX1 function due to its fundamental role in heart formation. In terms of 
compensation we assessed whether pharmacological inhibition of NCX1 might result in 
a direct up regulation of the NCX1 gene itself (Figure 5.9), however, NCX1 was down 
regulated, suggesting this was a consequence of decreased cardiomyocyte formation 
and not the result of compensation.   
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Overall this data shows that inhibition of NCX1 with CB-DMB significantly decreased 
the extent of cardiac gene expression and cardiomyocyte differentiation suggesting 
NCX1 has a fundamental role in the formation of cardiomyocytes and early heart 
development. 
5.3.2 Inhibition of Cav1.2 delays ESC-derived cardiomyocyte differentiation 
The L-type Ca2+ channel, Cav1.2 is the main route of sarcolemmal Ca2+ influx in mature 
cardiomyocytes (Bers 2000). Expression of Cav1.2 mRNA increased throughout the ESC 
differentiation from day 5 and was functionally relevant for the initiation of contractile 
activity within the stage 1 cardiac crescent. To assess the role of Cav1.2 on 
cardiomyocyte differentiation, a selective inhibitor was used to block channel function 
during ESC differentiation. Initial experiments with 500 nM nifedipine had no effect on 
cardiomyocyte gene expression or apparent differentiation. 500 nM nifedipine was 
used to investigate the role of Cav1.2 during differentiation due to nifedipine having a 
low IC50 value (~5 nM) in adult and ESC derived cardiomyocytes (Zheng et al. 
1992)(Brown 2009)(Kang et al. 2012). However, whilst conducting these initial 
experiments it was reported that 10µM nifedipine blocked cardiomyogenesis by 
inhibiting mesodermal commitment (Nguemo et al. 2013). In the Eomes-GFP model, 
treatment with 10 µm nifedipine throughout differentiation led to a significant 
decrease in the percentage of beating EBs at day 7 and 14. The difference in effects 
between 500 nM and 10 μm nifedipine could be due to 500 nM not completely 
inhibiting Cav1.2 during differentiation. Incomplete inhibition could be caused by the 
formation of EBs preventing drug penetration. Another potential reason could be that 
10 µM nifedipine inhibits other Ca2+ channels such as T-type channels or other L-type 
channel subunits, which were shown to be up-regulated during cardiomyocyte 
differentiation (chapter 4). High concentrations of nifedipine has been shown to inhibit 
T-type channel activity in both oocytes and HEK293 cells as well as in thalamic neurons 
(Shcheglovitov et al. 2005). 
Although there was a significant decrease in the overall formation of cardiomyocytes 
when treated with nifedipine from day 0-14, the number of beating EBs increased 50 
fold between days 7 and 14. This was also reflected in the difference between NCX1 
and Cav1.2 inhibition during differentiation; at day 7 nifedipine significantly reduced 
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the percentage of beating EBs, whilst at day 14 there was a significant increase relative 
to CB-DMB treatment. An increase in the percentage of beating EBs suggests that 
inhibition of Cav1.2 with nifedipine does not totally prevent cardiomyocyte formation 
but delays the rate of commitment or maturation. One explanation for the ability of 
ESCs to differentiate during Cav1.2 inhibition could be that other types of Ca2+ 
channels compensate for the lack of Cav1.2 function. Alternatively, Cav1.2 may only 
regulate certain cardiac specific genes which are not essential for cardiomyocyte 
formation. Transgenic mice with targeted Cav1.2 gene disruption died at around E13.5, 
however, at E12.5 their hearts were normal and beating at wild type rates, which the 
authors suggested explained as due to an unidentified Ca2+ channel and not an L-type 
Ca2+ channel (Seisenberger et al. 2000). This suggests that Cav1.2 is not fundamental 
for the formation of cardiomyocytes and that other Ca2+ channels may be more critical 
for early function.  
In terms of gene expression, inhibition of Cav1.2 throughout differentiation with 10 
µm nifedipine did not inhibit expression of the majority of cardiac-specific genes 
assessed including mature markers Myh6 and Tnnt2 as well as cardiac progenitor 
genes Nkx2.5 and Mef2c, although it did significantly inhibit Myh7 and Gata-4. Myh7 
encodes the embryonic isoform of myosin heavy chain, β-MHC, which is expressed 
during embryonic heart development prior to the adult isoform α-MHC (Myh6), as well 
as being re-expressed in the diseased heart. The fact that nifedipine treatment 
inhibited Myh7 expression and not other mature cardiomyocyte genes, suggests that 
Cav1.2 may directly regulate Myh7 expression, potentially due to Cav1.2-mediated 
signalling mechanisms or via its role in contraction. The complete loss of beating EBs at 
day 7 may be due to the decreased levels of Myh7 preventing contraction, however, 
up regulation of Myh6 at later stages may compensate and allow contraction to occur.  
The other cardiac gene inhibited by nifedipine treatment was Gata-4, an early cardiac 
marker of specification stages, suggests that Cav1.2 directly regulates Gata-4 gene 
expression via a mechanism independent from that controlling other early markers 
such Nkx2.5 and Mef2. Since Gata-4 has also been shown to be regulated by 
mechanical force (Schmelter et al. 2006), the lack of beating during nifedipine 
treatment might explain the decreased expression. 
145 
 
5.3.3 The role of NCX1 and Cav1.2 in pluripotent and mesoderm gene expression 
during ESC differentiation 
To investigate the stage at which NCX1 and Cav1.2 inhibition affected cardiomyocyte 
differentiation we studied the expression of mesoderm and pluripotent genes. 
Inhibition of NCX1 surprisingly resulted in the up-regulation of pluripotent markers 
Oct-4 and Nanog as well as the lateral plate mesoderm marker Brachyury whilst Mesp1 
a cardiogenic mesoderm marker was unaffected. Due to the decreased expression of 
cardiac progenitor markers this would suggest that inhibition of NCX1 prevents the 
formation of cardiac progenitors but does not block mesoderm commitment. 
The up-regulation of early differentiation genes could potentially be caused by NCX1 
having a direct role in the regulation of mesoderm formation or may indirectly affect 
mesoderm gene expression due to decreased cardiac progenitor formation.  In chapter 
5, we observed membrane-localised expression of NCX1 adjacent to Brachyury positive 
cells which suggests NCX1 activity indirectly feeds back to inhibit differentiation of 
neighbouring cells or up regulates mesoderm genes. Alternatively, in a cell 
autonomous manner, NCX1 could also have a direct signalling role at earlier stages of 
cardiomyocyte differentiation suggested by the punctate expression of NCX1 within 
day 4 EBs. 
Indirectly, the reduced amount of cardiomyocyte differentiation may result in a loss of 
repressive feedback signals. For example, Mesp1 can repress genes involved in 
pluripotency and early mesoderm induction, such as Brachyury and Goosecoid, by 
binding to the start codon of these genes and preventing transcription (Bondue et al. 
2008). The observed up regulation of mesoderm and pluripotent markers therefore 
may be due to a loss of repressive signals arising from the reduced cardiac progenitor 
formation. In contrast, Cav1.2 inhibition did not affect pluripotency or mesoderm gene 
expression but did result in significantly less expression of Mesp1 at day 14 of 
differentiation but not day 7 suggesting that Cav1.2 does not play a role in early 
cardiac differentiation, but is down regulated due to a consequence of delayed 
differentiation. 
Overall, this data shows that NCX1 has a role in the expression of pluripotent and 
mesoderm genes and suggests that NCX1 activity is essential for the progression of 
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mesoderm to cardiac progenitors. In contrast Cav1.2 potentially plays a later role in 
the maturation of cardiomyocytes acting once cardiac progenitors have formed. 
5.3.4 Inhibition of NCX1 blocks cardiomyocyte formation during mesoderm 
specification 
To assess the consequences of early NCX1 inhibition on cardiomyocyte formation, EBs 
were treated with CB-DMB for the first 4 days of differentiation before subsequent 
culture in control media until day 14. In the Nkx2.5-GFP ESC line, treatment from day 
0-4 with CB-DMB inhibited the formation of cardiomyocytes, however, to a lesser 
extent than treatment from day 0-14. At day 14 the expression of cardiac progenitor 
and mature cardiomyocyte genes was significantly reduced compared to DMSO 
control, however, there was a significant up-regulation in Myh6 and Mef2c expression 
at day 14 when treated with CB-DMB from day 0-4 compared to treatment from day 0-
14. In the Eomes-GFP line, treatment from day 0-4 with CB-DMB significantly reduced 
the percentage of beating EBs at 7, however, by day 14 there was no difference in 
comparison to treatment with DMSO. Together this data further suggests that NCX1 
plays an early role in the specification of cardiac progenitors and that removal of NCX1 
inhibition enables normal differentiation to proceed. In comparison, inhibition with 
nifedipine from day 0-4 had no effected on the percentage of beating EBs at day 14 
compared to treatment with DMSO from day 0-14 suggesting Cav1.2 does not 
influence early cardiomyocyte differentiation or mesoderm specification, supporting 
previous observations.  
5.3.5 Variation in the response of Nkx2.5-GFP and Eomes-GFP ESC lines to NCX1 
inhibition 
Despite the fact that inhibition of NCX1 resulted in a similar phenotype in the Nkx2.5-
GFP and Eomes-GFP ESCs, there were a number of differences between the two lines. 
Inhibition of NCX1 in the Nkx2.5-GFP line resulted in a more pronounced response to 
culture with CB-DMB than the Eomes-GFP ESC, with stronger down regulation of 
cardiac genes as well as greater up regulation of pluripotent and mesoderm markers. 
These differences are most likely due to the variation observed in the extent of 
cardiomyocyte differentiation between the two cell lines (Chapter 4).  During 
differentiation, the Eomes-GFP line resulted in beating EBs 1 to 2 days earlier than in 
the Nkx2.5-GFP line, suggesting cardiac progenitor formation occurred more rapidly. 
147 
 
Earlier differentiation may allow more cells to escape NCX1 inhibition due to 
mesoderm specification occurring whilst cells were still in hanging drops. The dense 
EBs formed between day 0-4 could potentially restrict drug penetration, also during 
the hanging drop culture drug containing media was not changed until day 4, meaning 
drug activity may have decreased over this timescale. In contrast, the slower rate of 
mesoderm specification and cardiac progenitor formation in the Nkx2.5-GFP line 
would mean there was longer exposure to NCX1 inhibition. The difference in rate of 
differentiation may also explain why at day 14, inhibition from day 0-4 in the Eomes-
GFP line had no effect on percentage of beating EBs whilst in the Nkx2.5-GFP line there 
was still a significantly reduced number of Nkx2.5-GFP positive cells. In addition, the 
Nkx2.5-GFP line had a relatively higher level of cardiac gene expression during 
differentiation compared to the Eomes-GFP line, which may explain why NCX1 
inhibition more strongly reduced gene expression in the former. 
5.3.6 The role of NCX1 and Cav1.2 during ex vivo embryo culture crescent formation 
Using ESCs as a model of cardiomyocyte differentiation this thesis has shown that 
NCX1 is required for the formation of cardiac progenitors whilst Cav1.2 play a role in 
cardiomyocyte maturation. To address the roles of Cav1.2 and NCX1 in a more 
physiological setting we adopted an ex vivo embryo culture approach. By isolating 
E7.25 embryos and culturing them for 12 hours with either CB-DMB or nifedipine we 
could investigate formation of the cardiac crescent. Culture with CB-DMB resulted in 
decreased expression of both cardiac progenitor and mature cardiomyocyte genes and 
ultimately failed coalescence of cardiac cells to form a crescent. Treatment did not 
adversely affect embryo viability as normal addition of somites was observed. When 
culturing embryos with CB-DMB the concentration of drug was increased from 1 µM to 
3 µM relative to the ESC cultures due to the embryos being cultured in their yolk sacs 
which could potentially decrease access of the drug and prevent NCX1 inhibition. In 
comparison, culture with 10 µM nifedipine did not affect embryo development and 
had no significant effect on cardiac gene expression or cardiac crescent formation. The 
high concentration of nifedipine used meant we did not increase the concentration of 
nifedipine for these experiments, although to conclusively rule out a role for Cav1.2 in 
cardiac crescent formation it would be important to determine a positive control for 
nifedipine activity ex vivo.  
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The embryo culture experiments provided further evidence to support the 
observations made using ESC models that NCX1 plays a fundamental role in cardiac 
progenitor specification whilst Cav1.2 is not required for the initial formation of 
cardiomyocytes but is likely more involved in later stage myocyte differentiation and 
maturation. 
5.3.7 Potential mechanisms involved in NCX1 and Cav1.2 regulation of differentiation 
In chapter 6, we that revealed both NCX1 and Cav1.2 played a role in cardiomyocyte 
Ca2+ influx and contraction, with NCX1 required for Ca2+ influx prior to the onset of 
beating. This difference in the functional roles for NCX1 and Cav1.2 may explain the 
observed differences between CB-DMB and nifedipine inhibition. Overall both NCX1 
and Cav1.2 inhibition reduced the formation of cardiomyocytes suggesting, that Ca2+ 
influx is not only critical for early function but also has a downstream role in signalling 
and gene regulation. The ability of NCX1 to regulate cardiac progenitor formation may 
be due to its ability to regulate Ca2+ influx at the earliest stages of cardiac crescent, 
whilst the functional role of Cav1.2 at later stages of crescent formation suggests an 
involvement in cardiomyocyte maturation. 
Ca2+ is key second messenger, known to be responsible for signalling in a large number 
of different cell types. In the adult heart, Ca2+ signalling has been strongly implicated in 
hypertrophy, acting as key regulator of gene expression and disease progression. 
During cardiac hypertrophy a number of foetal genes become up-regulated, such as 
Myh7, Nkx2.5 and Mef2c, these changes in gene expression correlate with the 
development of abnormal Ca2+ transients. In the diseased heart there is a distinct 
change in the properties of excitation contraction coupling, with a decrease in SR 
Ca2+uptake due to decreased SERCA expression along with increased sarcolemmal Ca2+ 
flux due to increases in NCX1 expression (Rourke et al. 1999).  Downstream Ca2+ 
signalling pathways involved in hypertrophy include the calcineurin and calmodulin 
kinase pathways (Shimoyama et al. 1999) (Hoch et al. 1999). It is, therefore, likely that 
Ca2+ influx, via reverse mode NCX1, at the earliest stages of cardiomyocyte 
differentiation may directly regulate cardiac progenitor gene expression via Ca2+-
dependent signalling pathways.  
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Inhibitors of NCX1 and Cav1.2 not only prevented Ca2+ influx at stage 1 but also 
inhibited early contractile activity, thus reducing the mechanical force applied to the 
cardiac progenitors and early forming cardiomyocytes.  Studies have shown in mouse 
embryonic stem cells that the expression of cardiac differentiation markers such as 
Gata-4 and sarcomeric α-actinin are increased after static stretching for 2 hours 
(Schmelter et al. 2006). Gata-4 was one of the only genes to be affected by nifedipine 
treatment at day 14 suggesting that a lack of contraction due to loss Cav1.2-dependant 
Ca2+ influx may influence gene expression via mechanical force signalling. In contrast, 
Gata-4 was unaffected during NCX1 inhibition further suggesting that NCX1 and Cav1.2 
function via different mechanisms to control gene expression.  
In chapter 6, we showed that at later stages of cardiac crescent formation only 
nifedipine prevented contraction which suggests that Cav1.2 has a role in maturation 
process of cardiomyocytes via mechano-signalling compared to NCX1. Studies in which 
cultures were selected for beating colonies and cardiomyocyte markers such as α-MHC 
and Nkx2.5, revealed that these contractile myocytes not only continued to increase 
expression of these markers when continuously stretched at 1.0Hz but were able to 
synchronously beat upon implantation into infarcted rat hearts (Gwak et al. 2008). This 
suggests that delayed cardiomyocyte maturation in the presence of nifedipine is due 
to the lack of contraction not regulating feed forward signalling pathways required for 
the expression of contractile proteins and maturation of cardiomyocytes via mechano-
signalling.   
5.3.8 NAADP signalling and lysosomal Ca2+ release via TPCs is require for specification 
and differentiation of cardiomyocytes 
To investigate the role of TPC1/2 in development, the recently identified Ned 
compounds were used in ESC differentiation experiments. These compounds are 
known to inhibit NAADP signalling and suppress lysosomal Ca2+ release, as shown in 
pancreatic beta cells (Cancela et al. 1999)(Naylor et al. 2009). Ned-K is a recently 
identified Ned compound suggested to be more specific and potent in the inhibition of 
TPC1/2. Although we have mainly used Ned-K in these studies, application of the 
previously published inhibitor Ned-19 had the same effect as Ned-K inhibition in 
preliminary experiments confirming these results (data not shown). The fluorescent 
properties of Ned-19 and Ned-K enable localisation of the compound to be observed. 
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From day 4 of differentiation speckled fluorescence could be observed throughout the 
cytoplasm of culture ESCs, suggesting localisation of the drug to the endo-lysosomal 
system, however, these preliminary observations using the auto fluorescence 
properties of Ned inhibitors need to be confirmed via other methods and co-
localisation experiments.  
Inhibition of TPC1/2 with 30 µM Ned-K from day 0-14 had a significant effect on both 
the number of Nkx2.5-GFP+ve cells as well as the expression of cardiac specific genes. 
Inhibition from day 0-4 significantly reduced GFP expression, but did not completely 
prevent formation of Nkx2.5-GFP+ve cells at day 14, in contrast to day 0-14 treatment. 
This was reflected by the increased expression of cardiac genes, notably those marking 
cardiac progenitors. Pluripotent markers Oct-4 and Nanog as well as Brachyury were 
also increased compared to DMSO control at day 14, suggesting that TPC1/2 Ca2+ 
release may have a role in undifferentiated cells and mesoderm formation, similar to 
that seen with NCX1 inhibition. The parallels observed between inhibition of NCX1 and 
TPC1/2 suggests either a potential interaction between the two proteins, or that they 
regulate cardiomyocyte differentiation via similar/convergent pathways. The ability of 
both NCX1 and TPC1/2 to regulate intracellular Ca2+ levels suggests both proteins are 
capable of regulating cardiomyocyte differentiation via downstream Ca2+ signalling. 
Transgenic knockout of TPC1/2 in mice does not affect embryo viability (Lin-Moshier et 
al. 2012)(Calcraft et al. 2009) suggesting that compensation can overcome TPC1/2 
disruption during development, further supporting TPC1/2 and NCX1 could act via the 
same signalling pathway and may suggest a degree of functional redundancy. 
Alternatively, TPC1/2 have also been described as Na+ selective channels (X. Wang et 
al. 2012), which suggests that Na+ release via TPC1/2 may lead to Ca2+ influx via the 
activation of reverse mode NCX1 activity due to increases in intracellular Na+.  
The activity of TPC1/2 is regulated via NAADP signalling which is reported to be the 
most potent Ca2+-mobilizing second messenger (Lee 2003) and has previously been 
shown to regulate skeletal muscle differentiation via TPCs (Aley et al. 2010). The 
inhibition of cardiomyocyte differentiation during treatment with Ned-K suggests that 
NAADP signalling is required for heart development. To assess in more detail the 
dynamics of NAADP signalling it will be crucial to directly measure the levels of NAADP 
151 
 
throughout differentiation, using an assay such as the biochemical cycling assay (Graeff 
& Lee 2002). 
In summary, these findings show for the first time that TPC1/2 and NAADP signalling 
have a role in the early determination of cardiac progenitors, with early inhibition 
being sufficient to delay the subsequent progression of differentiation. Taken together 
these findings suggest that lysosomes may act as early intracellular Ca2+ stores and 
support the hypothesis that early Ca2+ signalling is crucial for cardiac development. 
5.4 Summary 
In this chapter we have examined how inhibition of Ca2+ handling proteins influences 
cardiomyocyte differentiation and heart formation. We have shown that NCX1, Cav1.2 
and TPC1/2 are required for cardiomyocyte formation although inhibit differentiation 
at stages and potentially in different ways. In the following chapter we investigate the 
signalling mechanism which may link NCX1 and Cav1.2 function with cardiomyocyte 
differentiation.  
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6. Ca2+-DEPENDENT SIGNALLING REGULATES CARDIOMYOCYTE 
DIFFERENTIATION 
6.1 Introduction 
Previous chapters have revealed that both NCX1 and Cav1.2 are required for the 
formation of cardiomyocytes; subsequently we wanted to investigate the potential 
downstream signalling pathways which may link channel and exchanger activity with 
cardiomyocyte differentiation. The second messenger Ca2+ is known to play a key role 
in a wide range of different signalling pathways, controlling a variety of cellular 
functions. In the adult heart, Ca2+ signalling contributes to disease progression and the 
reactivation of foetal cardiac genes during pathological remodelling. Due to our 
observations that both NCX1 and Cav1.2 are required for early sarcolemmal Ca2+ influx 
during the initiation of contractile activity in heart we sought to investigate whether 
early changes in Ca2+ handling directly integrated with Ca2+ dependent signalling 
networks known to regulate developmental cardiac genes, which in turn could induce 
cardiomyocyte differentiation.  
6.2 Results 
6.2.1 Reduced external Ca2+ inhibits Eomes-GFP ESC Cardiomyocyte differentiation 
Ca2+ signalling is involved in a variety of different intracellular signalling pathways via 
the allosteric regulation of many enzymes and proteins (Berridge et al. 2000). To 
investigate whether the decrease in cardiomyocyte formation associated with NCX1 
and Cav1.2 inhibition was mediated by changes in Ca2+ influx, ESCs were cultured in 
reduced extracellular Ca2+. In previous ESC experiments the culture media contained 
1.8 mM Ca2+ which is similar to the physiological extracellular Ca2+ concentration 
([Ca2+]o) and widely used in most cell culture media, therefore, for these experiments 
the concentration of Ca2+ was lowered to 0.1 mM and 1.0 mM, in order to reduce the 
extracellular Ca2+ concentration and sarcolemmal Ca2+ influx. Exposure of ESCs to 0.1  
mM Ca2+ throughout differentiation resulted in a significant decrease in the number of 
beating EBs compared to 1.8 mM media at both day 7 (0.1 mM Ca2+, 2% (n=60); 1.8 
mM Ca2+, 25% (n=61). p=<0.001) (Figure 6.1a) and day 14 (0.1 mM Ca2+, 29% (n=80); 
1.8 mM Ca2+, 82% (n=91). p=<0.001) (Figure 6.1b). Chronic exposure to 1.0 mM Ca2+ 
significantly reduced the percentage of beating at day 14 compared to 1.8 mM Ca2+ 
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(1.0 mM Ca2+, 59% (n=65) vs. 1.8 mM Ca2+, 82% (n=91). p=0.0018) but not at day 7 (1.0 
mM Ca2+, 11% (n=55) vs. 1.8 mM Ca2+, 25% (n=61). p=0.09), whilst beating was 
significantly greater at day 14 than when ESCs were cultured in 1.0 mM Ca2+ compared 
to 0.1 mM Ca2+ media (p=<0.001). To investigate the role of Ca2+ during cardiomyocyte 
specification, ESCs were treated with 0.1 mM Ca2+ from day 0 - 4, before being 
returned to normal levels of Ca2+ for the remaining 10 days of differentiation. Under 
these conditions there was a significantly lower percentage of beating EBs compared 
to culture from days 0-14 in 1.8 mM Ca2+ (Day 0-4 0.1 mM – day 4-14 1.8 mM Ca2+, 
50% (n=40); Day 0-14 1.8 mM Ca2+, 82% (n=91). p=<0.001) . In contrast, when ESCs 
were treated with 1.8 mM Ca2+ from day 0-4 , before being cultured in 0.1 mM Ca2+ 
until day 14, there was no difference in comparison to treatment with 1.8 mM Ca2+ 
from day 0-14, however, there was significantly more beating EBs when compared to 
culture with 0.1 mM Ca2+ from day 0-14 (Day 0-4 1.8 mM – day 4-14 0.1 mM Ca2+, 74% 
(n=38); Day 0-14 1.8 mM Ca2+, 82% (n=91). Day 0-14 0.1 mM Ca2+, 29% (n=80). 
p=<0.001). To exclude the possibility that the effect of low Ca2+ was due to reduced cell 
proliferation, the total number of cells per EB were assessed. At both day 4 and day 7 
there was no difference in the number of cells per EB when cultured with 0.1 mM or 
1.8 mM Ca2+ containing media (Day 4; 0.1 mM Ca2+, 9688 cells/EB; 1.8 mM Ca2+, 12894 
cells/EB. Day 7; 0.1 mM Ca2+, 37230 cells/EB; 1.8 mM Ca2+, 46833 cells/EB) (Figure 6.1c, 
Figure 6.1d), this correlated with brightfield images of EBs in which the phenotype and 
cell outgrowth was similar under all conditions (Figure 6.1e-j). Together this data 
reveals that [Ca2+]o plays a fundamental role in the formation of ESC-derived 
cardiomyocytes, with reduced concentrations inhibiting cardiomyocyte differentiation 
but not preventing overall cell growth or proliferation. It also suggests that the 
concentration of [Ca2+]o is fundamental in the specification of cardiac progenitors 
occurring between days 0-4.  
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Figure 6.1: Reducing the external concentration of Ca2+ inhibits Eomes-GFP 
cardiomyocyte differentiation 
Chronic exposure of embryoid bodies to 0.1 mM external Ca2+ resulted in a significant 
decrease in the incidence of beating EBs at day 7 (a, 1.8 mM Ca2+, 25% (n=61); 1.0 mM Ca2+, 
11% (n=55); 0.1 mM Ca2+, 2% (n=60)). At day 14, 0.1 mM and 1.0 mM external Ca2+ reduced 
the percentage of beating EBs  although there was a significantly greater percentage of beating 
EBs when treated with 1.0 mM Ca2+ compared to 0.1 mM (b, 1.8 mM Ca2+, 82% (n=91); 1.0 
mM Ca2+, 59% (n=65); 0.1 mM Ca2+, 29% (n=80)). Initial treatment from day 0-4 with 0.1 mM 
Ca2+ before subsequent culture until day 14 in 1.8 mM Ca2+ resulted in a decreased number of 
beating EBs compared to control (Day 0-4 0.1 mM - Day 4-14 1.8 mM Ca2+, 50%, (n=40); Day 0-
4 1.8 mM - Day 4-14 0.1 mM Ca2+, 74%, (n=38)), however, there was a significant increase in 
the percentage of  beating EBs when cultured in 1.8 mM Ca2+  form day 0-4 before culture in 
0.1 mM Ca2+ until day 14 when compared to culture with 0.1 mM Ca2+ from day 0-14 (b). 
Treatment of Eomes-GFP ESCs with reduced concentrations of external Ca2+ did not affect the 
number of cells per EB at both day 4 (c, 0.1 mM Ca2+, 9688 cells/EB; 1.8 mM Ca2+, 12894 
cells/EB) or day 7 (d, day 0-7 0.1 mM Ca2+, 37230 cells/EB; day 0-7 1.8 mM Ca2+, 46833 
cells/EB; day 0-4 0.1 mM Ca2+, day 4-7 1.8 mM Ca2+, 37157 cells/EB; day 0-4 1.8 mM Ca2+, day 
4-7 0.1 mM Ca2+, 36283 cells/EB) or prevent EB formation and cell outgrowth. Bright field 
images confirmed that cultures were grossly unaffected by reduced external Ca2+ 
concentration at all stages of differentiation (e-j).Scale bars: 500μm. All error bars are mean ± 
S.E.M. Statistics: Fisher’s exact test with a Bonferroni correction for multiple comparisons. (* 
p<0.05; ** p<0.01; *** p<0.001). 
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6.2.2 Acute inhibition of NCX1 and Cav1.2 has no effect on cardiac gene expression of 
ESCs 
To assess whether inhibition of NCX1 or Cav1.2 played an acute role in regulating 
cardiac gene expression, RT-PCR was employed to assess the levels of signature genes 
after treatment for 4 hours with NCX1 and Cav1.2 inhibitors. At day 4 of 
differentiation, prior to cardiomyocyte beating, treatment with NCX1 inhibitors did not 
affect the expression of mesoderm genes (Brachyury & Mesp1) or cardiac-specific 
genes (Gata-4, Mef2c and Myh6)( Figure 6.2). Expression of Nkx2.5 was unchanged in 
all treatments at day 4 except when treated with 10μm CB-MB, which caused it to be 
significantly up-regulated (1.96-fold, p=0.043 (n=4)). This experiment was also 
repeated at day 7 of differentiation, after the formation of beating cardiomyocytes 
(Figure 6.3). Expression of Mesp1, Nkx2.5, Mef2c and Myh6 were all unchanged after 4 
hours in the presence of NCX1 or Cav1.2 inhibitors (CB-DMB, KB-R, SN-6 & nifedipine). 
This data shows that the short term application of NCX1 and Cav1.2 inhibitors does not 
acutely effect the expression of cardiomyocyte specific genes at day 4 or day 7, and 
suggests that NCX1 and Cav1.2 do not directly regulate cardiac gene expression. 
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Figure 6.2: Inhibition of NCX1 at day 4 of Eomes-GFP for 4 hours does not affect 
cardiac related gene expression 
Inhibition of NCX1 with CB-DMB, KB-R7943 or SN-6 for 4 hours at day 4 of Eomes-GFP ESCs 
differentiation had no effect on the expression of Brachyury (a), Mesp 1 (b), Gata-4 (c), Mef2c 
(e) or Myh6 (f), whilst Nkx2.5 was unaffected by all inhibitors expect doe 10 µM CB-DMB which 
caused a small but significant increase in expression (d). All error bars are mean ± S.E.M 
(DMSO n=5, 1 µM CB-DMB n=5, 10 µM CB-DMB n=5, 10 µM KB-R7943 n=3, 30 µM SN-6 n=4). 
Statistics: one-way ANOVA and Tukey test for multiple comparisons (* p<0.05; ** p<0.01; *** 
p<0.001). 
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Figure 6.3: Inhibition of NCX1 or Cav1.2 at day 7 of Eomes-GFP for 4 hours does not 
affect cardiac related gene expression 
Inhibition of NCX1 with CB-DMB, KB-R7943 or SN-6 as well as Cav1.2 with Nifedipine for 4 
hours at day 7 of differentiation had no effect on the expression of Mesp 1 (a), Nkx2.5 (b), 
Mef2c (c) or Myh6 (d). All error bars are mean ± S.E.M (n=3). Statistics: one-way ANOVA and 
Tukey test for multiple comparisons (* p<0.05; ** p<0.01; *** p<0.001). 
 
6.2.3 CaMKIIδ and Calcineurin gene expression during ESC Cardiomyocyte 
differentiation 
Two of the main enzymes involved in Ca2+ regulated signalling pathways within the 
heart include calmodulin kinase II (CaMKII) and calcineurin (Molkentin 2006). Whilst 
there are a number of different isoforms and subunits for each of these enzymes, this 
study focused on the CaMKII delta isoform and the alpha subunit of calcineurin, which 
are the predominant isoforms expressed in the heart (Edman & Schulman 
1994)(Muramatsu et al. 1992). During in vivo heart development, the genes Camk2d 
(encoding CaMKII Delta) and Ppp3ca (encoding alpha calcineurin subunit), showed no 
significant change between E7.5 and E8.5 (Figure 6.4a, Figure 6.4d). During Eomes-GFP 
ESC differentiation Camk2d was significantly up-regulated at day 5 compared to day 0 
of differentiation (2.7 fold ±0.3; p=<0.001) with expression increasing until day 14 (15.7 
fold ±2.3; p=<0.001) (Figure 6.4b). Ppp3ca gene expression also increased throughout 
differentiation (18.6 fold ±3.9; p=<0.001), becoming significantly elevated from day 4 
(2.5 fold ±0.6; p=0.036) (Figure 6.4e). This data demonstrates that the expression of 
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genes related to Ca2+ signalling increase throughout ESC cardiomyocyte differentiation 
in a similar manner to cardiomyocyte specific markers (Chapter 4).  
 
Figure 6.4: Gene expression of CaMKinaseII and Calcineurin increase throughout 
cardiomyocyte differentiation but are unaffected by NCX1 or Cav1.2 inhibition 
Temporal gene expression of Camk2d (a) and Ppp3ca (d) were assessed on whole embryos by 
qRT-PCR, normalised to E7.5; no significant differences were observed between E7.5 and E8.5 
(n=5). Gene expression was also assessed during Eomes-GFP cardiomyocyte differentiation 
with Camk2d (b) and Ppp3ca (e) increased over the 14 day timecourse with significant up 
regulation in Camk2d by day 5 and Ppp3ca by day 4 (n=5). Treatment throughout 
differentiation with either CB-DMB or Nifedipine did not affect expression of Camk2d at either 
day 7 (n=4) or day 14 (n=6) whilst Ppp3ca was significantly down regulated during CB-DMB 
treatment at 7 whilst being unaffected by inhibition at day 14. Inhibition of Cav1.2 with 
Nifedipine did not affect Ppp3ca expression at either day 7 or 14. All error bars are mean ± 
S.E.M. Statistics: ANOVA and Tukey test for multiple comparisons (* p<0.05; ** p<0.01; *** 
p<0.001). 
 
6.2.4 Effect of Cav1.2 and NCX1 on genes involved in known Ca2+-related signalling 
pathways 
To assess whether Ca2+ signalling genes were affected by inhibition of NCX1 or Cav1.2, 
expression levels were assessed after long-term treatment with CB-DMB or nifedipine. 
Chronic exposure to CB-DMB significantly decreased the expression of both calcineurin 
(Ppp3ca) (0.7 fold ±0.1; p=0.04) and NFAT (0.8 fold ±0.1; p=0.03) at day 7 of 
differentiation (Figure 6.4f, Figure 6.5d). NFAT remained significantly decreased at day 
14 when treated with CB-DMB (0.8 fold ±0.1; p=0.045), in contrast to Camk2d which 
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was unaffected by treatment at day 7 and day 14 (Figure 6.4c). The expression of the 
intermediate messenger calmodulin was also assessed as it is a Ca2+-dependent 
regulator of both CamKII and calcineurin. Calmodulin is encoded by three genes 
(Calm1-3), however, none of these were affected by CB-DMB treatment at day 7 or 14 
(Figure 6.5a-c). Similarly, no difference was observed in the expression of the Calm1-3 
when treated with Nifedipine at both day 7 and 14 (Figure 6.5e-h). Overall this data 
suggests that inhibition of NCX1 and Cav1.2 affected Ca2+ signalling-related genes in 
different ways, implicating these two proteins in effecting different signalling pathways 
during ESC cardiomyocyte differentiation. 
 
Figure 6.5: Inhibition of NCX1 or Cav1.2 does affect expression of Calmodulin genes 
whilst NCX1 inhibition reduces NFAT expression during Eomes-GFP cardiomyocyte 
differentiation 
Chronic treatment of Eomes-GFP ESCs with either 1 µM CB-DMB (a-c) or 10 µM Nifedipine (e-
g) did not affect the expression of Calmodulin genes Calm1, Calm2 or Calm3 at either day 7 or 
day 14 of differentiation. Treatment with 1 µM CB-DMB did, however, significantly reduce the 
expression of NFATc1 at both day 7 and 14 whilst 10 µM Nifedipine had no effect. All error 
bars are mean ± S.E.M (day 7, n=4; day14, n=6). Statistics: ANOVA and Tukey test for multiple 
comparisons (* p<0.05; ** p<0.01; *** p<0.001). 
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6.2.5 Inhibition of NCX1 reduces CaMKII activity during cardiomyocyte differentiation 
of Eomes-GFP cells 
In order to more accurately assess how sarcolemmal Ca2+ influx may regulate Ca2+ 
signalling during ESC differentiation, the enzyme activity of CaMKII was investigated 
due to its role in the regulation of Mef2c during adult pathological hypertrophy (X. Wu 
et al. 2006). Upon Ca2+ binding, CaMKII auto-phosphorylates at specific residues 
leading to constitutive and increased enzyme activity. Using specific antibodies it is 
possible to detect the auto-phosphorylated form of CaMKII and, with scanning 
densitometry, assess enzyme activity. Treatment of Eomes-GFP ESCs with CB-DMB or 
nifedipine throughout differentiation had no effect on the ratio of activated phospho-
CaMKII (pCaMKII) levels compared to total CaMKII, relative to GAPDH expression, at 
day 4 (mean+ SEM: DMSO, 0.93±0.33; CB-DMB, 1.09±0.07; nifedipine, 0.98±0.28; 
n=3)(Figure 6.8a, Figure 6.6b). However, at day 7 inhibition of NCX1 with CB-DMB 
significantly reduced the ratio of pCaMKII / total CaMKII in comparison to treatment 
with DMSO, whilst treatment with Nifedipine had no effect (mean+ SEM: DMSO, 
1.18±0.13; CB-DMB, 0.69±0.15; nifedipine, 1.13±0.06. DMSO vs. CB-DMB, p≤0.01; CB-
DMB vs. nifedipine, p≤0.05; n=3.) (Figure 6.6c, Figure 6.6d). This data reveals that NCX1 
can regulate CaMKII activity in a stage-dependent manner, whilst Cav1.2 inhibition 
does not influence this pathway.  
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Figure 6.6: Inhibition of NCX1 reduces the activation of CaMKinaseII at day 7 of 
Eomes-GFP cardiomyocyte differentiation 
Exposure of cultured ESC derived-cardiomyocytes NCX1 and Cav1.2 inhibitors effected 
downstream Ca2+ signalling via alterations in the levels of phosphorylated CaMKII (pCaMKII). 
The ratio of pCaMKII:total CaMKII was unaffected by chronic treatment with DMSO, 1 µM CB-
DMB or 10 µM Nifedipine at day 4(a, b), whilst at day 7 1 µM CB-DMB significantly decreased 
the ratio pCaMKII:total CaMKII compared to DMSO or Nifedipine (c,d). All error bars are mean 
± S.E.M (n=3). Statistics: ANOVA and Tukey test for multiple comparisons (* p<0.05; ** p<0.01; 
*** p<0.001). 
  
162 
 
6.3 Discussion 
6.3.1 The concentration of external Ca2+ influences cardiomyocyte differentiation 
The ability of NCX1 and Cav1.2 to mediate early Ca2+ transients, as well as inhibit 
cardiomyocyte formation suggests that Ca2+ may be fundamental in integrating early 
functional activity with gene regulation during heart development. It was, therefore, 
important to assess how global changes in extracellular Ca2+ influenced myocyte 
differentiation in order to determine whether inhibition via NCX1 and Cav1.2 could be 
mediated by Ca2+ alone. To investigate this Eomes-GFP ESCs were cultured in media 
with reduced external Ca2+ concentrations in comparison to the 1.8 mM Ca2+, used in 
previous experiments. In adult murine cardiomyocytes Ca2+ is driven into the cell upon 
the opening of Ca2+ channels by the sarcolemmal concentration gradient, which is a 
result of the intracellular concentration of Ca2+ ([Ca2+]i) being significantly lower 
(~0.1mM) than the extracellular concentration ([Ca2+]o) (1.0m-1.8mM). Lowering 
external Ca2+ would, therefore, decrease the concentration gradient across the 
sarcolemmal membrane and reduce the driving force required for Ca2+ influx. In terms 
of NCX1 function, reducing external Ca2+ to 0.1 mM would increase the reversal 
potential of NCX1 from -26mV to around 43mV and lead to greater forward mode 
NCX1 activity, therefore, reducing the ability of NCX1 to work in reverse mode and 
facilitate Ca2+ influx. 
Reducing external Ca2+ led to a significant decrease in cardiomyocyte differentiation, 
as assessed by the percentage of beating EBs at both day 7 and 14. In order to 
determine whether the reduction in beating EBs was due to a decrease in the 
formation of cardiomyocytes or a consequence of reduced Ca2+ on contractile function, 
EBs that had been cultured in low Ca2+ were returned to control (1.8 mM Ca2+) media 
for 2 hours prior to being assessed. By day 14, the percentage of beating EBs cultured 
in 0.1 mM Ca2+ was similar to that when NCX1 was inhibited, suggesting that both 
treatments may act via the same pathway, and that inhibition of cardiomyocyte 
differentiation via NCX1 could be mediated by Ca2+ influx. Culture with 1.0 mM Ca2+, 
which may more be physiologically relevant than 1.8 mM in terms of the in vivo [Ca2+]o 
in the mouse heart (Kashimura et al. 2010), had an intermediate effect on 
cardiomyocyte differentiation compared to 1.8 mM and 0.1 mM Ca2+. Together this 
suggests that the concentration of external Ca2+ directly relates to the formation of 
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cardiomyocytes, with increased [Ca2+]o promoting cardiomyocyte differentiation. 
Significantly, low [Ca2+]o from day 0-4 reduced the percentage of beating at day 14 
even after 10 days in control 1.8 mM Ca2+. In contrast, maintaining EBs in 1.8 mM Ca2+ 
from day 0-4 before culturing them from day 4-14 in 0.1 mM Ca2+ had no effect on the 
percentage of beating compared with culture in 1.8 mM from day 0-14. These findings 
suggest that Ca2+ is crucial for the early specification and formation of cardiac 
progenitors again consistent with the phenotype of NCX1 inhibition. However, once 
cardiac progenitors have formed and cardiomyocyte differentiation has begun, the 
requirement for Ca2+ becomes altered, which may be due to changes in the balance 
between sarcolemmal Ca2+ influx and the release of Ca2+ from intracellular stores such 
as the SR or lysosomes.  
Ca2+ is a major second messenger involved in the regulation of cell growth and 
proliferation (Berridge 1995), it was, therefore, important to assess whether 
proliferation was inhibited by the reduced [Ca2+]o. In terms of phenotype, EBs at day 4 
of differentiation were similar when cultured in low 0.1 mM and 1.8 mM Ca2+, this was 
also reflected in the number of cells per EB at day 4 and 7. Overall, this would suggest 
that although [Ca2+]o was reduced, the concentration was still sufficient to maintain 
normal cell proliferation and growth, however, a larger sample size would be required 
to conclusively determine this due to the substantial variation observed between 
experiments. A more accurate method for assessing the proliferation status during 
culture would be to use a dye such as BrdU, which incorporates itself into newly 
synthesised DNA and allows assessment of cell division. 
Overall this data shows that reducing the concentration of external Ca2+ inhibits 
cardiomyocyte formation and correlates with observations made using 
pharmacological inhibitors of NCX1, Cav1.2 and TPC activation. Together these results 
highlight a role for Ca2+ in the regulation of cardiomyocyte differentiation and suggest 
that the Ca2+ influx associated with early functional activity is required for subsequent 
heart development. 
6.3.2 Hypertrophic Ca2+ signalling during cardiomyocyte differentiation  
Cardiac hypertrophy is the abnormal enlargement of the heart due to increases in 
cardiomyocyte size as well as changes in other components of the heart such as the 
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extracellular matrix. Hypertrophy is an adaptive response to pressure or volume 
overload (e.g. hypertension), mutations in sarcomeric proteins or the loss of 
contractile mass from a prior myocardial infarction, leading to an increased risk of 
heart failure, arrhythmias and sudden cardiac death (Frey et al. 2004). A widely 
supported hypothesis is that changes in Ca2+ cycling mediate this hypertrophic 
response (Molkentin 2006) via the onset of abnormal Ca2+ transients and the 
reactivation of fetal cardiac genes, such as Mef2c, Nkx2.5 and β-MHC, via Ca2+-
dependent signalling pathways. In terms of cardiac physiology, hypertrophy leads to 
significant changes in ECC with a decrease in SR function and increased sarcolemmal 
Ca2+ flux, due to reduced SERCA2a levels as well as increased NCX1 expression (Rourke 
et al. 1999). The increased requirement for sarcolemmal Ca2+ flux during hypertrophy 
is similar to the physiology observed within the early embryo, as discussed in chapter 
6, suggesting that changes in Ca2+ dynamics during formation of cardiomyocytes may 
integrate with known hypertrophic Ca2+ signalling pathways. Ca2+ and calmodulin – 
dependent signalling pathways such as CaMKII and calcineurin which in turn have been 
strongly implicated in the induction of cardiac hypertrophy and the reactivation of 
fetal genes (Frey & Olson 2000)(Bassel-Duby & Olson 2003).  
Calcineurin is a Ca2+-dependent protein phosphatase, composed of a CaM-binding 
catalytic subunit and a smaller regulatory subunit and has been identified as a key 
regulator of cardiac hypertrophy via the de-phosphorylation and activation of the 
transcription factor NFAT. CaMKII is a serine/threonine kinase that binds Ca2+ via its EF 
hands leading to the activation and phosphorylation of downstream targets, including 
transcription factors such as Mef2c (X. Wu et al. 2006). Gain- and loss-of-function 
studies in genetically altered mice have demonstrated that CaM, CaMKII and 
calcineurin are all necessary to regulate pathologic cardiac hypertrophy (Molkentin 
2004)(Backs et al. 2009)(Mishra et al. 2010), however, little is known about their role 
during embryonic heart formation. This study has focused on the gene expression of 
the predominant cardiac isoform of calcineurin, the catalytic α subunit (encoded by 
ppp3ca) and the CaMKIIδ isoform (encoded by camk2d). Over the course of ESC 
cardiomyocyte differentiation both calcineurin and CaMKIIδ increased suggesting an 
elevated requirement for Ca2+-dependent signalling as differentiation progressed. In 
terms of gene expression profiles ppp3ca (encoding calcineurin subunit a) became 
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significantly up regulated at day 4 of differentiation whilst camk2d (encoding CaMKIIδ) 
increased at day 5. These increases correlated with the up-regulation of cardiac 
progenitor markers Nkx2.5 and Mef2c observed at the same time points in chapter 4 
and suggesting that both calcineurin and CaMKIIδ are required during the formation of 
ESC derived cardiomyocytes.  
The increased gene expression of CaMKIIδ and calcineurin observed during the 
formation of ESC-derived cardiomyocytes was not reflected during formation of the 
cardiac crescent between E7.5 and E8.5 in vivo. The lack of change in expression of 
these genes suggested that CaMKIIδ and calcineurin are not required for the formation 
of cardiomyocytes in vivo. In terms of calcineurin, this data would fit with previous 
studies which have shown that calcineurin and its downstream target NFAT are not 
required for the formation of the linear heart tube but instead are involved in the 
maturation of cardiomyocytes (Schulz & Yutzey 2004). Although this data shows that 
CaMKIIδ and calcineurin do not increase during formation of the cardiac crescent, it 
does not exclude them from having a role in signalling over this timecourse as gene 
expression does not directly correlate with protein levels or enzyme activity. Both 
CaMKII and calcineurin/NFAT are expressed within the early embryo and are known to 
have a role in lineage specification and the integration of Ca2+ signals during 
fertilisation (Li et al. 2011)(Knott et al. 2006), suggesting that these proteins are likely 
to be expressed prior to E7.5. This would also fit with the expression profiles of ESC 
differentiation marker genes (Chapter 4), as both CaMKIIδ and calcineurin were 
initially up regulated when mesoderm markers such as Brachyury and Mesp1 were 
maximally elevated during gastrulation at E6.5. It is likely that other non-cardiac 
specific isoforms of these enzymes, such as CaMKIIγ or CaMKIV, may have more 
predominant roles during early embryonic development and contribute to the 
formation of the cardiac crescent potentially compensating for the later expression of 
the cardiac isoforms. Overall whilst CaMKIIδ and calcineurin gene expression does not 
increase during in vivo formation of the heart these signalling pathways are present 
and potentially active within the embryo at E7.5, however, samples prior to E7.5 would 
need to be analysed in order to compare the in vivo and ESC models when using 
relative gene expression or by assessing enzyme activity at the protein level to 
examine Ca2+ dependent signalling during in vivo cardiomyocyte formation.  
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6.3.3 Specific roles of NCX1 and Cav1.2 in Ca2+-dependent signalling 
Activity-dependent gene expression triggered by Ca2+ entry into cardiomyocytes is 
reported to be responsible for the progression of cardiac diseases but whether specific 
sources of Ca2+ act distinctly or merely supply Ca2+ to a common pool remains 
uncertain. To begin to assess how Cav1.2 and NCX1 inhibition may influence Ca2+ 
dependent signalling pathways, gene expression of related genes were examined after 
chronic inhibitor treatment. CaMKII and calcineurin signalling is regulated by the 
upstream Ca2+ binding second messenger calmodulin which is encoded by three genes; 
Calm1, Calm2, Calm3. Inhibition of NCX1 and Cav1.2 had no effect on the expression of 
all three calmodulin genes. The inability of CB-DMB or nifedipine to affect calmodulin 
suggests that calmodulin is not regulated by sarcolemmal Ca2+ influx, however, the 
expression of calmodulin in all eukaryotic cells (Stevens 1983) potentially masks any 
changes in cardiomyocyte specific gene levels and makes it difficult to conclude how 
NCX1 or Cav1.2 may regulate calmodulin.  
The expression of calcineurin and NFAT genes was significantly down regulated by 
chronic inhibition of NCX1 suggesting the calcineurin pathway may be regulated by 
NCX1 mediated Ca2+ flux, however, this decrease could also represent the reduced 
formation of cardiomyocytes during NCX1 inhibition. By day 14 of CB-DMB treatment 
the significant reduction in the relative expression of calcineurin was lost, potentially 
due to up-regulation of calcineurin in the small proportion of cardiomyocytes that 
form during CB-DMB treatment or because of increased expression in other cells types 
other than cardiomyocytes as differentiation progresses. In contrast, the gene 
expression of NFAT remained down regulated at day 14 which is likely to be a 
consequence of the significant decrease in calcineurin and NFAT gene expression at 
day 7. NFAT is known to positively feedback to regulate its own expression, therefore, 
any decrease in NFAT would exacerbate the inhibitory effect in comparison to control. 
Whilst NFAT is not required for the formation of cardiomyocytes the decrease in NFAT 
expression suggests that NCX1 could also regulate cardiomyocyte maturation as well 
as formation. In contrast inhibition of Cav1.2 did not affect the expression of either 
calcineurin or NFAT, suggesting that NCX1 and Cav1.2 inhibit cardiomyocyte formation 
via different signalling pathways, as will be discussed later. 
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Mef2c is one of the main transcription factors regulated by CaMKII activity via the 
phosphorylation and removal of repressive HDACs (histone deacetylases) from the 
nucleus thereby altering chromatin structure and allowing Mef2c mediated 
transcription (X. Wu et al. 2006). Inhibition of NCX1 throughout ESC differentiation 
caused significant decreases in the expression of Mef2c, however, removal of NCX1 
inhibition at day 4 resulted in the recovery of Mef2c expression (Chapter 5) suggesting 
that CaMKII may be required for Mef2c regulation during ESC cardiomyocyte 
differentiation. Upon Ca2+ binding, CaMKII is known to auto phosphorylate at specific 
residues, leading to constitutive activation and an increase in kinase activity (Ishida et 
al. 1996). Using specific antibodies for total CaMKII and auto-phosphorylated CaMKII a 
significant decrease was observed in the auto-phosphorylation of CaMKII at day 7 of 
ESC differentiation when NCX1 was inhibited in comparison to DMSO or Cav1.2 
inhibition. This was in contrast to CaMKIIδ gene expression which was not effected by 
NCX1 inhibition and, therefore, highlights the importance of performing direct assays 
to assess signalling dynamics. The inability of NCX1 inhibition to reduce CaMKIIδ gene 
expression even when other cardiac specific genes were down regulated (Chapter 5) 
could suggest that CaMKIIδ is up-regulated in the small percentage of cardiomyocytes 
that form during NCX1 inhibition as a potential compensatory mechanism for the 
overall decrease in CaMKII enzyme activity, however, this was not conclusive at the 
protein level. When assessing enzyme activity using western blot analysis it was not 
possible to measure the activity of the cardiac CaMKIIδ isoform alone as current 
antibodies detect the phosphorylation state of all CaMKII isoforms. At day 4, NCX1 
inhibition had no effect on CaMKII auto-phosphorylation, despite treatment from day 
0-4 inhibiting cardiomyocyte differentiation (Chapter 5), thus suggesting that CaMKII 
signalling is not involved in the early signalling required for cardiac progenitor 
specification and that other Ca2+ related signalling pathways are required. The inability 
of CB-DMB to reduce CamKII auto-phosphorylation at day 4 also corresponds with the 
timecourse of CaMKIIδ gene expression, as significant increases in CaMKIIδ expression 
did not occur until day 5 of differentiation, suggesting CaMKII signalling may not be 
occurring prior to day 5. The ability of CamKII to impact on cardiomyocyte 
differentiation would also be influenced by the expression of its downstream targets. 
In terms of cardiac related genes regulated by CamKII, Mef2c expression did not 
increase until between days 5 and 7 during ESC differentiation suggesting that even if 
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CamKII was active prior to day 4 it would not be required for the regulation of Mef2c. 
That said, CaMKII activity may have a role in the initiation of Mef2c activity, via its 
ability to phosphorylate and remove repressive HDACs (Zhang et al. 2002) thereby 
altering the epigenetic landscape and allowing Mef2c mediated transcription to occur. 
The inability of Cav1.2 inhibition to reduce CaMKII activity suggests that whilst both 
Cav1.2 and NCX1 can prevent Ca2+ transients at day 7,the specific source of 
sarcolemmal Ca2+ determines the Ca2+ dependent signalling pathway regulated. The 
differences in NCX1 and Cav1.2 regulation of CaMKII activity potentially correlate with 
the differences observed in NCX1 and Cav1.2 function during the initiation of Ca2+ 
transients and the timecourse of NCX1 and Cav1.2 expression during formation of 
cardiomyocytes (Chapter 4). Chapter 4 showed that NCX1 was up regulated before 
Cav1.2 at both the RNA and protein level, whilst NCX1 mediated Ca2+ influx preceded 
Cav1.2 activity suggesting that NCX1 could influence Ca2+ signalling at earlier stages of 
cardiomyocyte formation and lead to stronger downstream effects at day 7.  
In chapter 5 it was suggested that Cav1.2 may have a more predominant role in 
controlling cardiac signalling via mechanical stretch at later stages of differentiation, 
this is further supported by the observation that inhibition of Cav1.2 with nifedipine 
did not affect CaMKII activity. Contraction can trigger mechanical signalling via a 
number of different mechanisms, including-stretch activated Ca2+ channels but also via 
Ca2+-independent signalling pathways such as the Akt and MAPK pathways working 
through G-protein coupled receptors and integrins. It could, therefore, be suggested 
that Cav1.2 may be involved in signalling pathways that are not directly controlled by 
Ca2+. To investigate alternative pathways it would be interesting to inhibit contraction 
during ESC differentiation without affecting either Ca2+ transients or actin/cytoskeletal 
dynamics. 
Another factor which may influence the signalling properties of NCX1, Cav1.2 and 
TPC1/2 could be their subcellular localisation and the formation of micro-domains. In 
adult cardiomyocytes cellular micro-domains are known to regulate the signalling 
properties of different pathways, and localisation of Ca2+ to specific micro-domains 
determines how Ca2+ regulates downstream signalling (Ibarra et al. 2013). This 
suggests that in early cardiac progenitors NCX1 and Cav1.2 are located within different 
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micro-domains and, therefore, regulate Ca2+ signalling in different ways. On the other 
hand, discrete Ca2+ signalling domains may have not yet formed in early cardiac 
progenitors allowing signals which become restricted in the adult to propagate 
throughout the cytoplasm and act at the nucleus. Micro domains can be created by the 
formation of signalling complexes made up of a number of different interacting 
proteins such as A kinase anchoring proteins (AKAPs) and the cytoskeleton. It has been 
shown that both NCX1 and Cav1.2 can form macromolecular signalling complexes with 
a range of different signalling molecules including protein kinases (PKA and PKC), 
protein phosphatases (PP2A and PP1) and AKAPs suggesting that the signalling 
properties of these two proteins could be dynamically regulated by the associated 
proteins expressed throughout differentiation (Schulze et al. 2003)(Harvey & Hell 
2013). 
Overall this data shows that NCX1 is capable of regulating CaMKII activity suggesting 
that early sarcolemmal Ca2+ flux has a role in signalling, that could potentially regulate 
gene transcription and differentiation, however, there are a wide range of other 
mechanisms by which NCX1 and Cav1.2-mediated Ca2+ handling could regulate the 
signalling and gene transcription required for cardiomyocyte differentiation. 
6.3.4 Alternative Ca2+ signalling mechanisms during cardiomyocyte formation 
Whilst CaMKII and calcineurin have been strongly implicated in Ca2+-dependent 
signalling pathways in the heart a number of more novel mechanisms may be capable 
of directly linking Ca2+ influx with gene transcription. In the brain, Cav1.2 has been 
reported to acutely control gene expression over a period of 5mins via the 
transcription factor CREB (cAMP response element-binding protein) (Ma et al. 2014), 
whilst in isolated cardiomyocytes the acute activation of EPAC, a guanylyl exchange 
protein, triggers Ca2+ mediated HDAC nuclear export within 60 minutes (Pereira et al. 
2012). To determine whether NCX1 or Cav1.2 had an acute role in the regulation of 
cardiac gene expression during differentiation. ESCs were treated for only 4 hours such 
that any changes in expression would be due to direct signalling effects and not as a 
consequence of cell division or protein turnover. Neither treatment affected cardiac-
related gene expression after 4 hours of inhibition suggesting NCX1 or Cav1.2 did not 
acutely regulate transcriptional activity and that NCX1 and Cav1.2 indirectly influence 
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cardiac gene expression via other cellular process such as metabolism. However, due 
to the ESC model used, acute inhibition is likely to be masked by the myriad of cell 
types present and the large variation in maturity of cardiomyocytes during 
differentiation. Previous studies which have investigated the acute role of Ca2+ channel 
activity and gene regulation have typically used pure populations of single cells. 
Although ESCs have been staged by the overall level of gene expression at various days 
of differentiation, ESC derived cardiomyocytes do not represent a pure population of 
cells at the same stage of differentiation. Therefore, if a specific gene or subset of cells 
was acutely affected by inhibition the response could potentially be masked by other 
cells which already express that gene or by cells which do not require NCX1 or Cav1.2 
for the expression of that particular gene. 
As well as Ca2+ acting via downstream signalling molecules to regulate transcription 
within the nucleus, Ca2+ also directly binds certain transcription factors to regulate 
activity. DREAM (Downstream Regulatory Element Antagonistic Modulator) binds to 
DNA at low Ca2+ concentrations and represses transcription; upon direct Ca2+ binding 
DREAM dissociates from DNA allowing transcription to occur (Carrión et al. 1999). In 
neonatal cardiomyocytes, DREAM has been shown to regulate the expression of 
Cacna1c (encoding Cav1.2) creating a physiological feedback mechanism enabling 
cardiomyocytes to adjust Ca2+ influx via Cav1.2 to the concentration of intracellular 
Ca2+ (Ronkainen et al. 2011). The early influx of Ca2+ during cardiac differentiation may, 
therefore, be capable of directly regulating the binding and transcriptional activity of 
certain transcription factors, such as DREAM, and thereby indirectly regulate the 
expression of downstream cardiac specific genes 
Cardiomyocyte signalling and the regulation of gene transcription could also be 
regulated by the electrophysical properties of NCX1- and Cav1.2-mediated 
sarcolemmal ion flux. Electrical charge is known to affect interactions between 
nucleotides as well as playing a key role in protein folding (Snodin et al. 2015). A novel 
mechanism termed excitation-transcription coupling has been described in 
sympathetic neurons which links channel activity due to membrane depolarisation 
with activation of the nuclear transcription factor CREB independently of Ca2+ influx 
(Wheeler et al. 2008)(D’Arco & Dolphin 2012). In Drosophila, electrochemical cues 
have been shown to regulate Wnt signalling complexes at the plasma membrane. The 
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binding and recruitment of key Wnt signalling molecules, dishevelled and frizzled, was 
regulated by both pH and electrical charge with the membrane localisation of 
dishevelled being dependent on Na+/H+ exchanger activity at the plasma membrane 
(Simons et al. 2009). These studies highlight the role that electrical charge can have on 
cellular interactions and adds a new level of complexity to cellular signalling. Similar 
mechanisms may be occurring in early cardiomyocytes due to the electrogenic nature 
of the NCX1 and the role of Wnt signalling during cardiomyocyte differentiation 
(Gessert & Kühl 2010) as well as the inward current generated by Cav1.2 activation. 
Although these studies have highlighted CaMKII signalling as a key pathway, which can 
potentially integrate NCX1 Ca2+ handling and gene regulation, as well as provided some 
preliminary insight into the other Ca2+ signalling pathways involved, a much broader 
study would be required to further examine the role of Ca2+ signalling in 
cardiomyocyte differentiation. 
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6.4 Summary  
In summary, we have shown that reducing extracellular Ca2+ prevents cardiomyocyte 
differentiation in a manner similar to that observed during NCX1, Cav1.2 and TPC1/2 
inhibition suggesting Ca2+ is fundamental for cardiomyocyte differentiation. We have 
also begun to investigate how NCX1 and Cav1.2 activity integrates with specific Ca2+ 
signalling pathways during ESC cardiomyocyte differentiation, revealing a role for NCX1 
in the regulation of CaMKII activity and highlighted differences in the mechanisms by 
which NCX1 and Cav1.2 can regulate downstream Ca2+ signalling, however, as 
discussed above further studies are needed to address this in more detail.  
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7. CONCLUDING REMARKS 
In order for the adult heart to supply the body with sufficient oxygen and nutrients it 
relies on the coordinated influx and efflux of Ca2+ via ECC. In the failing heart, the 
hypertrophic response is mediated by alterations in Ca2+ handling and Ca2+ dependent 
signalling pathways, leading to changes in transcription and thereby linking 
cardiomyocyte function with gene expression. It is well documented that the heart is 
the first organ to form and function in the embryo proper, with contractile activity 
occurring prior to the formation of mature cardiomyocytes. This highlights a potential 
link between early heart function and subsequent cardiomyocyte differentiation. 
Whilst contractile activity is known to regulate cardiac gene expression via mechanical 
force, only a small number of studies have begun to investigate how early function 
though Ca2+ dynamics may regulate cardiomyocyte differentiation during the initial 
stages of heart development.. 
To begin to understand how function may integrate with heart formation, it was 
essential to precisely characterise the temporal development of the heart from the 
earliest specification of pre-cardiac mesoderm to linear heart tube stage in order to 
assess when and how contraction was initiated. To this end we developed a staging 
method focusing on murine cardiac crescent development, which allowed us to 
accurately correlate morphogenesis and differentiation with channel/exchanger 
expression and contractile activity. Whilst characterising the formation of the cardiac 
crescent we observed single cell Ca2+ transients prior to the onset of contraction, 
suggesting that Ca2+ dynamics, independent of contractile activity, may regulate 
cardiomyocyte differentiation during early heart development. Moreover, we 
identified NCX1 as a mechanism for generating pre-contractile Ca2+ transients via its 
ability to trigger Ca2+ influx through reverse mode of action, a role superseded by the 
expression of L-type Ca2+ transients.  
Whilst the dynamic nature of immature cardiomyocyte electrophysiology has 
previously been described, and NCX1 suggested to be responsible for the initiation of 
cardiac function, we believe our findings represent the first observation of NCX1-
meditead pre-contractile Ca2+ transients in the intact mammalian heart. Inhibition of 
sarcolemmal Ca2+ handling via NCX1 and Cav1.2 as well as Ca2+ release form 
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intracellular lysosomal stores via TPCs caused a significant reduction in ESC 
cardiomyocyte differentiation, although to varying degrees, highlighting a requirement 
for Ca2+ during early differentiation of the forming heart. Inhibition of NCX1 had the 
most significant effect on cardiomyocyte formation (most likely due to its early 
expression and function) and was capable of regulating CaMKII auto-phosphorylation, 
something that was not observed during Cav1.2 inhibition. This finding implicates 
distinct sources of Ca2+ as modulators of specific signalling pathways during 
cardiomyocyte differentiation and is extremely relevant in the diseased adult heart in 
which NCX1 is up-regulated and SR function decreases. 
This study is by no means a complete investigation, and has raised further questions 
which will require future experiments to address, as described throughout the 
individual chapters. In terms of early cardiomyocyte physiology, further insight will be 
gained by fully characterising the electrophysiological and molecular basis of pre-
contractile individual cell Ca2+ transients, as well as their lineage identity at both the 
whole tissue and single cell level. This data would allow us to address the 
heterogeneity observed in the dynamics of single cell Ca2+ transients prior to 
contraction as well as determining how single cell Ca2+ transients develop into co-
ordinated propagating Ca2+ waves across the cardiac crescent. In parallel, it will be 
essential to assess the potential off-target effects of pharmacological inhibition. Whilst 
a wider range of drugs could be employed, it would also be appropriate to study 
genetic animal models. As detailed in Table 1.1, a number of different mouse models 
have been previously described which ablate relevant cardiac channels and exchangers 
and result in embryonic lethality due to cardiac defects. Using the methods and staging 
we have applied in this thesis, it would be interesting to investigate early cardiac 
crescent formation in these models. In addition, due to the dynamic nature of 
embryonic cardiomyocyte electrophysiology and the fundamental requirement for 
early heart function during development, it would be relevant to examine whether 
compensation occurs in order to maintain this early function. Whilst gene deletion 
studies would allow us to more accurately define the specific roles of certain Ca2+ 
handling and signalling molecules, overexpression studies would also be useful in 
implicating specific pathways required for the formation of the heart.  We would 
hypothesise from our data, that overexpression of both NCX1 and CaMKII would lead 
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to enhanced cardiomyocyte differentiation. Whilst we began to look at potential 
signalling pathways required for the integration of function and gene transcription, it 
will be essential to further explore these and other more novel pathways. This thesis 
has also highlighted the need for using pure populations of specific cardiac progenitor 
cell types as well as direct readouts of signalling activity in order to make any definitive 
conclusions regarding Ca2+ signalling and cardiac gene transcription. 
Insight into how heart form (muscle differentiation and morphogenesis) and function 
(Ca2+-handling, contraction and downstream gene expression) are related during 
development of the cardiac crescent has a number of potential clinical implications. 
Firstly, these studies are highly relevant in helping to understand the basis of 
congenital defects, but more importantly the analogous roles of Ca2+ in the early heart 
and adult hypertrophy with regards to cardiac function and foetal cardiac gene 
induction to promote physiological or pathological myocyte growth, respectively, 
mean these studies have a much broader context. Investigating how contractile 
activity arises during heart development and is coordinated across individual cells of 
the cardiac crescent will give insight into cardiac arrhythmias and the role of abnormal 
Ca2+ handling in the reactivation of developmental genes during disease, potentially 
informing on the development of new therapies to prevent pathological gene 
reactivation. Gaining mechanistic insight into cardiomyocyte formation will also aid 
with understanding how best to produce and integrate de novo cardiomyocytes from 
both stem and progenitor cell types during cardiovascular regenerative medicine, and 
will be crucial to any tissue reparative strategy in which de novo cardiomyocytes are 
generated in order to restore the muscle of a diseased heart. 
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Figure 7.1: Schematic overview summarising the onset of Ca2+ transients within the 
developing cardiac crescent and the role of NCX1 and Cav1.2 in regulating Ca2+ influx.  
Ca2+ transients were initially observed within stage 0 cardiac crescents as spontaneous 
asynchronous oscillations before the onset of propagating Ca2+ waves at stage 1. Within the 
stage 0 cardiac crescents, Ca2+ transients were mediated by NCX1, however no contraction was 
observed, thus correlating with the absence of sarcomere formation. As the cardiac crescent 
developed sarcomeres could be detected at stage 1, with both NCX1 and Cav1.2 having a role 
in the generation of propagating Ca2+ transients. At stage 3, and within the linear heart tube, 
NCX1’s role in Ca2+ transient initiation was lost and transients were solely generated by Cav1.2.  
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